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Abstract 
Cutaneous Squamous Cell Carcinoma (cSCC) is the most common human tumour with 
malignant potential which is responsible for over 1 in 4 skin cancer deaths in the UK. High 
risk groups exist such as, immunosuppressed patients and those with the genetic condition 
recessive dystrophic epidermolysis bullosa whom are burdened with increased cSCC 
incidence, metastasis and mortality. Current clinically available molecular targets for cSCC 
are limited. Moreover, the key molecular events in cSCC remain poorly defined, presumably 
including both loss/gain of DNA or through gene silencing by DNA modifications. 
Understanding the molecular events which lead to cSCC is paramount for developing 
successful, novel molecular targets for therapeutic purpose. Preceding this thesis, our group 
used two independent methods to identify potential molecular targets: microarray 
technology (Watt 2011) and Sanger sequencing (Wang 2011), of which some of the targets 
identified from these studies, formulate the basis of this thesis.  
Using microarray technology, a comparison between gene expression profiles of 
cultured cSCC and normal keratinocytes, identified a gene signature specific for cSCC. From 
this signature, five genes were identified as being over-expressed in cSCC compared to 
normal and whose gene expression was important for cell survival. Subsequently, three of 
these genes were further explored within this thesis: germ cell associated 2 (GSG2), 
bradykinin receptor B1 (BDKRB1) and protease serine 21 (PRSS21). To begin, genes were 
confirmed to be over-expressed at both mRNA and protein level. Following this 
conformation, several endpoints were monitored using standard assays of cell viability, 
proliferation and apoptosis, in cSCC keratinocytes using gene specific siRNA. Using this 
validation method, PRSS21 showed the most promise as a molecular target. Depletion of 
24 
 
PRSS21 resulted in decreased cell viability through an increase in cytotoxicity and apoptosis. 
Therefore PRSS21 was further validated as a molecular target through stable over-
expression in an immortalised normal human cell line with no endogenous PRSS21 
expression. Subsequently, using 3D organotypic cultures, it was shown that the expression 
of PRSS21 clearly transformed these cells into an invasive phenotype, compared to the 
control. Finally, PRSS21 was shown to interact with the tumour suppressor maspin, 
potentially negatively regulating maspin dependant apoptosis. This data strongly suggests 
that both PRSS21 and maspin are potential targets in cSCC. 
The second method of identifying molecular targets was direct sequencing of 
tumour DNA, which identified loss of function notch mutations in ~75% of cSCC. It has been 
postulated that loss of notch function contributes to cSCC through a reduction in 
differentiation. Using three cSCC cell lines of known notch status (wild type/loss of 
function/notch null), cells were grown in organotypic culture, and the expression of markers 
associated with differentiation studied. With the aid of a gamma secretase inhibitor to 
inhibit notch signalling the contribution of notch to the expression of differentiation 
markers was studied in cSCC cells compared to normal human keratinocytes (NHK). There 
was a significant reduction in differentiation within the cSCC cell lines compared to NHK, 
regardless of notch status, and differentiation could be further reduced by the presence of 
GSI in the cSCC with wild type/loss of function notch expression. Furthermore, over-
expression of a gamma secretase regulatable intracellular notch1 (ICN1) construct, showed 
an induction of involucrin in these cells, compared to cells overexpressing an empty vector 
control, confirming that notch1 contributes to differentiation. 
Overall this work highlights the importance of validating targets before embarking on 
expensive, time consuming experiments. In doing so, it reveals two potential molecular 
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targets which could be important for the progression of cSCC, PRSS21 and maspin. 
Additionally it confirms the potential mechanism of notch loss of function in suppressing 
differentiation, suggesting that its re-activation would be is a valid approach to cSCC 
therapy. 
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 Chapter 1: Introduction 
 
1.1 NORMAL HUMAN SKIN 
As the outermost layer of the body, the skin acts to protect us from everyday environmental 
insults. Formed from multiple cell types which undergo continuous self-renewal; where the 
cells have the ability to go through numerous cell divisions while maintaining the 
undifferentiated state. Thus, it is a complex system - involving a fine balance between 
proliferation and differentiation of cells, creating a protective barrier against the 
environment (Poumay and Coquette 2007). Normal skin structure comprises of two main 
compartments – the superficial epidermis and the deeper dermis (figure 1.1). Derived from 
different embryonic components, they retain fundamentally different morphology. 
Furthermore, they are simultaneously separated, yet connected by the basement 
membrane, which acts to tightly anchor the epidermis and the dermis together using 
anchoring fibrils and hemidesmosomes which strengthen the skin structure. The basement 
membrane also functions as an important epithelial and stromal interface, not only to 
selectively regulate compounds/molecules but to regulate migration and invasion of normal 
cells, such as melanocytes and Langerhans cells (Burgeson and Christiano 1997) but also to 
create a barrier against invasion of malignant cells. (Liotta, Lee et al. 1980). The skin also has 
other appendages such as hair, sweat and sebaceous glands of epithelial. 
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Figure 1.1 Hematoxylin and Eosin (H&E) Staining of the Human Skin 
The “yellow line” represents the basement membrane (BM), sebaceous gland (SG), hair 
follicle (HF), blood vessel (BV) are also noted in this image. The section can also be divided 
into the epidermis and dermis, which are the two major compartments of the skin. Image 
taken at 40x magnification. 
Figure 1.1 
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1.1.1 The Epidermis 
The epidermis consists of stratified squamous epithelium and is a highly structural pattern 
of cell growth required for epidermal renewal, cellular cohesion and barrier formation 
(Gambardella and Barrandon 2003). Primarily, it is made up of epithelial cells called 
keratinocytes however; other non-epithelial cells are also embedded within the epidermis 
such as melanocytes, Langerhans’ cells and merkel cells. Melanocytes function to produce 
melanin – a pigment which helps to protect the skin against ultraviolet (UV) damage and are 
sparsely situated along the stratum basale (Torrora and Derrickson 2006). Merkel cells 
which also occur at a low frequency within the epidermis are thought to function as sensory 
receptors, as some are associated with nerve endings; however their function is of long 
standing debate (Moll, Roessler et al. 2005). Additionally, the epidermis also gives rise to 
hair follicles and sebaceous glands (Torrora and Derrickson 2006).  
1.1.1.1 Epidermal Differentiation 
The cells in the epidermis follow a programmed life cycle beginning at their site of origin in 
the stratum basale and migrating through to the stratum corneum where they terminate; a 
process known as differentiation (figure 1.2). Epidermal differentiation, along with cellular 
proliferation, functions to form a barrier against environmental insults. A lack of regulation 
of epidermal differentiation can result in fluid imbalance, heat loss and infection (Cartlidge 
and Rutter 1992) but also neoplastic transformation (Rheinwald and Beckett 1980; Yuspa 
and Morgan 1981). 
 
The keratinocytes within the epidermis are at different stages of maturation and can be 
subdivided into 4 layers the stratum basale, the spinous layer, the stratum granulosum and 
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the stratum corneum (figure 1.2).  Immediately above the basement membrane is the first 
layer, the stratum basale. The keratinocytes in this layer are the keratinocyte progenitor 
cells also known as epidermal “stem cells”. These are considered as a small population of 
undifferentiated, basal keratinocytes which can produce transit amplifying (TA) cells; it is 
the TA cells which account for the majority of cells in the basal layer. Epidermal stem cells 
are capable of a rapid turnover rate, to form a highly organised stratified tissue, required for 
skin renewal (Potten and Bullock 1983; Morris, Fischer et al. 1985). However, the precise 
mechanisms of control are not yet clear (Fuchs and Horsley 2008).  They are capable of 
dividing to generate more progenitor cells or alternatively, they differentiate losing contact 
with the basement membrane to form the spinous layer. As these cells progress into the 
stratum granulosum and stratum corneum, towards their external environment, they incur 
a number of genetic and metabolic changes controlled by both extrinsic and intrinsic factors 
mainly at a genetic level (Schallreuter and Wood 1995).  In culture, differentiation can be 
modulated by the addition of calcium which influences cell-cell interactions and allows 
stratification through the formation of cellular adhesion molecules - desmosomes. However 
in 2D culture, since the stratum corneum cannot form, it is impossible to study the stratum 
granulosum and stratum corneum layers. However, it has been demonstrated that using 3D 
culture methods, full differentiation is possible (Prunieras, Regnier et al. 1983). Additionally, 
a number of proteins can be used as biological markers of differentiation which are noted 
below. 
 
The stratum basale region is composed of a network of keratins 5 and 14. As keratinocytes 
begin to terminally differentiate they detach from the basement membrane and migrate 
upwards. Cells in the spinous layer establish intracellular contact through desmosomes and 
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expression of keratins 1 and 10. These cells also express involucrin which is cross-linked 
either to its self or to other protein components which contribute to the formation of the 
cornifed envelope. In the overlying granular layer, cells acquire lipid-containing granules and 
express fillagrin and loricrin, which also contribute to the outermost cornified layer which 
helps to provide an effective epidermal barrier to the environment (Watt 1989; Christiano 
1997). 
 
 
 
Figure 1.2 Schematic Diagram Showing Keratinocyte Organisation Within the Epidermis. 
There are 4 distinct layers within the epidermis which are noted on the right hand side. The 
keratinocytes within the epidermis are at different stages of maturation, during which they 
undergo changes in cellular morphology. On the left hand side the arrow indicates the 
direction of epidermal migration and hence cellular migration to the external environment. 
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1.1.1.2 Keratin Expression in the Epidermis 
The keratin filament proteins play an important role in epithelial differentiation and provide 
physical resilience for epithelial cells. For instance, mutations in keratin lead to inherited 
tissue fragility such as epidermolysis bullosa (Lane, Rugg et al. 1992). As evidenced in the 
section above, keratins are present in various forms throughout the differentiating 
epidermis. The cells in the stratum corneum form the outermost keratinized layer, where 
the cells flatten and exocytose lamellar granules containing precursors of lipids and keratin. 
Eventually these cells die, losing their nuclei and cytoplasmic organelles, leaving a highly 
structured keratin layer behind. This dense network of keratin helps to keep the skin 
hydrated by preventing water evaporation and is important for barrier function (Poumay 
and Coquette 2007).  
1.1.2 Signals that regulate skin differentiation 
The mechanisms associated with stratification have been well established in terms of 
morphogenetic changes, however the molecular basis for differentiation are less well 
established. Multiple signalling pathways have been identified especially those associated 
with skin barrier function (Blanpain 2007, Blanpain 2006). Important pathways include 
notch, mitogen-activated protein kinase (MAPK), nuclear factor κβ (NFκβ) and 
transcriptional regulators p63, AP2 family and CCAAT/enhancer binding protein (C/EBP) and 
interferon regulatory factor 6 (IRF6). The complex interplay between these complexes has 
begun to emerge. However central to the process of differentiation is controlled by p63 and 
canonical notch pathway which contributes to the basal-spinous switch. The notch pathway 
will be further discussed below. 
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1.1.2.1 Introduction to the notch signalling pathway 
While Drosophila have only one notch receptor and two ligands, mammals possess four 
notch receptors (Notch 1-4) and five ligands (Jagged1 and 2 and Delta-like 1, 3 and 4) which 
adds a depth of complexity to the pathway (figure 5.1) (for review see (Kopan and Ilagan 
2009). The receptors are synthesised in the endoplasmic reticulum as single trans-
membrane polypeptides, before being transported to the cell surface via the trans-Golgi 
network. During trafficking the receptors are cleaved at an S1 cleavage site which creates 
ligand-binding and trans-membrane subunits, which are held covalently together. The 
extracellular domain (NEC) consists of variable numbers of EGF-like repeats that participate 
in ligand binding. The Notch/LIN domain supersedes these and prevents ligand-independent 
receptor activation. The transmembrane domain (NTM) of the Notch receptor includes a 
recombination signal-binding protein 1 for J-κ (RBP-J) association molecule (RAM) domain 
and ankrin repeats (ANK) which participate in downstream signalling and protein:protein 
interactions. Additionally, a C-terminal PEST (P) domain is a peptide sequence which acts a 
signal peptide for protein degradation. Notch signalling is initiated by ligands expressed on 
neighbouring cells or through secretion into the extracellular space. The ligands are part of 
the Delta-Serrate-Lag2 (DSL) family of trans-membrane proteins. Mammals have four 
ligands which activate the notch receptors (JAG1, JAG2, DLL1 and DLL4). They too have 
variable numbers of EGF repeats, but also the JAG1 and JAG2 have a cystine-rich domain 
(CD).  
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Figure 5.1 The Structure of Notch Ligands and Receptors 
Mammals express five notch ligands – Jagged 1 & 2, Delta-like (DLL) 1, 3, 4. Mammals have four notch receptors, notch 1-4 which consist of 
trans-membrane subunits (NTM) and extracellular (NEC). The NTM is comprised of a RAM domain, ankyrin repeats and a C-terminal PEST 
domain.The NEC consists of a LIN12/Notch repeat (LNR) and 29-34 EGF repeats. Additionally, the ligands have an N-terminal DSL domain and 
variable number of epidermal growth factor (EGF) repeats. Jagged 1 & 2 serrate ligands also have a cystine rich domain (CR). 
 
NTM NEC 
Figure 1.3 
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1.1.1 Canonical Pathway 
Notch signalling is normally initiated by ligands expressed on neighbouring cells however 
ligands can also be secreted to activate the notch signalling pathway (figure 5.2, for review 
see (Kopan and Ilagan 2009). Following notch activation, two successive protolytic cleavages 
follow. The first is mediated by a metalloprotease of the ADAM family – tumour necrosis 
factor-α- converting enzyme (TACE), which cleaves the receptor in the extracellular domain, 
close to the NTM domain. The released extracellular domain is then transendocytosed by the 
ligand. This then exposes the next cleavage site, which is mediated by γ-secretase, which is a 
multi-protein complex consisting of presenilin, nicastrin, APH1 and PEN2. Following this final 
cleavage the intracellular domain is free to translocate to the nucleus where it binds to its 
downstream transcription factor, the DNA-binding factor RBPJ (also known as CSL) and co-
activators of the mastermind-like (MAML) family to create a CSL/ICN/MAML transcription 
complex. The best characterised targets of this transcription complex activation are the 
members of the HES and HERP families of bHLH transcriptional repressors (Iso et al 2003).  
However, a number of other direct targets have been identified which depend on cellular 
context. Genetic studies suggest that most notch signalling is via this canonical pathway 
with transactivation of target genes by the CSL/ICN/MAML transcription complex. However 
recent studies suggest that notch can also function independently of ligand transcription, 
through post-translational activation of other pathways (for review see Andersson et al 
2012). However, depending on dose and cellular context notch signalling can induce a 
number of cell fate decisions where a number of roles for notch and cancer have emerged 
(Dotto et al 2008, South et al 2012). The significant involvement of notch signalling in cancer 
is exemplified by the sequencing of tumours which has revealed a number of somatic 
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mutations in notch receptor genes (Agrawal, Frederick et al. 1154; Aster, Blacklow et al. 
2011; Wang, Sanborn et al. 2011). 
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Figure 1.4 Canonical Notch Pathway 
Notch signalling is initiated by a ligand on a neighbouring cell which on binding to the receptor induces a proteolytic cascade. The following 
first cleavage S2 is by ADAM 10 or ADAM-17 metalloproteinase at a site external to the transmembrane domain. The second cleavage S3 is by 
a gamma secretase complex which allows the release of the intracellular domain of notch (ICN). This ICN then is translocated to the nucleus 
where allosteric changes may occur in CSL that facilitate displacement of transcriptional repressors. The transcriptional co-activator 
Mastermind (Mam) then recognises the ICN/CSL complex and recruits co-activators to activate transcription. 
ICN 
ICN 
Receptor 
Gamma secretase 
ADAM 17 
Figure 1.4 
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1.1.2 The Dermis 
The dermis resides directly beneath the epidermis and is divided into two layers the 
papillary and the reticular layer. The thin upper layer is the papillary dermis composed of 
elastin and collagen fibres, which lies immediately below and interdigitates with the 
epidermis above. Anchoring fibrils, composed largely of type VII collagen are responsible for 
attaching the dermis to the basement membrane (McGrath 2004). In contrast, the reticular 
dermis is characterised by denser and coarser interwoven collagen and elastin fibres to give 
this region added strength and elasticity. Both of these regions contain blood and lymph 
vessels, nerves but also dermal proteins such as collagen and elastin, which are secreted by 
fibroblast cells. Fibroblasts are important for creating the extracellular matrix, which provide 
a structural framework (stroma) giving the skin important anatomical and structural 
function. Indeed, both layers contain different sub-populations of dermal fibroblasts which 
interact with the epidermis and play an important role in cutaneous wound healing and skin 
bioengineering (Sorrell and Caplan 2004). Below the dermis is a layer of fat which helps the 
body to retain heat. 
1.2 MALIGNANT CHANGES IN THE EPIDERMIS 
The epidermis constantly exposed to various insults, such as ultraviolet (UV) radiation and 
those mechanical and chemical, often incurs a number of physiological and genetic changes. 
Hence a number of neoplasms originate from the cutaneous epithelial cells (Owens and 
Watt 2003). Growths can destroy the organisation of the epidermal and dermal layers, 
forming a distinctive mass. The most common cutaneous neoplasm is basal cell carcinoma 
(BCC) followed by cutaneous squamous cell carcinoma (cSCC) and the melanocytic 
malignancy, malignant melanoma (MM). The focus of this thesis is cSCC which usually 
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present as a nodular keratinising tumour or as an ulcer, with little evidence of keratinisation. 
cSCC diagnosis is established histologically in terms of histopathological subtype, degree of 
differentiation, tumour depth, level of dermal invasion and the presence of vascular or 
lymphatic invasion (Motley, Preston et al. 2009). A histological image of a well differentiated 
cSCC can be found in figure 1.3, which shows how invading keratinocytes from the 
epidermis to the dermis can alter the organisation of the skin. 
 
 
Figure 1.3 Hematoxylin and Eosin (H&E) Staining of cSCC 
The “yellow line” representing the basement membrane is divided by keratinocytes invading 
into the dermis bellow, as indicated by the arrow. The division between the epidermis and 
dermis is not as clear as in the normal human skin H&E represented in figure 1.1 Image 
taken at 40x magnification. 
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1.2.1 Cutaneous Squamous Cell Carcinoma (cSCC) 
cSCC and BCC cancers come under the collective term: non-melanoma skin cancers (NMSC) 
with cSCC accounting for 20% of all cases (Kwa, Campana et al. 1992; Alam and Ratner 
2001). Over 99,000 non-melanoma skin cancers (NMSC) were registered in the UK in 2010, 
the incidence of which has been rising at an alarming rate over the past two decades. 
Tayside in Scotland, for instance, has seen a 4-fold increase in all skin cancers in the last 20 
years and in 2011 2,982 cSCC were registered in Scotland (ISD Scotland 2011). Additionally, 
this figure is expected to be underestimated due to the recording of NMSC cases being 
incomplete.  
 
In addition to the normal population, high risk groups exist. For example the risk of cSCC is 
increased 100 fold in transplant patients due to immunosuppression during treatment (Penn 
and Starzl 1972; Jensen, Hansen et al. 1999 Seckin, Barete et al. 2013). Additionally, our lab 
has a longstanding interest in a particular subtype of the genetic skin blistering disease 
epidermolysis bullosa (EB) - recessive dystrophic epidermolysis bullosa (RDEB). EB is a rare 
skin fragility disorder, characterised by chronic blistering of the skin mucosae following 
minor mechanical trauma. Its incidence in America has been documented as 19.6 per million 
live births from 1986-1999, with a prevalence of 8.22 per million population (Fine 1999).  
1.2.1.1 Epidermolysis Bullosa 
EB can be classified into 4 main groups based on the ultra-structural level of blister 
formation in the basement membrane zone. The 4 main groups are: EB simplex (EBS), 
junctional EB (JEB), dystrophic EB (DEB) and kindler syndrome. DEB can be referred to as 
“dominant” or “recessive” as the disorder can be inherited in an autosomal dominant 
(DDEB) or autosomal recessive (RDEB) manner, respectively and can be grouped into 
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localised or generalized subtypes based on the extent of blistering. RDEB skin is much more 
fragile than DDEB skin (Eady, Fine et al. 2004) and includes the most severe subtype, severe 
generalised (sev-gen) which can lead to disfiguring blistering. The RDEB sev-gen subtype is 
of particular interest in our lab not only due to it severity, but also as these patients suffer 
cSCCs as a major complication of the disease (Fine, Johnson et al. 2009). The cumulative risk 
of developing cSCC in patients with RDEB sev-gen stands at more than 90% by the age of 50 
(Fine, Johnson et al. 2009). This remarkably high incidence of cSCC compared to the normal 
population, suggests that there are likely to be differences in pathogenesis of the disease.  
Paradoxically, although most cSCC in RDEB patients are histologically differentiated 
(McGrath, Eady et al. 2004), they are biologically aggressive with the propensity to recur and 
metastasise to different sites. RDEB patients develop multiple cSCCs 3-3.5 per patient 
despite excision. This is a devastating disease. Moreover, RDEB patients have a 90% life time 
risk of developing metastatic cSCC which is main cause of death in this group (Fine, Johnson 
et al. 2009). 
1.2.1.2 Metastatic Potential and Recurrence 
Despite BCCs forming the majority of NMSC (80% of all NMSC), BCC rarely metastasise 
whereas cSCC can. In the normal population, cSCC tumours with high metastatic risk include 
those that are greater than 2cm, poorly differentiated tumour grade and invasive tumours 
infiltrating beyond the dermis (Kwa, Campana et al. 1992; Rowe, Carroll et al. 1992). Of 
particular note, is the tumour grade, which is a broad description of a tumour, in which 
tumour differentiation is an important feature. For instance, low grade tumours can be 
defined as showing substantial cellular differentiation, uniform cell size, infrequent cellular 
mitoses and infrequent nuclear irregularity. Intact intercellular bridges are also present. 
However, high-grade tumours are described as showing poor differentiation, frequent 
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spindle cell characteristics, necrosis and high mitotic activity. In general a well differentiated 
tumour indicates a better prognosis; poorly differentiated tumours have more than double 
the recurrence rate and triple the metastatic rate of a better differentiated cSCC (Gleason 
and Mellinger 1974; Motley, Preston et al. 2009). 5 year recurrence rate of primary 
cutaneous lesions is 8%, and the 5 year metastatic rate is 5%, however regional metastasis 
to lymph nodes and distant organs leads to a poor survival rate; 5 year survival in this group 
is 25%- 50% (Rowe, Carroll et al. 1992; Veness, Porceddu et al. 2007). This poor outcome is 
amplified by the propensity of biologically aggressive cSCC to recur, making disease control 
difficult. Furthermore, metastasis is the most common cause of death in cancer patients and 
currently there is no effective treatment for metastatic disease. 
1.2.2 Treatment of cSCC 
Protection from sun exposure is paramount to the prevention of cSCC. Secondary to this, 
early detection currently provides the best prognosis. The American Academy of 
Dermatology and the American Cancer Society have recommended yearly total body 
examinations for all patients over 40 (Jerant, Johnson et al. 2000). However, implementing a 
screening program consisting of community and general practitioner education, in addition 
to, screen clinics for the general population would place a significant burden on health care 
resources in the UK. For this reason it is advised that self-checking of the skin for any 
suspicious lesions is carried out regularly. The main treatment available for cSCC is wide 
local surgical excision which can be followed by dissection of regional lymph nodes and 
adjuvant radiation therapy (Clayman, Lee et al. 2005). Electrodessication, curettage excision 
or cryosurgery can eradicate low risk tumours in a cost effective manor (Martinez and Otley 
2001) however, if there is a risk of recurrence and metastasis then Mohs surgery or surgical 
excision provide the best prognosis at a greater cost (Motley, Preston et al. 2009). 
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Additionally, current treatment for metastatic disease includes both systemic (i.e. high 
doses of chemotherapy), local therapy (i.e. radiation) or a combination of both however the 
efficacy of such treatments is limited and there is much need for more effective treatments. 
1.2.3 Risk Factors for cSCC 
Below is detailed some of the major risk factors in the causation of cSCC. 
1.2.3.1 Sun Exposure 
Chronic sun exposure is the major risk factor for the development of cSCC. Epidemiological 
and molecular data strongly suggest that UV radiation is the principal carcinogen implicated 
in NMSCs (Dazard, Gal et al. 2003). Additionally, the incidence doubles with each 8-10 
degree decrement in geographic latitude and is highest at the equator which receives the 
highest intensity of sunlight. The ultraviolet B (UVB, 290-315nm) portion of UV from the 
sunlight is principally responsible for DNA damage. Furthermore, UVB is highly 
immunosuppressive, a key process in malignant transformation (de Gruijl, Longstreth et al. 
2003). However, mounting evidence suggests that ultraviolet A (UVA, 315-400nm) adds to 
the risk (LeVee, Oberhelman et al. 1997; Moyal and Fourtanier 2001). UVA penetrates 
deeper into the skin and is 20 times more abundant than UVB, which only comprises ~5% of 
the total UV radiation that reaches the earth. In addition to environmental radiation, 
exposure to therapeutic radiation such as psoralen and UVA (PUVA), which is used to treat 
skin disorders, can cause up to a 6 fold increase in cSCC (Chuang, Heinrich et al. 1992). Use 
of tanning devices such as sun beds which emit UV radiation (mainly UVA) are also 
associated with increased risk of cSCC, with odds ratios of 2.5 (95% confidence interval [CI] 
=1.7 -3.8) (Karagas, Stannard et al. 2002). 
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Lifestyle changes and the increase of “package holidays” have boosted voluntary exposure 
to sun-light. Those individuals which have fair-skin have the highest risk of developing skin 
cancer and a history of sunburn during childhood may be a very important risk factor in the 
development of cSCC (Suchniak, Baer et al. 1997). Although UV radiation is thought to be 
the main risk factor for the development of skin cancer, there are a large number of other 
risk factors, some of which are detailed below. 
1.2.3.2 Inherited Skin Disorders Associated with cSCC Predisposition 
Genetic predisposition to cancer is generally through inherited mutations in tumour 
suppressor or tumour promoting genes which are important for normal cell function. One of 
the most prominent examples where patients are genetically predisposed to the 
development of cSCC is Xeroderma Pigmentosum (XP). This genetic disease is characterised 
by an extreme sensitivity to UV, and development of lesions at a very young age. UV can 
cause UV-signature mutations such as cyclobutane pyrimidine dimers (CPD) or 6-4 
photoproducts (6-4PP). DNA integrity and stability are essential, so our body has evolved a 
number of DNA damage detection and repair mechanisms. Failure to repair mutations may 
result in tumour formation. People with XP have mutations in the genes involved in 
nucleotide excision repair (NER) resulting in some cells being unable to repair DNA damage, 
namely CPDs and 6-4PP. Subsequently, they also have a 2000 fold increased risk of 
developing skin cancers and these tumours have a high frequency of UV signatures found in 
the tumour suppressor, tumour protein 53 – (TP53) gene (Benhamou and Sarasin 2000). 
70% of XP patients develop malignant skin lesions and 50% of these are NMSC (Kraemer, 
Lee et al. 1994). Interestingly, the incidence of metastasis in this group is comparable to that 
of the normal population which is around 4% (Kraemer, Lee et al. 1987). XP is a rare 
disorder; it is estimated to affect 1 in 1 million people across America and Europe. 
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In addition to XP, there are a number of other inherited syndromes associated with the 
predisposition of cSCC these include: multiple self-healing squamous epitheliomata, 
Albinism, EB, Epidermodysplasia verruciformis (EV), Fanconi anaemia, Dyskeratosis 
congenita, Rothmund-Thomson syndrome, Bloom syndrome and Werner syndrome (for 
review see Ng et al 2011). In particular mutations in specific DNA repair genes increase error 
prone DNA replication and repair in keratinocytes which contributes to the increase in cSCC 
formation. For instance, Blooms syndrome is caused by a mutation in the BLM gene which is 
a member of DNA helicase family associated with DNA repair and Fanconi Anaemia is 
characterised by an increase in the number of chromosome breaks of which 13 genes have 
been associated with the inheritance of this disease so far.   
1.2.3.3 Precursor Lesions and Pre-invasive Skin Conditions 
Actinic keratoses (AK) are focal areas of epithelial dysplasia, which can occasionally precede 
cSCC (Lanssens and Ongenae 2011). They are also known as “solar keratosis”, found 
prominently on sun-exposed parts of the body, in response to excessive sun exposure over 
many years (Schwartz 1997). TP53 mutations are commonly found in AKs; one study found it 
to be around 70-80% of white patients affected with AK (Park, Lee et al. 1996). In severe 
combined immunodeficient (SCID) mice, UVB irradiation induced AK (Nomura, Nakajima et 
al. 1997). However studies show that only 1-10% of AK develop into cSCC (Marks, Foley et 
al. 1986; Dodson, DeSpain et al. 1991). Other pre-malignant lesions include Kerato-
acantoma and Bowen disease (Lanssens and Ongenae 2011). 
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1.2.3.4 Immunosupression 
As mentioned above UVB and to a lesser extent UVA can induce immunosuppression 
causing multiple effects including: DNA damage, cytokine production and alteration of 
langerhans’ cell function. Immunosuppression has also been shown to contribute to the 
formation of cSCC. Studies have shown that there is a 65-250 fold increase in the risk of 
developing cSCC amongst solid-organ transplant patients (Penn and Starzl 1972; Jensen, 
Hansen et al. 1999). These patients are given immunosuppressive drugs to reduce the 
chances of allograft rejection however, this also increases their risk of developing cSCC at a 
younger age and developing lesions that are more biologically aggressive with increased risk 
of recurrence and metastasis compared to the normal population (Glover, Niranjan et al. 
1994; Kaplan and Cook 2005).  
 
This increased risk has been associated with the dose of immunosuppression and UV 
exposure. For instance, heart transplant patients which receive the highest doses of 
immunosuppression, have a 2.9 fold increased risk than kidney transplant patients (Jensen, 
Hansen et al. 1999). This risk also seems to be higher in regions closest to the equator. This 
is illustrated by Australian kidney transplant patients, which have a 4 fold increased risk of 
developing cSCC than Dutch transplant patients (Bouwes Bavinck, Euvrard et al. 2007).  
1.2.3.5 HPV 
Human papilloma virus (HPV) infection has been linked to a small number of skin cancers. 
Although this link is controversial, one particularly large study analysed the occurrence of 
HPV in 2,366 patients either with cSCC, BCC or healthy controls. Positivity to at least one β 
HPV type was associated with an overall odds ratio of 1.3 for cSCC (95% CI 1.04 to 1.61) 
(Karagas MR et al 2010).HPVs are circular double stranded DNA viruses of which over 100 
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serotypes exist. The E6 and E7 oncoprotiens can inhibit the human tumour suppressors 
TP53 and pRb respectively, which is the main cause of carcinogenesis caused by HPV 
infection (Connolly, Manders et al. 2013). The infection can cause warts, laryngeal 
papillomas and cancers of the genital and anal areas. Additionally, the inherited disorder EV 
is characterised by the development of cSCC and these patients have an abnormal 
susceptibility to widespread HPV infection (Masini, Fuchs et al. 2003). 
1.2.3.6 Inflammation and Erythema 
Although immunosuppression is considered to be a risk factor for cSCC, inflammation is also 
paradoxically involved in cSCC establishment. Both UVA and UVB rays can cause 
inflammation and erythema, DNA damage and gene mutations which are capable of 
initiating skin cancer. Inflammatory substances play a number of roles in initiation, 
promotion and progression of a tumour. UV light, in particular UVA, has been demonstrated 
to increase inflammatory infiltrates which enhances tumour growth. Production of sub-
lethal levels of reactive oxygen species and nitric oxide can drive cancer development 
through induction of DNA damage (Sluyter and Halliday 2001; Fortina, Piaserico et al. 2004). 
These molecules can further stimulate cancer by increasing cell proliferation which assists 
tumour establishment (Wiseman and Halliwell 1996; Lonkar and Dedon 1999). 
 
1.3 KNOWN MOLECULAR MECHANISMS OF cSCC  
Over the last 30 years cancer has been revealed to be a disease involving dynamic changes 
in genetics. The general perception is that cancer develops via a multistep process. In a 
seminal review, Hanahan and Weinberg discuss how tumorigenesis requires fundamental 
events to occur, in order to drive transformation of normal human cells into a highly 
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malignant population. In their original review (Hanahan and Weinberg 2000) six hallmarks 
were hypothesised: (I) evading apoptosis (II) self-sufficiency in growth signals (III) 
insensitivity to antigrowth signals (IV) sustained angiogenesis (V) limitless replicative 
potential (VI) tissue invasion and metastasis. In a follow up review, “re-programming of 
energy metabolism” and “evading immune destruction” were added to the hallmarks of 
cancer, in addition to the contribution of “enabling” characteristics such as underlying 
genetic instability. They also highlight that tumours are complex tissues in which malignant 
cells are supported by a tumour microenvironment and that our understanding of this 
support network, is critical to the understanding of the pathogenesis and the development 
of effective therapies (Hanahan and Weinberg 2011). The tumour microenvironment 
includes a number of other cells such as blood vessels, immune cells and fibroblasts, in 
addition to a number of extracellular matrix signals. Work in our lab, has shown that the 
tumour microenvironment is a key driver of aggressive cSCC in patients with RDEB (Ng, 
Pourreyron et al. 2012).  
 
Yet, the key molecular events or “driver mutations” in cSCC initiation and progression are 
poorly defined and are likely to include “signature” changes to both tumour suppressors and 
oncogenes which control a number of critical cellular hallmarks.  
1.3.1 Common Dysfunctional Genes Associated with cSCC Formation 
Over the last decade there has been a major effort to understand the molecular 
pathogenesis of cSCC neoplasms, in the hope of providing new opportunities for molecular 
based therapeutics. A number of key signalling pathways have been identified to be 
involved in cSCC.  These include genes that act as oncogenes or tumour suppressors, where 
their gain-of-function or loss-of-function contributes to the formation of a number of 
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different tumour types. A select few common dysfunctional genes associated with cSCC 
formation are noted below which are part of key signalling pathways involved in 
maintaining cellular order, these are summarised in figure 1.4. On their discovery, it was 
thought that they would be potential molecular targets for cSCC. However current evidence 
has yet to clinically prove them as targets for cSCC, which exemplifies the need to continue 
the search for novel molecular targets. 
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Figure 1.4 Key Signalling Pathways in cSCC 
Mutations induced by UV radiation and environmental stress can perturb multiple cellular 
pathways leading to the contribution of cSCC. Arrows indicate positive relationships 
whereas T-bars indicate inhibitory relationships. Molecules/pathways that are underlined 
form subtitled discussions within the text (for review see Ridky and Khavari 2004 or 
Ratushney et al 2012). 
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1.3.1.1 Tumour Protein 53 (TP53) 
The tumour protein 53 (TP53), is a tumour suppressor which responds to a remarkably large 
number of DNA damage stresses including hypoxia, heat shock and nutritional. It 
orchestrates a number of anti-proliferative effector functions, namely; cellular senescence, 
autophagy, apoptosis and acting at cell cycle checkpoints, which contribute to its tumour 
suppressor activity. Dubbed as the “guardian of the genome”, it results in prevention of 
genomic instability and protection of tumourogenesis (Lane 1992; Vogelstein, Lane et al. 
2000). The contribution of p53 to cancer in general, has been exemplified by a number of 
observations including families with Li-Fraumeni cancer syndrome, whom are predisposed 
to the development of cancer - ~60% of these patients have mutations in the TP53 gene 
(Malkin 1994). Knockout TP53 mice which develop tumours at a very young age 
(Donehower, Harvey et al. 1992; Lozano 2010) and 50% of all cancers are shown to contain 
TP53 mutations in both alleles or exhibit loss of heterozygosity (Olivier, Hollstein et al. 2010; 
Robles and Harris 2010). Additionally in skin, TP53 has been shown to be mutated at a 
slightly higher frequency ~60% (South unpublished; Brash 2006) and is the most 
prominently studied aberration in skin cancer. Of note, TP53 is activated in response to UV 
DNA damage; hence it protects the skin by maintaining its genetic integrity (Smith and 
Fornace 1997).  
 
Although there is a vast amount of data which implicate TP53 mutations in the development 
of cSCC, its involvement in the pathogenesis of the disease is still not clearly understood. For 
instance TP53 knockout mice display resistance to the development of cSCC through the 
expression of oncogenes such as v-ras or TGFα in a multistage carcinogenesis model, yet 
these mice develop cSCC following UV exposure (Greenhalgh, Wang et al. 1996; Jiang, 
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Ananthaswamy et al. 1999). Additionally, loss of TP53 failed to act as a classical initiator for 
12-O-Tetradecanoylphorbol-13-Acetate (TPA) promotion (Greenhalgh, Wang et al. 1995; 
Greenhalgh, Wang et al. 1996). These data would suggest that a compensatory mechanism 
for TP53 loss maybe occurring. Functionally, TP53 is complicated by another two related 
orthologs of TP53 which have been described to be important for developmental function, 
TP73 (CNS development, Celli et al 1999) and TP63 (epithelial formation, Yang et al 1999), 
increasing evidence suggests their involvement in cancer (Tan 1001, Yam 2000, 
Ahomadeghe 2000, Dong 2002). In addition to this, a large number of different functional 
splice forms of p53, p63 and p73 are under study (Khoury and Bourdon 2010) and chemical 
modifications resulting from stress signals can also alter their functions (Meek and Anderson 
2009). 
 
A number of studies have been conducted in attempt to “restore” wild-type TP53 function. 
The role of TP53 inducing apoptosis post chemotherapy drug treatments has been 
demonstrated (Lowe and Ruley 1993). Additionally, studies have tried to stabilise TP53 
protein levels either with an mouse double minute 2 homologue (MDM2) antagonist, to 
increase genotoxic stress (Ohnstad, Paulsen et al. 2011) or ‘stapled’ TP53 based peptides 
that prevent antagonist inhibition (Bernal, Wade et al. 2010) However, although 
preservation of TP53 function is an attractive possibility for cancer therapy, mutation of 
TP53 renders cancer cells more resistant to TP53 cancer therapies, due to lack of TP53 
mediated apoptosis making targeted therapy difficult. 
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1.3.1.2 MAPK Pathway 
Mitogen-activated protein kinase (MAPK) pathway regulates a diverse set of processes and 
its activation is frequently found in cSCC, at both mRNA and protein level (Einspahr, Calvert 
et al. 1158; Dajee, Lazarov et al. 2003; Zhang, Shen et al. 2007; Hameetman, Commandeur 
et al. 2013). A number of families of MAPKs have been defined in mammalian cells 
including, extracellular signal-regulated kinases 1 & 2 (ERK 1, ERK2), Jun N-terminal kinases, 
p38 kinase isozymes, ERK3/ERK4 and ERK5. The ERK pathways are the most studied of the 
mammalian MAPK pathways and a complete pathway from receptor to MAPK has been 
defined for the ERK1 and ERK2 kinases, which act downstream of the RAS proto-
oncoprotein. Activation of the pathway begins with ligands such as hormones or growth 
factors, which act by binding to the cell-surface receptor tyrosine kinases or G-coupled 
receptors, leading to activation of ras. Ras-GTP then triggers activation of raf to the plasma 
membrane followed by phosphorylation of MEK1/2 and ERK1, ERK2. Activation can lead to 
proliferation or differentiation depending on the strength and timing of the signal (Scholl, 
Dumesic et al. 2004).  
 
In particular, ras an upstream component of the MAPK pathway has the potential to be an 
important oncogenic influence in cSCC. There are 3 RAS genes, Harvey sarcoma ras (H-ras), 
Kirsten sarcoma ras (K-ras) and human neuroblastoma ras (N-ras). Ras was first implicated in 
cSCC when it was discovered there were H-ras mutations in the papilloma’s of the mice 
treated with 7,12-dimethylbenz[a]anthracene (DMBA), in the chemical carcinogenesis 
model (Balmain, Ramsden et al. 1984). However, oncogenic ras alone is not sufficient to 
induce an invasive cSCC in human keratinocytes and it is necessary to co-express it with 
another oncogene to stimulate cSCC formation (Ridky and Khavari 2004). Khavari and 
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colleagues, have used ras in combination with cyclin dependant kinase 4 (CDK4) expression 
(Lazarov, Kubo et al. 2002) or with IκBα-inhibition of NF-κB (Dajee, Lazarov et al. 2003) to 
efficiently transform human keratinocytes into an invasive SCC.  
 
Variable levels of ras mutations have been found in cSCC and AK (Pierceall, Goldberg et al. 
1991). Data from COSMIC indicates 21% of cSCC have activating RAS mutations, which is 
fairly low (South unpublished; Bamford, Dawson et al. 2004). Disparity between the low 
frequency of ras mutations and frequent induction of the MAPK pathway suggests that ras 
may be activated due to upstream events or cross-talk between the PI3K-AKT-mTOR 
pathways (Ridky and Khavari 2004, Britten 2013). However, activated ras is not required for 
increased levels of GTP-bound ras which is observed in the majority of cSCC tumours (Dajee, 
Lazarov et al. 2003).  
 
A new dimension to the ras controversy has arisen from a striking finding; the use of 
selective RAF inhibitors induces a high frequency of KA and cSCC as well as warty 
papillomas, developing soon after onset of drug treatment in 25% of patients (Arnault, 
Wechsler et al. 2009). For instance, BRAF drugs that inhibit MEK/ERK signalling in cells that 
express oncogenic BRAF, paradoxically induced MEK/ERK signalling in cells that express 
oncogneic ras. Additionally, Ras inhibitors in the clinic have been largely disappointing 
(Beeram, Patnaik et al. 2003; Zhu, Hamilton et al. 2003). Although the reason is not entirely 
clear it is thought to be due to off target effects (Prendergast and Du 1999) or the drugs 
inability to distinguish from mutant and wild-type forms of ras.  
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1.3.1.3 Rb Pathway  
The retinoblastoma protein (pRb) pathway is a vital controller of the cell cycle. Virtually the 
entire process involved in the activation of DNA replication and the regulation of the G1/S 
transition is under the control of the pRb (Weinberg 1995). The Rb pathway consists of five 
families of proteins – cyclin dependant kinase inhibitors (CDKN), D-type cyclins, cyclin-
dependant protein kinases (cdk), Rb, and E2F. In this pathway the CDKN and Rb families of 
proteins functions as tumour suppressors and the D-cyclins, cdks and E2F promote cell 
proliferation.  
 
Elements of the Rb pathway are mutated in a wide variety of cancers including cSCC. 
Disruption of the pRb pathway leads to increased proliferation, rendering cells insensitive to 
anti-growth factors which block transition from G1 to S phase of the cell cycle. Disruption 
can occur in a variety of ways throughout this signalling pathway. For instance, cyclin-
dependant kinase inhibitor 2A (CDKN2A, p16ink4a ) inhibits progression of the G1 phase of 
the cell cycle by blocking cyclin-dependant kinase 4 (CDK4) from phosphorylating pRb 
(Brown et al 1999). Loss of this tumour suppressor results in dysregulated CDK4 and 
promotion of cell division. Furthermore, CDKN2A is located within the 9p22 chromosomal 
region. This region is the most frequently deleted in cancer – loss of heterozygosity as well 
as loss of parts or the entire short arm of chromosome 9 are frequently observed in cSCC 
(Quinn, Campbell et al. 1994). Additionally CDK4 is frequently over-expressed in cSCC which 
renders the kinase insensitive to CDKN2A inhibition (Lazarov, Kubo et al. 2002).  
 
The CDKN2A gene generates at least 2 alternatively spliced variants one of which acts to 
stabilise TP53 by inhibiting MDM2 mediated degradation; P14ARF and p16INK4a, a cyclin 
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dependant kinase inhibitor, which regulates pRb (Sherr 2001). Despite being on the same 
locus, it represents an independent complex signalling network which interconnects both Rb 
and TP53. Hence therapies targeting the pRb pathway, which prevent the assembly of 
cyclins with cdks using small molecules, represent a formidable challenge due to the 
extensive molecular mechanisms involved (Pauletich et al 1999). Cdk inhibitors may prove 
useful for some tumours, however because certain cdks play non-cell cycle roles, it is 
important that the inhibitors are specific so to reduce any unanticipated effects (Toogood 
2001). Alternatively a complementary approach, based on synthetic lethality may prove 
useful. For instance, cells that lack pRb manifest defects in E2F regulation are more sensitive 
than normal cells to cdk2 inhibitors (Chen et al 1999). 
 
1.3.1.4 NF-κB/Rel 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB/Rel) proteins play a 
key role in regulating immune response to infection; regulating pro-inflammatory and anti-
apoptotic genes. NF-κB is also clearly of great importance for skin homeostasis and is 
strongly linked to cancer. However the pathway is complex involving 5 subunits: RelA (p65), 
p50, p52, RelB and c-Rel which exist in un-stimulated cells as dimers bound to (nuclear 
factor kappa-light-chain-enhancer of activated B cells – inhibitor) IκB family of proteins. 
Binding to IκB prevents the complex from translocating to the nucleus. In the canonical 
pathway, stimulation leads to activation of the IκB kinase (IKK) complex, which in turn, 
phosphorylates IκB proteins to allow NF-κB to enter the nucleus and activate response 
pathways. The different subunits are not all involved in the same signalling pathways, the 
canonical pathway involves the p65/p50 subunits but other pathways, induced by different 
stimuli use other subunits in a highly context dependant manner. The canonical pathway of 
56 
 
IκB inhibitory proteins hold p65/NF-κB inactive until signalling pathways involving IKKs result 
in release of NF-κB to allow it to enter the nucleus (Dixit and Mak 2002). 
 
Consistent with a role for NF-κB in oncogenesis are observations that inhibition of NF-κB 
either alone or with cancer therapies, leads to tumour death or growth inhibition however 
paradoxically, blockade of NF-κB has been shown to promote an anti-proliferative effect 
which means NF-κB can either promote or oppose tumour development depending on 
context. Mouse studies show that inhibition of NF-κB increased the susceptibility to cSCC 
development (van Hogerlinden, Rozell et al. 1999). Additionally when IkB blockade was co-
expressed with oncogenic ras it can transform the human keratinocytes through increasing 
proliferation and creating an invasive neoplasm with features similar to that of cSCC (Dajee, 
Lazarov et al. 2003). This factor and the signalling pathways involved are an attractive target 
for cancer prevention and therapy however currently we lack in-vivo studies establishing the 
definitive role of NF-κB signalling in cSCC. In order to appropriately move NF-κB inhibitors in 
the clinic for other cancers, it is fundamental to determine the molecular mechanisms that 
dictate the complexity of oncologic and therapeutic outcomes that are controlled by NF-κB. 
1.4 TARGETED THERAPIES 
Our ability to perform genome-wide gene expression analysis offers opportunities not only 
to expand our current knowledge of the pathogenesis of cancer, but also to develop new 
therapies directed at specific molecules. Determining the gene expression of tumours and 
logically designing targeted anticancer drugs should increase treatment efficacy while 
decreasing toxicity. Although several mutations contribute to malignancy, not all need to be 
corrected to achieve significant therapeutic effects. Most attempts to treat cancers in model 
systems through replacement of single tumour suppressor genes or inhibition of individual 
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oncogenes have resulted in tumour killing or growth arrest. The success of a number of 
targeted drugs which have been approved for the treatment of specific types of cancer; 
transtuzumab (Herceptin, (Cobleigh, Vogel et al. 1999; Druker, Talpaz et al. 2001)) for HER-2 
amplified and BRCA- mutated breast cancer and vemurafenib (Zelborafk, (da Rocha Dias, 
Salmonson et al. 2013; Kudchadkar, Smalley et al. 2013)) for late stage melanoma patients 
with a BRAF V600E mutation has greatly encouraged the development of targeted 
therapies. While the appearance of drug resistance has slightly dampened our hopes, it 
underpins the need for combinational therapies to achieve sustained remission. 
 
This thesis describes follow up functional studies on data generated by Dr AP South’s lab 
using: gene expression profiling and next generation sequencing. These two methods will be 
further described in chapters 3 and 5 respectively. 
1.5 AIMS OF THE THESIS 
The aims of the thesis are generally to identify novel molecular targets for cSCC therapy. In 
order to address this, at the beginning of this thesis the three main areas of investigation 
were as follows: 
1. The gene expression profiling revealed 21 up-regulated potential molecular targets 
for cSCC which were screened using siRNA knockdown with cell viability as a readout 
(details in chapter 3, Watt et al. 2011). The first aim was to repeat this RNAi screen 
of the 21 genes with cytotoxicity as a readout. 
2. The RNAi screen identified five potential molecular targets which were capable of 
reducing cell viability in cSCC cell lines (which are detailed in chapter 3, Watt et al 
2011). The second aim was to further validate three of these targets, germ cell 
associated 2 (GSG2), bradykinin receptor B1 (BDKRB1), protease serine 21 (PRSS21).  
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3. In a separate project, next generation sequencing identified ~75% loss of function 
notch1 and notch2 mutations (of which are details in chapter 5, Wang et al 2011). 
The third aim was to further investigate the contribution of notch in cSCC.  
 
Additionally, this thesis aims to understand these potential molecular targets to the 
contribution and function in cSCC in hope of targeting these pathways for potential 
preventative and combative therapies for a currently untargeted disease. 
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 1. Chapter 2: General materials and methods 
2.1 CHEMICALS AND MATERIALS 
2.1.1 General Reagents 
100bp DNA ladder                                                                                                        Invitrogen, UK 
IKb DNA ladder                                                                                                             Invitrogen, UK 
Alkaline phosphatase (AP)                                                                                         Roche, Germany 
Calcium Chloride                                                                                 Fluka Biochemika, Switzerland 
EDTA-free protease inhibitor cocktail tablets                                                      Roche, Germany 
Electrophoresis grade agarose                                                                                   Invitrogen, UK 
Hepes                                                                                                                     Fisher Scientific, UK 
Isopropanol                                                                                                          Fisher Scientific, UK 
Rainbow marker                                                                                                    Invitrogen, UK 
RNase-free water                                                                                                          Invitrogen, UK 
Set of dNTPs                                                                                                                   Invitrogen, UK 
Sodium chloride                                                                                                   Fisher Scientific, UK 
Tris-Base                                                                                                                Fisher Scientific, UK 
Triton X-100                                                                                                          Fisher Scientific, UK 
 
2.1.2 Assay Kits 
Cell Titre 96 AQone One solution cell proliferation assay                                      Promega, USA 
ECL advance western blotting detection kit                                                          Amersham, UK 
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FastStart high fidelity PCR system                                                                                Roche, UK 
QIAquick gel extraction kit                                                                                  Qiagen, Germany 
QIAquick mini prep kit                                                                 Qiagen, Germany 
QIAquick maxi Prepkit                                                                                      Qiagen, Germany 
TOPO TA cloning kit                                                                                                Invitrogen, UK 
Wizard plus Minipreps DNA purification system                                                     Promega, UK 
 
All chemicals and cell culture reagents were purchased from Sigma-Aldrich Company Ltd. 
(Dorset, UK) unless otherwise described.  
2.2 GENERAL BUFFERS 
2.2.1 10x Phosphate Buffered Saline (PBS) 
For 1L, 80g sodium chloride (1.37mM), 2g potassium chloride (27mM), 14.4g 
NaH2HPO4(100mM), 2.4g KH2PO4 (18mM) were dissolved in 800ml of H20 and pH to 7.4 
before being made up to 1L. 
2.2.2 10x TBE 
For 1L, 104g Tris Base (1.1M) +55g Boric Acid (900mM) + 40ml 0.5M EDTA (25mM) were 
dissolved in 800mls of H2O and adjusted  to pH 8.3 before being made up to 1L. 
2.2.3 Tris Tween Buffer Solution (TTBS) 
For 1L, 6.05gTris/HCL (50mM), 8.76g sodium chloride (150mM), 1ml 0.1% (v/v) tween were 
dissolved in 800mls of H2O and adjusted to pH 8.0 before being made up to 1L. 
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2.2.4 Transfer Buffer 
14.4g glycine (192mM) + 3.03g Tris base (25mM) dissolved in 400ml dH2O then made up to 
800ml with dH2O and add 200ml methanol to give a final volume of 1L. 
2.2.5 RIPA Buffer 
For 100mls 875mg sodium chloride (150mM) + 1.0% Triton X-100 + 10µl sodium 
deoxycholate (5%) + 500µl sodium dodecyl sulphate (20%) + 5ml Tris (1M)  and filled with 
H2O to reach 100ml. 
2.2.6 Fixatives 
4% (w/v) paraformaldehyde (PFA, Sigma-Aldrich, Poole, UK) was made up in PBS. PFA 
powder was dissolved in water by stirring at 60°C and adding drops of NaOH until the 
solution had cleared. The 4% PFA solution was stored at 4°C until required. 
 
Methanol:acetone was made up as a 1:1 ratio of methanol (VWR, France) and acetone 
(VWR, France). 
2.3 TISSUE CULTURE 
2.3.1 Keratinocyte Isolation and Growth 
All human samples were collected after informed, written consent and in accordance with 
Helsinki guidelines. Primary keratinocytes were isolated from fresh tumour or normal (non-
malignant) skin samples and grown with a 3T3 layer, which had been mitotically inactivated 
(Rheinwald and Beckett 1981). 3T3 cells are a fibroblast cell line originally established from 
primary mouse embryonic fibroblast cells (Todaro and Green 1963). Primary keratinocyte 
isolation was performed by Karin Purdie from the Centre for Cutaneous Research Institute 
of Cell and Molecular science, Whitechapel, London, UK and Andrew South from the Centre 
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for Oncology and Molecular Medicine, Division of Medical Sciences, Ninewells Hospital and 
Medical School, University of Dundee, Dundee, UK. For the isolation and keratinocyte 
culture method, see Cancer Cell Culture: Methods and Protocols (Purdie, Pourreyron et al. 
2011). Briefly, tumour tissue was placed in transport medium (Dulbecco’s Modified Eagle’s 
Medium (DMEM), supplemented with 10% FBS, 1x penicillin/Streptomycin (peni/strep), 
100x 5,000 unit Penicillin/5,000 µg streptomycine/mL, GIBCO/Invitogen Ltd, Paisley) and 1x 
fungisone (100x, GIBCO/Invitrogen Ltd Paisley, UK) following excision and transported to the 
laboratory as quickly as possible. Transport medium can be used to store tissue at 4°C for up 
to 4-5 days; however cell viability reduces over time. Once in the lab, tumour tissue is 
washed in PBS before being “minced” into small fragments into a petri dish containing 1x 
EDTA/Trypsin (GIBCO/Invitrogen Ltd, Paisley, UK). The tumour fragments were then 
transferred to a tube containing trypsin and incubated at 37°C for an hour and shaken 
vigorously every 10 minutes throughout this period. Subsequently, an equal volume of 
(DMEM) with 10% foetal bovine serum (FBS, PAA laboratories Ltd, Somerset, UK) was added 
and the cells passed through a 100µm cell strainer. The cell suspension was then centrifuged 
at 500xg for 5 minutes and the recovered cells plated out into 100 mm dishes containing 
keratinocyte medium with a feeder layer of 3T3 cells before being incubated overnight at 
37°C in 5% CO2. Any undigested pieces of tumour were digested using collagenase D (Roche 
diagnostics, Burgess Hill, UK) in DMEM/10%FBS and left overnight at 37°C in 5% CO2. 24hs 
later this collagenase/tissue suspension was then passed through a 100µm cell strainer and 
plated out into 100 mm dishes containing keratinocyte media (table 2.1) and feeders and 
incubated overnight at 37°C in 5% CO2.‘Keratinocyte media’ containing 10% serum and 
growth factors has been previously described by Rheinwald and Beckett and was used as 
the culture medium used for most cells, unless otherwise stated. Primary keratinocytes are 
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usually observed after 48h post isolation. All cultures are established on a feeder layer of 
3T3 cells however tumour keratinocytes were then subsequently grown in the absence of a 
3T3 feeder layer, while normal human keratinocytes (NHK) depended on their presence. 
Table 2.2 shows a list of cSCC cell lines used within this thesis. 
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Product name Company Amount 
Dulbecco’s Modified Eagle Medium  Gibco Life Technologies Ltd, Paisley, UK 300ml 
Ham’s F-12 Nutrient Mixture Gibco Life Technologies Ltd, Paisley, UK 100ml 
Foetal Bovine Serum PAA, Summerset, UK 10% 
Cholera toxin AbDSerotec (Kidlington,UK) 8.4 ng/ml 
Epidermal Growth Factor (EGF) Sigma-Aldrich (Poole, UK) 5 µg/ml 
Hydrocortisone Sigma-Aldrich (Poole, UK) 0.4 µg/ml 
Insulin Sigma-Aldrich (Poole, UK) 5 µg/ml 
Transferrin Sigma-Aldrich (Poole, UK) 5 µg/ml 
3,3’,5-Triiodo-L-thyronine sodium salt Sigma-Aldrich (Poole, UK) 13 ng/ml 
 
Table 2.1: Composition of Keratinocyte Media 
This media was originally defined by Rheinwald and Green (Rheinwald and Green 1975) and 
adapted for culture of tumorigenic lines (Rheinwald and Beckett 1981). All the components 
listed were mixed together and stored at 4°C and used within a year.  
 
Additional cell lines include:  
Phoenix cells which are a retroviral packaging line based on a genetically engineered 293T 
cell line, (a human embryonic kidney line transformed with adenovirus E1a) which are highly 
transfectable and are capable of carrying episomes for long term stable production of 
retrovirus. Retroviruses are an efficient means to deliver DNA expression constructs to 
mammalian cells. These cells were maintained at 37°C, 5% humidified atmosphere with 5% 
CO2in media containing only DMEM with 10% FBS (Pear, Nolan et al. 1993).  
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K1 cells which are normal HPV immortalised keratinocytes. These cells were maintained in 
the same keratinocyte media as the cSCC cell lines. 
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Table 2.2: Patient Data from Cell Lines Used Within This Thesis 
Cell lines were isolated and established by either Karin Purdie from the Centre for Cutaneous Research Institute of Cell and Molecular science, 
Whitechapel, London, UK or Andrew South from the Centre for Oncology and Molecular Medicine, Division of Medical Sciences, Ninewells 
Hospital and Medical School, University of Dundee, Dundee, UK. IC; immunocompetant, REDB; Recessive Dystrophic Epidermolyosis Bullosa, T; 
transplant 
Cell line Patient Age  Sex Tumour 
location 
Histology Metastasis 
SCCIC1 Immuno-competent 77 M Right temple Mod differentiated Yes 
SCCIC8 Immuno-competent, on PUVA 51 F Buttock Poorly differentiated  
SCCIC12 Immuno-competent 87 F Left calf Moderately-poorly 
differentiated 
 
SCCIC15 Immuno-competent 73 M Penis Moderately differentiated   
SCCRDEB2 Col7A1 c.3832-1G>A 54 M  N/A Poorly differentiated No 
SCCRDEB4 Col7A1 c.8244incC/c.8244insC 32 F Left forearm Moderately differentiated  N/A 
SCCT1 Renal transplant 61 M Forearm Well differentiated No 
SCCT2 Renal transplant 66  M  Hand Well differentiated  
SCCT8 Renal transplant 67 M Ear Poorly differentiated  
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2.3.2 Cell Maintenance 
All cells were grown in an antibiotic free environment and incubated at 37°C with 5% 
CO2:95% air in a humid atmosphere. All cell culture procedures were conducted in a Class II 
laminar flow cabinet. Where possible, equipment was autoclaved before use. Cells were 
routinely split using trypsin (GIBCO/Invitrogen Ltd, Paisley, UK) or trypsin diluted in 
PBS/versine (GIBCO/Invitrogen Ltd, Paisley, UK) and then centrifuged to remove the trypsin, 
before being re-suspended in fresh keratinocyte media and passaged 1/5 or 1/10. If cells 
had a fibroblast contamination, as many fibroblasts as possible were removed using diluted 
trypsin prior to keratinocyte removal. If cells required counting for experimental purposes, 
cell number was determined by a CASY®ModelTT cell counter (Roche Diagnostics Ltd, 
Burgess Hill, UK). This cell counter utilises multiple channel technology to give highly 
accurate cell counts. When counting cells 100µl of cell suspension was placed into 900µl of 
CasyTon (Roche Diagnostics Ltd, Burgess Hill, UK). Measuring is performed by suspending 
cells in CasyTon which is an electrolyte solution. During the measuring process a pulsed 
voltage is applied to the measuring capillary (which contains multiple channels) via a 
platinum electrode. The electrolyte filled capillary represents a defined electrical resistance 
and during the passage of individual cells through the capillary, the volume is the amount of 
electrolyte solution displaced, which enables the number of cells/ml. Additionally 
information on viability can be assessed; Intact cells are considered to be insulators and an 
increased level of resistance is achieved. By contrast, dead cells whose membrane is 
permeable have reduced resistance. Hence cell viability can be assessed by membrane 
integrity. An output of viable cells/ml was used unless otherwise stated. 
The Casy has a good measuring range, >1:70000 in terms of volume and >1:40 in terms of 
diameter 
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2.3.3 Cryostorage of Cells 
Cells were re-suspended at a concentration of 1 million cells per ml in freezing medium 
which is FBS with 10% DMSO. The FBS was always obtained from the same batch, as batch 
to batch variations can affect cell culture. Additionally, a new batch is always checked for its 
suitability before use. Cells were then aliquoted into cryovials (Themo Scientific Nunc, NC, 
USA) into 1ml volumes before being transferred into freezing (CoolCell®, Biocision, CA, USA) 
containers and placed at -80°C. 24 hours later they were transferred into long term storage 
in liquid nitrogen.  
 
Thawing of cells from long term storage at -80°C, was carried out as possible under a hot 
running tap or a water-bath at 37°C for 1-2 minutes. Once thawed, the cells were 
transferred into 4mls of keratinocyte media before being centrifuged at 260g for 3 minutes. 
The media was then aspirated off and the cells re-suspended in fresh keratinocyte media 
without epidermal growth factor (EGF). The keratinocytes adhere to the culture plastic more 
efficiently in the absence of EGF, and were placed into a T25 flask following re-suspension.  
2.3.4 Cell Fixation 
Cells were seeded onto sterile glass cover-slips, of which there were 3 per well of a 6 well 
plate. Cells were then left to adhere overnight in an incubator at 37°C prior to fixation. To fix 
cells using methanol:acetone, first the media was removed and the cells washed in 1ml PBS. 
500µl of ice-cold methanol:acetone was added to each well and placed at -20°C for 20 
minutes. Methanol:acetone was then removed and cells washed 3x5 minutes with 1ml PBS. 
For fixation in PFA, the media was removed and cells washed, as above and cells incubated 
in 500mls PFA for 20 minutes at room temperature (RT). Fixed cells were then either used 
immediately or were stored at 4°C in PBS until required. 
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2.4 SIRNA TRANSFECTIONS 
Knockdown of target gene expression was achieved by transfecting cells with the top thee 
oligonuceotides as ranked by Sigma-Aldrich, Poole, UK. Knockdown was then optimised by 
firstly transfecting the oligonucleotides individually and as a pool of all three, to see which 
obtained the biggest knockdown of gene expression. Transfection was performed using 
lipofectamine 2000 (Invitrogen Ltd, Paisley, UK) according to the manufactures instructions. 
Briefly, cells were transfected at 90-95% confluency using 5µl lipofectamine diluted in 250µl 
of Opti-Mem I reduced serum medium (Opti-Mem, Invitrogen Ltd, Paisley, UK) and 
incubated for 5 minutes, whilst a total of 5µg DNA was diluted in 250µl of Opti-Mem and 
this too was incubated for 5 minutes. After 5 minutes both mixtures were combined and 
incubated at room temperature for 20 minutes. Then the combined mix was added to the 
cells drop-wise, and cells returned to the incubator overnight. The most important aspect of 
siRNA transfections is to maintain the correct ratio of siRNA:lipofectamine. siRNA 
transfection was carried out for either 24 or 48 hours and duration is indicated in the results 
section where appropriate. 
2.5 RNA/DNA MANIPULATIONS 
2.5.1 RNA Extractions – Isolation and Purification 
Cells were washed twice with ice cold PBS. In a fume hood, RNABee (Amsbio, Abingdon, UK) 
which contains phenol and guanidium thiocyanate, was added, to extract RNA. The phenol is 
water saturated and when used at a pH of 4.5, DNA is soluble in the phenol phase rather 
than the water phase, allowing the separation of the RNA from the DNA. Additionally, the 
guanidium thiocyanate in the RNAbee solution helps to lyse the cells and prevent the 
activity of RNAase enzymes denaturing the sample. Cells were scraped into the RNAbee 
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solution and the lysed cell suspension transferred to an ice-cold eppendorf. Chloroform was 
added in a 1:5 ratio to RNAbee, to the eppendorfs and the RNA samples were shaken 
vigorously for 30 seconds before being left for 15 minutes at 4°C. The samples were then 
subjected to centrifugal force (12,000g) for 15 minutes at 4°C. Centrifugation separates the 
sample into different phases; the lower blue phenol-chloroform phase (organic phase), 
interphase and the upper colourless aqueous phase. The RNA is exclusively in the aqueous 
phase and the DNA and proteins are in the interphase and organic phase. The aqueous 
phase is then transferred to a fresh tube and approximately the same volume of isopropanol 
is added to precipitate the RNA. At this stage the sample can be stored at -20°C until ready 
to complete the protocol. The sample is then placed in a centrifuge and spun (12,000g; 
5mins; 4°C) where RNA is formed as a white pellet at the bottom of the tube. The pellet was 
then washed with 70% ethanol and the tube flicked until the pellet detaches. Tubes were 
then centrifuged again for further 5 minutes. The ethanol was then removed and the pellet 
was allowed to air dry for 5 minutes. Finally, the pellet was re-suspended in 30-50µl of 
nuclease free water (H2O) or Tris/EDTA buffer (TE buffer, 10mM tris, 1mM EDTA) 
2.5.1.1 cDNA Synthesis 
The RNA was then used to generate cDNA which could be used for quantitative PCR 
analysis. 1µg template RNA was incubated with the Quantitect Reverse Transcription Kit 
(QIAGEN Ltd, West Sussex, UK), to synthesise cDNA and to remove any contaminating 
genomic DNA according to the manufacturer’s instructions. Briefly, the template RNA was 
diluted in DNAse free H20 to give a final concentration of 1µg in 12µl. Then 2µl of gDNA 
wipe-out buffer was added to give a total volume of 14µl. This was then mixed before 
incubating at 42° for 2 minutes. This reaction should clear any contaminating genomic DNA 
in the template RNA. This reaction was then combined with 1µl reverse transcriptase; 4µl 
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buffer and 1µl primer mix before incubating for 15 minutes at 42° to reverse transcribe the 
RNA into cDNA. The sample was then incubated at 95° to inactivate the reverse 
transcriptase. All reactions were prepared on ice. 
2.5.1.2 Spectrophotometry 
DNA and RNA were both quantified using the Nanodrop (Themo Scientific, Nanodrop 2000, 
NC, USA). Nucleotides such as RNA and DNA absorb at 260nm, which can be used to 
measure any molecules absorbing at that wavelength. The ratio of absorbance at 260nm 
and 280nm is used to assess the purity of the RNA or DNA within the sample. A ratio of ~2.0 
is generally accepted as “pure” for RNA whereas DNA has a lower ratio of ~1.8 due to the 
higher 260/280 ratio of Uracil compared to Thymine. DNAse free H2O or TE buffer was used 
as a blank to adjust for any background. TE buffer can be used as an alternative to solubilise 
RNA while the EDTA in the buffer protects the sample from degradation by nucleases.  
2.5.1.3 Primer Design 
Primers were manually designed and tested for gene expression unless otherwise stated. 
Primers are specific sequences designed to amplify a specific DNA sequence. All primers 
fulfilled the following parameter, in order to design the most efficient primer sets: 
1. The 3’ portion of each primer (about 15-20 bases) must be complementary to the 
DNA template. GC content, of around 20-80% range with 50% being the optimal was 
used to increase the stability of the primer. 
2. The 3’ portions of primers used in PCR should not be complementary to each other, 
because this facilitates the formation of primer-dimers. Additionally, long stretches 
(>4) of identical nucleotides were avoided.  
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3. Each primer pair was searched in BLASTN (Altschul, Madden et al. 1997) from the 
NCBI website (http://blast.ncbi.nlm.nih.gov/BLAST.cgi). This was to identify any 
homologous matches to ensure a single product was amplified.  
All primers were obtained from Eurofins MWG Operon (Ebersberg, Germany) and the 
primers reconstituted in DNAse free H20 to give a final concentration of 1nm/µl stock 
concentration according to the data sheet. This was then diluted 1 in 50 to give a 20pMol 
working solution. Recommended annealing temperatures were also included on the data 
sheet. However if insufficient amplification occurred, the annealing temperatures can be 
calculated manually using the following equation:  
69.3 + (0.41(GC%)) – 650/Oligo. Length 
2.5.1.4 Reverse Transcriptase PCR (RT-PCR) 
Reverse transcriptase Polymerase Chain Reaction (RT- PCR) is a variant of the polymerase 
chain reaction (PCR) which is used to quantitatively detect gene expression in sample cDNA. 
Generally it is used to check that the PCR primers were amplifying the correct product 
before quantitating the expression using quantitative PCR (described in section 2.5.1.6). RT-
PCR was carried out either in 25 – 50µl volumes. Each 25µl reaction contained all the 
components listed in the table below (table 2.3). 
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Product  Volume (µl) company 
10x PCR buffer 2.5 stratagene 
Forward primer 1 MWG  
Reverse primer 1 MWG 
Taq polymerase 0.25 stratagene 
cDNA 1.5 N/A 
dNTPs 0.5 Qiagen 
DNAse free H2O 18.25 Invitrogen 
Table 2.3 RT-PCR reaction mix 
All the products listed in the table were mixed together, forming the RT-PCR mix. 
 
When analysing a number of samples a master mix was made up before adding the cDNA. 
Standard cycling conditions were used which are indicated below, where the annealing 
temperature is defined by the primer set and extension time can vary depending on the 
length of amplicon (1Kb products require 1 minute extension) (figure 2.1).  
 
Figure 2.1: Standard PCR Cycling Times.  
2.5.1.5 Agarose Gel Electrophoresis 
PCR products were resolved on an agarose gel, were the percentage of agarose used in the 
gel depends on the size of product to be visualised (2% agarose gel for 0.1-1Kb fragments, 
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0.8-1% for 1-5Kb fragments). DNA fragments are resolved on the basis of size and charge. To 
begin, a 2% gel was dissolved in the microwave before adding Syber®safe DNA gel stain 
(Invitrogen 533102, 10µl/100mls) which allows the bands to be visualised using a UV light 
transilluminator (254nm). Syber®safe is a safer version of ethidium bromide – a DNA 
intercalating agent. The solution was allowed to cool slightly before pouring into a gel tray 
with combs and allowing it to set. Once the gel was solidified the PCR products were 
prepared with a 10x running buffer containing glycerol and bromophenol blue and 5-10µl of 
sample loaded into each well. The agarose gels were then run at ~100 Volts for 
approximately 40 minutes before being visualised using the Versadoc (BioRad Laboratories, 
Hertfordshire, UK).  
2.5.1.6 Quantitative PCR 
Quantitative PCR (qPCR) allows the user to amplify and simultaneously quantify a targeted  
DNA molecule. Subsequently the user can then calculate the gene expression relative to an 
additional housekeeping gene which is expressed at relatively constant levels in a cell. For 
quantitative measurement of mRNA SYBER Green Master Mix (QIAGEN, Hilden, Germany) 
was used. SYBER green is a nucleic acid gel stain which intercalates with double stranded 
DNA. PCR reactions were set up using the Automated PCR workstation QIAgility (QIAGEN, 
Hilden, Germany) and the Rotor-Gene Q (QIAGEN, Hilden, Germany) was used to detect 
fluorescence. The fluorescence is dependent on the amount of DNA.  The rotor-Gene Q 
detects the intensity of the florescence and Rotor-gene Q series software (version 1.7) was 
used to calculate cycle threshold (Ct) values from the intensity of the fluorescence by the 
ΔΔCT method (Livak and Schmittgen 2001).  
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Gene Primer sequence (‘5-‘3) Tm°C 
GSG2 F – ccagcctcaggtcagagttctc 
R - ctgtgcttgacagacctgga 
60.4 
BDKRB1 F – ctgaagtgcagtggcacaat 
R – ctctggttggaggattggag 
60.2 
PRSS21 F – accctccaggaagttaggt 
R - ataaggcacagggacacagg 
59.4 
PR_SAL1 F- ctcgtcgacgaattcggcaccaggccatg 
R – atggtcgacggctcaggttaggctccag 
65.2 
Maspin F – ggtggggattccatagaggt 
R- aatcggcatccacagaaaag 
57.35 
Table 2.4 A List of Primer Sequences Used Within This Thesis 
2.6 GENE SUB-CLONING 
Sub cloning is a basic procedure in molecular biology required to move inserts from one 
vector to another to gain the desired functionality of insert. For this project the PRSS21 
construct purchased from origene which was in a CMV vector, was removed and transferred 
into a pBABE vector which can be used for mammalian and retroviral expression. This 
enables PRSS21 to be stably expressed using retroviral transduction in a cell line rather than 
transiently expressed. Additionally, when expressed in a cell line with no endogenous 
PRSS21, over-expression can be used to explore the function of PRSS21 in this cell type. 
 
Purified plasma Human cDNA for PRSS21 (transcript variant 1) was obtained from Origene 
(Origene Technologies Inc, MD, USA). The PRSS21 cDNA purchased was inserted in the 
vector pCMV6-XL4. The plasmid cDNA was used to transformed E. Coli and grown on agar 
plates (section 2.5.1) before being inoculated (section 2.5.2) and purification of plasmid DNA 
(section 2.5.3 and 2.5.4), which are noted in the appropriate sections below. 
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2.6.1 Transformations of Escherichia Coli (E-coli) 
Electro-competent E-coli cells were transformed using electroporation. Electroporation is a 
method in which foreign DNA is introduced into host cells by applying a high voltage to 
increase the permeability of the cell membrane. Using this method 0.5µl of DNA was added 
to 20µl of Top10 electro-competent cells (Life Technologies/Invitrogen, Paisley, UK) in a 
2mm electroporation curvette (Peqlab, Hampshire, UK) and kept on ice. The curvette was 
then electroporated at 20V and curvettes were immediately placed on ice after 
electroporation and 750µl of Super Optimal Broth (S.O.C) medium added. S.O.C medium is a 
nutrient rich bacterial medium used for microbiological culture. The contents of the 
curvette were then transferred to a falcon tube and shook at 37°C for 45 minutes. The 
transformed E.coli was then spread onto agar plates containing 0.1mg/ml ampicillin. Plates 
were then incubated overnight.  
2.6.2 Inoculation of Colonies 
Colonies that had grown on the agar plates were inoculated by picking single colonies with a 
pipette tip and placing in 5mls of Lysogeny broth (LB) containing 0.1mg/ml ampicillin. 
Cultures were grown at 37°C overnight. Glycerol stocks were created when a new clone had 
been produced. A glycerol stock was made by adding 800µl of overnight culture to a 2ml 
cryovial before adding 200µl of 80% glycerol and mixed. The vial was then frozen and stored 
at -80°C for further use. 
2.6.3 Preparation of Plasmid DNA (5ml Plasmid Cultures) 
A Wizard® plus Miniprep DNA purification system (Promega, UK) was used to elute the DNA 
from the overnight culture.  5ml LB broth that had been growing at 37°C overnight was 
aliquoted into three eppendorfs and a centrifuge used at 10,000 xg for 5 minutes to pellet 
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the cells. The supernatant was then re-suspended, lysed and neutralised using three 
different solutions provided in the kit, with centrifugation steps in-between. The 
supernatant was then purified using a resin and passed through a mini-column which bound 
the DNA. The DNA was then washed using multiple steps to purify the DNA before elution of 
the DNA in 30µl nuclease-free water. The DNA was then quantified using the Nanodrop 
(section 2.5.1.2). 
2.6.4 Preparation of Plasmid DNA (100ml plasmid cultures) 
Preparations of cultures of 100ml were prepared using a Qiagen plasmid plus kit (QIAGEN, 
Hilden, Germany), according to manufactures instructions. Briefly, cells were harvested by 
centrifugal force at 6000xg for 15 minutes at 4°C. The pellets were then re-suspended, lysed 
and neutralised using solutions in the kit before being passed through a QIAcartriage and 
high speed maxi tip provided in the kit. The DNA, which is bound to the high speed tip is 
then washed multiple steps before finally eluting DNA from the maxi tip, of up to 1mg. 
2.6.5 Primer Design With Restriction Sites 
Following purification of PRSS21 plasmid the PRSS21 gene had to be amplified from the 
vector DNA by PCR. However as the parent vector for PRSS21 (CMV6-XL4) did not have 
compatible sites with the destination vector (pBABE); primers were designed to include 
restriction sites. The primers noted below included SAL1 restriction sites: 
PR_SAL1FWD: cgcgtcgcagcattcggcaccaggc (29) 
PR_SAL1REV: atggtcgacggctcaggttaggctccag (28) 
 
It must be noted that these restriction sites must not occur with the PRSS21 cDNA otherwise 
this will affect restriction digest. A RT-PCR was performed (see section 2.5.1.4) as before and 
products resolved on an agarose gel (2.5.1.5). 
78 
 
2.6.5.1 TOPO Cloning 
TOPO cloning is a technique in which DNA fragments can be cloned in to a TOPO vector 
(Invitrogen Ltd, Paisley, UK) without the requirement of DNA ligases but relies on the 
biological activity of DNA topoisomerase I. Topoisomerase in a biological setting acts to 
cleave and re-join super coiled DNA ends to facilitate replication. It is important that fresh 
PCR amplified PRSS21 product is used for a TOPO reaction. With added restriction sites, a 
TOPO® reaction was performed using a Taq polymerase that lacks proof reading activity. 
The following reaction was set up: 
1µ fresh PCR product 
1µ Salt solution (provided by the manufacture) 
5µ ddH2O 
1 Topo® vector (provided by the manufacture) 
The reaction was then incubated for 5 minutes at room temperature, and placed on ice 
following reaction incubation. The TOPO® cloning reaction was then used to transform E. 
Coli and grown on agar plates (section 2.5.1) before being inoculated (section 2.5.1) and 
purification of plasmid DNA (section 2.5.2). An RT-PCR was performed (section 2.5.1.4) and 
the products resolved on a gel (section 2.5.1.5) to determine if PRSS21 had been 
successfully inserted into the TOPO® vector. 
2.6.6 Restriction Enzyme Digestion 
To begin sub-cloning the PRSS21 insert had to be cut out of the TOPO® vector using 
common restriction enzyme sites to the pBABE destination vector, that are within their 
multiple cloning sites. Restriction enzyme digestion of PRSS21 TOPO® vector DNA was 
carried out in 3x 50µl volumes under the following conditions: 
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5µl plasmid DNA  
10µl restriction enzyme SAL1 
5µl restriction buffer 
5µl BSA (10x)  
35µl H2O 
 
In addition to the PRSS21 TOPO® DNA, pBABE empty vector DNA was also digested in the 
same manor. These reactions was then incubated at 37°C overnight before being run on a 
1% agarose gel using electrophoresis. A 1% agarose gel was made (Standard melting point, 
Invitrogen, 16500-500) with 10µl Syber® Safe DNA gel stain. 
2.6.6.1 Agrose Gel Purification of DNA 
After electrophoresis the agarose gel was placed on a UV transilluminator (254nm) to 
visualise the DNA and the desired bands were excised with a scalpel. Any extra gel was 
removed to minimise the gel slice. The slice was then transferred to a 1.5ml eppendorf and 
weighed at ~230mg. QIAquick gel extraction kit was used to extract and purify DNA from the 
gel.  
2.6.6.2 Agarose Digestion 
To the gel slice 230µl of Buffer QG (provided by the kit) was added to the gel slice and the 
slice incubated at 50°C on a heating block for 10 minutes until the gel had completely 
dissolved. During this time the eppendorf was vortexed every 2-3 minutes to help the gel to 
dissolve. At this point the colour of the mixture was yellow. Then 230µl of isopropanol was 
added to increase the yield of DNA. The sample was then placed in a QIAquick spin column 
in a provided 2 ml collection tube to bind the DNA to the QIAquick column for 1 minute. The 
flow through was then discarded and the tube placed back into the tube. The column was 
then washed with 0.75 ml PE buffer (provided by the kit) and subjected to centrifugal force 
for another minute. The flow through was then discarded and the QIAquick column 
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centrifuged for an additional 1 minute at 13,000 xg. The QIAquick column was then 
transferred into a clean 1.5ml microcentrifuge tube and to elute the DNA, 50µl of nuclease 
free water was added to the centre of the membrane, left to stand for 1 minute and the 
column centrifuged for a further 1 minute. 
2.6.6.3 Ligation of DNA Reaction 
DNA ligase facilitates the joining of DNA strands together allowing the joining of the PRSS21 
insert into the pBABE vector. A quick DNA ligase kit was used to perform the ligation 
reaction (Cat. M2200, New England Biolabs Inc., MA, USA). To begin, 50ng of the pBABE 
vector was combined with a 3-fold molar excess of the insert and the volume adjusted to 
10µl with dH2O. Then 10µl of 2x Quick Ligation Buffer was added along with 1µl of Quick T4 
DNA ligase and mixed thoroughly. The reaction was then centrifuged briefly before 
incubating at room temperature for 5 minutes. The reaction was then chilled on ice and 
used to transform E.coli (section 2.6.1), which were grown on agar plates, colonies chosen 
(section 2.6.2) and PRSS21 pBABE plasmid DNA prepared (section 2.6.3). Plasmid DNA was 
then sent for sequencing to identify if the PRSS21 insert had been inserted into pBABE 
construct and had been inserted in the correct orientation properly. 
2.6.7 Retroviral Transductions 
Using healthy phoenix cells that have been split once every 2-3 days and not left confluent 
for any length of time, phoenix cells were seeded at 3.5 x 106 in a T25 per each transfection. 
These were then left overnight in the incubator to adhere. The next day the media was 
changed on the phoenix cells to 2.5ml of pre-warmed normal media. These cells were then 
transfected with Lipofectamine 2000 according to manufactures instructions. In another 
tube 2.5µg of DNA was mixed with 250µl OPTIMEM which was also left for 5 minutes. After 
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5 minutes these two tubes were mixed together and incubated for 20 minutes at room 
temperature. Following this time 500µl of this mix was added to the media on the phoenix 
cells and mixed gently. This was then incubated overnight. The next day the phoenix cells 
were recovered by replacing the media with fresh media and incubating overnight. 24hs 
later the cells were split into a larger flask T150 and expanded. Once the transfected 
phoenix cells had reached confluency the media was changed on the phoenix cells to a small 
volume (i.e. for a T150, 32mls of media was used) of the target media (normally 
keratinocyte media). These cells were incubated at 32°C overnight. On the same day the 
target cells were seeded at 2 x 104 cells per well of a 6 well plate and grown overnight at 
37°C. The next day the conditioned media from the phoenix cells was collected and replaced 
with target media and returned to the incubator set at 32°C so that more virus could be 
collected. The conditioned media was filtered through a 0.45µm non-pyrogenic filter to 
remove phoenix cells. Polybrene was then added to this to prevent the viral particles from 
sticking to the plastic at a concentration of 8µg/ml. The media on the target cells was 
replaced with 2-3mls of filtered virus containing conditioned media. The cells were then 
spun in a centrifuge at 300g for 1 hour at 32°C. After this time the cells were immediately 
placed in the incubator at 32°C for another hour before replacing the media with fresh, pre-
warmed 37°C media and recovered overnight at 37°C. This infection cycle was then 
repeated 2 more times to increase transfection efficiency. Then 48 hours following the last 
infection the cells were selected using 2-10µg/ml puromycin for pBABE-puro. 
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2.7 3D ORGANOTYPIC CULTURES 
2.7.1.1 Collagen Matrigel Invasion Assay 
The night before beginning the procedure the Matrigel (VWR ref 734-1100) was placed on 
ice in the fridge to defrost overnight. Plastic clonal rings (Sigma, ref: C3858-50EA) were 
sterilised in 70% ethanol for at least 10 minutes before washing them in PBS and putting 
them into a 6 well plate. Then to seal the ring, 200µl of microwave sterile noble agar (0.5% 
in PBS, autoclaved) was poured around the base of the ring. Before starting the procedure, 
all the components required were placed on ice and the pipette, tips and a 50ml falcon tube 
was placed at 4°C. To begin the procedure NHF were trypsinised and re-suspended in DMEM 
with 10% FCS at 2x106 cells/ml. Then in an ice cold 50ml falcon tube the following 
components were added together: 3.5 volumes of collagen (Type 1 rat tail, VWR ref 734-
1097), 3.5 volumes of matrigel, 1 volume of 10x DMEM (invitrogen 21430-020). These were 
then mixed gently and the pH was adjusted by adding Sodium hydroxide (NaOH, 1M) until 
the mixture became orange/pink (usually after around 100µl of NaOH). Then 1 volume of 
FCS and if fibroblasts are to be added, 1 volume of fibroblasts were added to the mixture. 
This was then mixed well before adding 800µl of gel mixture per ring. The gels were then 
placed in the incubator for 30 minutes to polymerise, before very gently adding 400µl of 
pre-warmed fibroblast medium with peni/strept on the gel and 1 ml around the ring. The 
next day keratinocytes were trypsinised and re-suspended in keratinocyte medium with 
peni/strep at a concentration of 1x106 cells/ 700µl. The fibroblast medium was gently 
removed using a 1 ml pipette before adding 1 million keratinocytes onto each gel. 1ml of 
keratinocyte media with peni/strep was added around the ring and gels returned to the 
incubator overnight. The next day the ring was removed gently using a 200µl tip to detach 
the gel from the ring. A nylon disk, which had been previously sterilised in 70% ethanol, 
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washed in PBS and autoclaved, was placed under the gel and used to lift the gel onto a grid 
in a 6 well plate. Pre-warmed keratinocyte medium with peni/strep was added to reach 
underneath the gel – this was to lift the gel to provide an air/liquid interface (figure 2.2). The 
gels were then fixed a minimum of 7 days following lifting onto the grid. The gel on the 
nylon disk was transferred to 4% parafomaldyhyde in PBS to fix the gel for a minimum of 3 
hours (preferentially overnight) before being transferred to 70% ethanol. Once in ethanol 
the samples were then kept in ethanol for a few days or processed and embedded straight 
away. Before the sample was processed the section was cut in half and placed into a 
histology cassette before being processed by an automated tissue processor (Shandon, 
Citadell 1000, Thermo Scientific) which dehydrates, clears and infiltrates the sample in wax 
before manually embedding the sample in a wax block which can be clamped into a 
microtome and sections cut from the sample. When embedding the sample is carefully 
orientated in molten wax and a cassette is placed on top of the mould, topped up with more 
wax and the entirety on a cold plate to solidify. When the block is solidified with its attached 
cassette it can be removed from the mould and is ready to be cut using the microtome 
(leica, RM2235). 
2.7.1.1.1 Invasion Quantification 
Sections were cut using the microtome and stained using haematoxylin and eosin stain. The 
images were then taken using a standard light microscope. The images were first processed 
using colour deconvolution into an 8-bit image and analysed using Image Pro PLUS® 
software. The invasion index was calculated based on the total number of invading particles 
(excluding the surface epithelium) times the total area of the particles for each image. 
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Figure 2.2 Schematic Showing Collagen Matrigel Invasion Assay Principal 
A Schematic showing collagen matrigel system, in which a specialised collagen matrigel is 
used to represent the extracellular matrix (ECM). On day -1 ECM is mixed with fibroblasts and 
allowed to solidify in a ring before covering with media. The next day (day 0) keratinocytes are 
seeded onto the gel. Then day 1 is where the gel is raised above the liquid interface, allowing 
stratification of the keratinocytes. The collagen matrigel also facilitates invasion of 
keratinocytes into the gel due to its composition. Adapted from (Froeling, F.E. et al 2010). 
 
 
85 
 
2.7.1.2 Fibrin Gels 
A second 3D organotypic method was also used which involved mixing fibrinogen and 
thrombin together which coagulate to form a gel. The gels were made firstly by dissolving 
5.32ml NaCl (1.1% v/v) to 250mg fibrinogen (F3879, Sigma-Aldrich, Poole, UK). This solution 
was then agitated on a roller for 20 minutes at room temperature before being transferred 
into a 15ml falcon tube and placed on ice. Additionally a 5ml aliquot of thrombin (1 KIU of 
thrombin, T4648, Sigma-Aldrich, Poole, UK) was added to 333.3ml of 2mM CaCl2 to give a 
stock solution of 3 IU/ml) was thawed and subsequently stored on ice. Before mixing the 
thrombin and fibrinogen together the fibrinogen was filtered sterilised using a 0.2µM filter. 
Then 5mls of thrombin was mixed with 5mls of fibrinogen to make the basis of the gel. Once 
these two components had been mixed together the following steps had to be performed 
quickly and on ice to prevent the gel from solidifying. Normal human fibroblasts (NHF) were 
trypsinised and counted to give a 2 million/ml stock solution in DMEM with 10% FBS. Then 
750µl of this stock solution was added to the 10mls of the fibrin gel and mixed gently on ice, 
being cautious not to make any air bubbles within the gel. Then 1ml of this solution was 
added per well of a 12 well plate. This was left to set at room temperature for 15 minutes. 
After this time the set gel was covered with NHF medium with 6.3µl/ml stock aprotinin. The 
stock solution of aprotinin was made by adding 6mls of NHF medium to a vial of aprotinin 
(sigma-10820) to give a stock solution of 5000 units/ml. The gel was then left overnight at 
37°C. The next day the media covering the gel was removed and replaced with 2 million 
keratinocytes in a total of 3 mls. These were then returned to the incubator and left to 
adhere overnight before being lifted using the same technique noted in (2.5.1.1) collagen 
matrigels. 
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2.8 PROTEIN EXPRESSION 
2.8.1 Protein Extractions - Western Blotting 
All protein extractions were carried out on ice. The cells were washed with ice cold PBS 
before being lysed in RIPA buffer (see section 2.2.5 for details) containing protease 
inhibitors (Roche complete protease inhibitor cocktail, Roche diagnostics, Burgess Hill, UK). 
Cells were then scraped into the buffer mixture and transferred into cold eppendorfs and 
left on ice for 30 minutes to allow for cell lysis. Following cell lysis, cell samples were 
centrifuged for 15 minutes at 13,000 xg at 4°C and the supernatant stored at -80°C until 
required for western blot. The total protein concentration of the lysates was measured 
using the Bradford assay according to the manufactures conditions (Sigma-Aldrich, Poole, 
UK). For the Bradford assay, serial dilutions of bovine serum albumin (BSA, Sigma-Aldrich, 
Poole, UK) were used to create a standard curve. The protein concentration of the lysates 
was then calculated by diluting the sample 1/10, and incubating it with Bradford reagent 
(Sigma-Aldrich, Poole, UK) and reading the absorbance of the sample of which protein 
concentrations were extrapolated from the standard curve. Generally protein samples were 
loaded onto a 4-12% Bis-Tris gel (Novex, Invitrogen Ltd, Paisley, UK) unless otherwise stated. 
Unless otherwise stated, 20µg of protein was loaded per lane. This was run using a NOVEX 
gel system (Invitrogen Ltd, Paisley, UK) and MES running buffer (Invitrogen Ltd, Paisley, UK) 
at 150V for approximately 1 hour. The gel was then transferred onto a Hybond C 
nitrocellulose membrane (GE healthcare Life Sciences, Buckinghamshire, UK) by wet transfer 
method. To block the membrane, it was incubated in 5% Marvel milk in PBST (phosphate 
buffered saline, 0.1% tween) – unless otherwise stated. The primary antibody diluted in 
block was then added either for an hour at room temperature or overnight at 4°C. Following 
incubation with the primary antibody the blot was then washed for 3 x 5 minutes in PBST 
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before adding the secondary antibody and rocking for 1 hour at room temperature (for 
primary antibody details see figure 2.5). After this time the secondary antibody was then 
removed and the blot washed for 4 x 5 minutes in PBST before detecting the bands using 
enhanced chemiluminescence (GE healthcare, Life Sciences, Buckinghamshire, UK) detection 
method. For this method, blots were incubated in ECL for 5 minutes before being developed 
in the dark room onto film (GE healthcare, Life Sciences, Buckinghamshire, UK) and the 
bands produced were compared to the protein molecular weight markers (Full-range 
Rainbow Molecular Weight Marker, GE healthcare, Life Sciences, Buckinghamshire, UK) to 
determine the molecular weight of the protein. 
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Antibody (species) Dilution and dilutant Company (Catalogue no.) 
PRSS21 (mouse) 1/1000 dilution in 5% Marvel milk in PBST Abcam (AB68534) 
Maspin (mouse) 1/1000 dilution in 5% Marvel milk in PBST Abcam (Ab95451) 
GSG2 1/1000 dilution in 5% Marvel milk in PBST Bethyl laboratories (A302-241A) 
Notch1 (rabbit) 1/3000 dilution in 5% Marvel milk in PBST Gift from Jon Aster. 
Activated notch (rabbit) 1/1000 dilution in 5% BSA in PBST Cell signalling (2421S) 
GAPDH (mouse) 1/1000 dilution in 5% Marvel milk in PBST Sigma (G8795-200UL) 
Actin (mouse) 1/1000 dilution in 5% Marvel milk in PBST Abcam (ab8226) 
c-MYC (mouse) 1/1000 dilution in 5% Marvel milk in PBST Origene (TA150121) 
Involucrin (mouse) 1/10000 dilution in 5% Marvel milk in PBST Sigma (I9018) 
LH1 (mouse) 1/500 dilution in 5% Marvel milk in PBST Gift from Declan Lunny 
Table 2.5: Information on Antibodies Used for Western Blot Within This Thesis 
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2.8.2 Immunofluorescence of Cells 
Cover-slips were cleaned and autoclaved before cells were seeded on them. Following 
fixation (for method see 2.3.4) cells were then washed 3x in PBS at room temperature and 
either stored in PBS at 4°C until required or used straight away for staining. Cover-slips were 
then carefully transferred onto a sheet of parafilm which self-contained any liquid on the 
cover-slip. Cover-slips were then incubated in PBST (PBS/0.1% triton X-100) for 5 minutes at 
room temperature. After 5 minutes this was then removed and replaced with a blocking 
agent (PBST/3% bovine serum albumin (BSA)) for 20 minutes at room temperature. After 
this time the primary antibody was then added in the blocking agent for 1h at room 
temperature or overnight at 4°C. Cover-slips were then incubated with a species specific 
secondary at room temperature for 40 minutes. During this time and steps subsequently 
after this, the cover-slips were protected from light. Cover-slips were then washed 3 times 5 
minutes in PBS at room temperature before adding 10µl of Prolong® Gold anti-fade (Life 
technologies, Paisley, UK) was added to each cover-slip. This is a mounting medium which 
contains a DAPI counterstain. The cover-slips can then be immediately mounted onto a 
cover-slide. Slides were then either visualised after 15 minutes or stored at room 
temperature before being visualised using a fluorescence microscope. 
2.8.2.1 Immunofluorescence of Paraffin Embedded Sections 
Parafin embedded tissues were first cut into sections (4µM) using a microtome, before 
being mounted onto a slide. Slides were then dried overnight at 37°C. Slides were firstly 
deparaffinised in histoclear three times for 2 minutes. Following these slides were then 
rehydrated by firstly immersing slides in decreasing concentrations of ethanol (100%, 100%, 
95%, 80%) for 2 minutes each. The slides were then immersed in running tap water for 3 
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minutes. Heat induced antigen retrieval was then used, for which the slides were placed in 
citrate buffer (10mM sodium citrate, 0.05%, Tween 20, pH 6) and heated in a microwave for 
3x 3 minutes on full power. The slides were then cooled in the buffer at room temperature 
for 30 minutes before proceeding. After this time the slides were then rinsed for 3x 5 
minutes in PBS. Sections were then isolated using a wax pen and incubated in PBST for 5 
minutes before blocking in 3% BSA in PBST. Slides were then placed in a humidity chamber 
to prevent the sections from drying out. Primary antibody diluted in block was added to the 
slides for 1 hour at room temperature. Slides were then rinsed in PBS 3x for 5 minutes 
before being incubated in a species specific horseradish peroxidase secondary antibody for 
40 minutes. During this time and subsequently the slides were kept protected from light. 
Slides were then washed 3x in PBS before 10µl of a DAPI mount counterstain was added per 
section and mounted onto a cover-slip. 
2.9 FUNCTIONAL ASSAYS 
2.9.1 Cell Viability Assay 
Water soluble MTS is reduced to an insoluble purple formazin product by dehydrogenases 
of living cells especially in mitochondria. Following this reaction, solubilisation of the purple 
formazin product allows spectrophotometric comparison of cell viability in response to toxic 
insult (Cory et al. 1991). To begin, cells were seeded into 96 well plates at a cell density of 
0.5 x 104 cells per well, in 200µl of keratinocyte media then allowed to adhere overnight. 
Where applicable cells were transfected using siRNA targeted to a particular gene and the 
appropriate controls included (see section 2.4 for siRNA transfection details). Immediately 
after the addition of the transfection reagent, 20µl of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell titre 96 aqueous 
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solution (Promega, Madison, WI) was added and left at 37°C for 3 hours this formed time 
point zero. Absorbance was read at 490nm using the platereader (M3, SpectraMax, 
molecular devices, CA, USA). After T0, the plate was returned to the incubator and MTS was 
added at set time points between 24 and 96 hours after treatment. Each time the MTS was 
added the plate was incubated for 3h before reading on the plate reader. MTS is toxic to the 
cells so each time MTS is added the cells in the well are not re-usable for another time 
point. 
2.9.2 Cell Cycle Analysis 
Cells were incubated with 30µM 5-bromo-2-deoxyuridine (BrdU, B9285, Sigma-Aldrich 
Poole, UK) for 30 minutes at 37°C. BrdU was made up in water as a 900µM (30X) stock and 
stored at -20°C. The media was then removed from the cells and transferred to a falcon 
tube along with the trypsinised cells. The sample was then centrifuged for 5 minutes at 
1,500 RPM at 4°C (Sorvall RT7 plus, DJB labcare Ltd, Buckingshire, UK). Cells were then 
resuspended in PBS and then ethanol (70%) was added dropwise while vortexing. This was 
then left to incubate at 4°C overnight. Samples were then subjected to centrifugal force at 
13,000 xg for 5 minutes at 4°C before pouring off the supernatant. 2ml per tube of fresh 
pepsin solution was prepared at 1mg/ml in 20mM HCL (pH 1.5) and pre-warmed to 37°C. 
2ml of the pepsin solution was then added to each falcon tube and mixed for 30 minutes at 
37°C. The samples were then pelleted by centrifugation (13,000 xg, 5 minutes) before 
pouring off the supernatant. 1ml 2M HCL was then added to the pellets for 18 minutes at 
room temperature and then topped up with PBS before centrifugation (13,000 xg, 5 
minutes). Pellets were the washed again in PBS and a following time in antibody buffer 
(100ml PBS, 500µl tween, 0.5g BSA), pelleting cells each time by centrifugation (13,000 xg, 5 
minutes). Pellets were then resuspended in 200µl of Becton Dickinson anti-BrdU antibody 
92 
 
diluted 1:50 in antibody buffer and incubated for 1h at room temperature. Following this, 
the cells are then pelleted and washed in PBS to remove the antibody. Cells are then 
pelleted again and re-suspended in PBS containing 25µg/ml propidium iodide solution (stock 
solution 1mg/ml) which acts as a counter stain and can be used to differentiate between 
apoptotic and normal cells. Samples are then kept on ice in the dark until analysed on the 
FACScan (LSR Fortessa, Becton Dickinson). 
2.9.3 Cytotoxicity Assay 
To measure cytotoxicity, the Cytotox 96 assay (Promega, UK) was used which measures the 
amount of lactate dehydrogenase (LDH) released from the cells into the media. The colour 
range is proportional to the number of lysed cells. Lysates are collected from all the wells. 
The lysis buffer is diluted and added to untreated well and left for 45 minutes at 37°C. This is 
then collected as with the others and is used as the high control, while the UT lysate is low 
control. All lysates are subjected to centrifugal force (250xg) for five minutes at 4°C. 50µl of 
lysates are plated per well of a 96 well plate, with media being used as the background. The 
50µl of substrate is added to each well and left in the dark to develop for 30 minutes. Finally 
50µl of stop solution is added to each well and the colour change is measured using a plate 
reader at 490nm 
2.9.4 Annexin V Staining Method 
Cells were seeded at a cell density of 2.5x105cells/well of a 6 well plate, with 3 wells seeded 
per treatment. The following day, the cells were treated with siRNA targeted to BDKRB1, 
GSG2 or PRSS21 (following siRNA transfection protocol, see section 2.4). Controls were also 
included; a positive cell death siRNA (AllStars, Qiagen, Hilden, Germany), no treatment and 
mock control only. The cells were then left for 48 hours before collecting all the media and 
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cells following treatment. Cells were then centrifuged to pellet the cells at 2500rpm for 5 
minutes, before pouring off the supernatant. Cells were then washed twice with ice cold 
PBS before being re-suspended in 1x binding buffer at a concentration ~1x106. 100µl of this 
solution was then transferred to a 5ml tube. 5µl of FITC Annexin V (Becton Dickinson, NJ, 
USA) was added to each tube and 10µl of 7-ADD (Becton Dickinson, NJ, USA) was added, the 
cells gently mixed and incubated for 15 minutes at room temperature in the dark. After 15 
minutes 400µl of binding buffer was added to each tube before being analysed on the 
FACScan (Becton Dickinson, NJ, USA). 
2.9.4.1 Cell Death ELISA 
Cells were seeded into 24 well plates at a cell density of 1x105 cells per well and transfection 
was carried out as previously described (section 2.4).  For detection of apoptosis the Cell 
Death ELISA (Roche Diagnostics, IN, USA) was used to determine nucleosomal cleavage and 
release into cytoplasm upon DNA degradation (this was carried out according to the 
manufactures instructions). At different time points between 48- 96 hours, 20µl of cell 
extracts were plated in a streptavidin coated 96 well plate and incubated for 2 hours with 
80µl immunoreagent (anti-histone-biotin antibody and anti-DNA-peroxidase antibody) 
before washing three times with wash buffer and adding 100µl substrate reagent for 20 
minutes. The absorbance was then read on the plate reader at 405nm. 
2.9.5 Cell Migration Assay  
Keratinocyte migration was assessed by an in-vitro scratch assay, where cells are grown to 
confluency and physically scratched using a tip and images taken at the time of the scratch 
and at a number of time points after to assess the migratory capacity of cells following 
treatment. Briefly cells were seeded at a cell density of 5x105 per well a 24 well plate. 
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Confluent cultures were then treated with mitomycin C (10µg/ml) for 3 hours at 37°C to 
inhibit proliferation. Subsequently a uniform scratch was made using a P200 plastic tip. Cells 
were then washed 3x 5 minutes in PBS to remove any excess cells and returned to the 
incubator in media at 37°C. Before returning to the incubator, cultures were photographed 
to represent the scratch at T0, then again 4 and 18 hours later. To calculate the percentage 
change in area, the areas were calculated using CS4 Adobe Photoshop and the percentage 
change in area over time calculated. 
2.9.6 Proximity Ligation Assay (PLA) 
The proximity ligation assay (PLA) (Duolink, sigma-Aldrich, Poole, UK) is a modified version 
of immunofluorescence in that it utilises secondary antibodies called PLA probes which have 
short DNA oligonucleotides attached. The assay principal allows for protein-protein 
interactions to be detected. To begin, an SCCRDEB2 keratinocyte xenograpft tissue section 
mounted on a slide was incubated over night at 4°C, with two primary antibodies raised in 
different species, which recognise both PRSS21 and Maspin. A no primary control was also 
included. Both antibodies were made at a 1 in 100 dilution and mixed together. The next 
day, the slide was washed 2x in PBS before adding 50µl of both rabbit and mouse PLA 
probes to 150µl of block, and adding 40µl of this PLA probe solution per xenograft tissue 
section. The tissue section was then incubated in a humidified chamber for 2 hours at 37°C. 
Subsequently a ligation reaction was performed by mixing 40µl of ligase buffer with 155µl 
H2O and 5µl of ligase, again adding 40µl of this ligase solution per section. The tissue was 
incubated in a humidified chamber for a further 30 minutes at 37°C. After this time, the 
xenograft was washed with buffer A (which was provided by the kit) for 2x 5 minutes before 
the polymerase step. For the polymerase step, 40µl of stock was added to 155µl of H2O and 
5µl of polymerase. This was mixed together before adding 40µl per section and incubating 
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at 37°C for 2 hours. The sample was then washed in buffer B (which was provided by the kit) 
for 2x 10 minutes and a quick wash in 0.1% dilution of buffer B. The sample was then dried 
in the dark before mounting using DAPI mounting media. 
2.10 STATISTICAL ANALYSIS 
Unless otherwise stated, the data was reported as the mean ± SD from a representative 
experiment. The t-test was used for comparing results, and statistical significance was based 
on P<0.05. All experiments were performed at least 3 times each time with 2 or more 
independent observations. 
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 Chapter 3 Validation of Targets Identified from Gene Expression Array 
3.1 INTRODUCTION 
3.1.1 Gene Expression Array and Identification of cSCC Gene Signature (Watt  
2011) 
Previous work published from our lab used microarray technology to elucidate potential 
molecular targets in cSCC by revealing a cSCC gene signature (Watt 2011). An integrative 
gene expression analysis was devised comparing gene expression in a range of clinical data 
sets containing normal skin, cSCC and the hyper-proliferative condition psoriasis. 435 
dysregulated genes, which were capable of distinguishing cSCC from normal skin (in-vivo) 
were identified by comparing cell populations isolated from cSCC and normal human 
keratinocytes (in-vitro). These genes were then stratified against three in-vivo data sets; one 
of which was performed by our group comparing RNA isolated from fresh frozen cSCC (n=9) 
and non-cSCC skin (n=5) while the remaining two were from publically available 
experiments (GDS2200 (Nindl, Dang et al. 2006) and GSE7553 (Riker et al. 2008)). Of these 
genes, 154 were expressed in the same way across three independent in-vivo data sets.  
 
A comparison between fold change of psoriatic data sets from lesional and non-lesional 
areas (GSE13355 and GSE14905 (Romanowska, Reilly et al. 2010)), and fold change of cSCC 
versus normal skin (Watt et al 2011) revealed that the majority of the 154 genes 
dysregulated in-vivo cSCC were also dysregulated in psoriasis. The purpose of this 
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comparison was to identify cSCC specific genes through comparison with a hyper-
proliferative, benign condition. However, 37 genes did not show similar dysregulation and 
hence were termed ‘cSCC specific’. Of the 37 cSCC specific genes, 29 of these genes were 
concordantly regulated in-vitro and in-vivo – 8 of which were down regulated and 21 which 
were up-regulated. The fold change of the 21 up-regulated cSCC genes are detailed in Table 
3.1. 
3.1.1.1 Microarray Technology 
Microarrays have been utilised for a large number of studies to analyse the expression of 
thousands of genes quickly and efficiently (Southern, Maskos et al. 1992). They have been 
used to validate a number of hypothesis including: characterising disease states, molecular 
response to therapeutics, prognosis and typically looking at changes between disease and 
normal (Meltzer 2001; Mohr, Leikauf et al. 2002). The latter is important when devising 
customised targets for personalised medicine.  
 
Microarrays are small “chip” like slides made from glass or silicon. Attached to the slides are 
probe DNA sequences which allow for the hybridisation of complementary DNA strands. The 
technique is based on hybridization, which uses DNA probes to identify complementary 
molecules that are able to base-pair with one another. On binding, the substrates are 
washed to remove any unspecific binding. Hybridised sequences generate a fluorescent 
signal due to the fluorescently labelled samples. The signal varies depending on the amount 
of sample bound to the probe. Microarrays use relative quantification, where the intensity 
of a sample is compared to the intensity of the same gene under a different condition 
(Shalon, Smith et al. 1996). 
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Table 3.1 Fold Change of 21 cSCC Up-regulated Targets Identifed Using Microarray Technology  
The table shows the in-vitro and in-vivo fold change of the 21 cSCC specific up-regulated 
genes. The fold change was determined by comparing in-vitro cSCC to NHK and in-vivo to 
normal skin (Watt et al 2011). 
 
GENE Gene ID (NCBI) In-vitro cSCC FC In-vivo cSCC FC 
BDKRB1 623 8.4 1.3 
BUB1 699 3.3 2.7 
C20orf20 55257 2.3 1.3 
C6orf150 115004 19.2 3.1 
PSMG3 84262 2.4 1.4 
CDC25C 995 5.4 1.5 
CENPN 55839 4.7 2.2 
ELF4 2000 2.6 2.1 
FLT3LG 2323 3.8 1.4 
FUCA2 2519 4.2 1.6 
GSG2 83903 5.8 1.3 
LOC152217 152217 2.6 1.3 
NUTF2 10204 1.6 1.5 
PARP1 142 2.5 1.5 
PLK1 5347 3.7 3.1 
PRSS21 10942 7.4 1.5 
RSRC1 57319 2.5 1.8 
SH3TC1 54436 4.3 1.5 
SUPT16H 11198 2.3 1.5 
WDHD1 11169 2.8 2 
WDR67 93594 2.5 1.5 
3.1.2 RNAi screening (Watt 2011) 
Following identification of 21 up-regulated genes, RNA interference (RNAi) mediated 
knockdown of each gene individually, using a custom made siRNA library was carried out 
(Watt 2011). Three individual oligonucleotides per gene, in addition to a pool of all three 
oligonucleotides, was assessed using cell viability as readout over a time course. Using this 
siRNA knockdown method, two cSCC keratinocyte populations were screened, SCCRDEB2 
and SCCIC1, compared to non-targeting negative control siRNA. All three oligonucleotides 
targeted to Polo-like-kinase (PLK1) and C20orf20 consistently reduced cell viability. These 
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two genes are currently under study by other members of Dr AP South’s team. In addition to 
these targets a further three genes were highlighted as potential targets, due to being 
capable of reducing cell viability in-vitro using 2/3 siRNAs and the pool: PRSS21, GSG2 and 
BDKRB1. In follow up of this work performed in the lab, these three genes have been further 
validated in this thesis as potential targets for cSCC.  
3.1.2.1 RNAi Technology (Watt 2011) 
RNAi technology has revolutionised studies to determine the role of a gene. Furthermore it 
has enabled researchers to explore the role of a gene’s expression in different disease states 
such as cancer. Synthetic small interfering RNAs (siRNA) can be easily and inexpensively 
used to silence gene function in cultured mammalian cells. The phenomenon of specific RNA 
inactivation was first discovered in plants as a defence mechanism against virus infection 
(Wassenegger, Heimes et al. 1994; Hamilton and Baulcombe 1999) and later in 
Caenorhabditis elegans (Fire 1999). It was discovered that they produced small double 
stranded nucleotides that act specifically to down regulate gene expression. The mechanism 
is driven by a key enzyme, Dicer, which is a cytosolic ribonuclease capable of digesting long 
double stranded RNAs into short RNA (figure 3.1). These double strands are then un-wound 
and a single strand associated with the RNA-induced silencing complex that leads to target 
destruction by cleaving mRNA that is complementary to siRNA (Wall and Shi 2003). A 
number of transfection methods are available which allow cellular uptake of synthetic 
siRNA. Broadly speaking they can be divided into biological, chemical and physical, and 
depending on the nature of the genetic material, can be transient or stable (for a review see 
(Kim and Eberwine 2010). 
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Of note siRNA treatments have been developed for a number of diseases, for example 
BACE1 in Alzheimer’s disease or for the BCL/ABL translocation in chronic myloid leukaemia, 
where siRNA induces apoptosis (Ryther RC et al 2005). However, in cSCC delivery and 
degradation of siRNA present limitations for use in patients and formulation of small 
molecular inhibitors/ agonists would have much greater potential. 
 
 
Figure 3.1 Model for RNAi Mediated Degradation 
Long double stranded RNA (dsRNA) is cleaved by DICER into short double stranded 
fragments called small interfering RNA (siRNA) which results in the recruitment of Ago2 and 
other complexes. Subsequently, Ago2 cleaves the siRNA then associates with the target 
mRNA allowing association of RNA induced silencing complex (RISC) that leads to target 
silencing. 
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3.1.3 Germ Cell Associated 2 (GSG2) 
Germ cell associated 2 (GSG2, also referred to as haspin, haploid germ cell-specific nuclear 
protein kinase) is a serine/threonine kinase, first discovered as a testis specific gene; 
however Higgins and colleagues have previously detected its mRNA expression, at low levels 
in other proliferating and differentiated tissues (Higgins 2001). This would suggest that the 
gene is not exclusively germ cell specific. GSG2 functions to phosphorylate histone H3 at 
Ser-3 during mitosis which is necessary for cell cycle progression (Dia 2005). Histones play a 
central role in transcription regulation, DNA repair, DNA replication and chromosomal 
stability through being essential components of the nucleosome. Histone H3 is one of five 
main histone proteins involved in structure of chromatin and can undergo several types of 
post translational modifications including phosphorylation of serine amino acids (Zhang and 
Reinberg 2001). Additionally, GSG2 regulates the cell cycle of haploid germ cells by 
positioning and activating aurora B and other components of the chromosomal passenger 
complex (CPC) at the centromeres. This ensures chromatid cohesion, metaphase alignment 
and normal progression through the cell cycle. RNAi depletion of GSG2 perturbs 
chromosome biorientation and sister chromatid cohesion (Dai and Higgins 2005; Dai, 
Sullivan et al. 2006; Markaki, Christogianni et al. 2009; Higgins 2010). Hence, its importance 
in mitosis and regulation of other cancer associated proteins and processes, would highlight 
it as a good potential target for cancer.  
 
There is not a vast amount of literature on GSG2 and its expression in cancer, although it has 
been shown to be over-expressed in lymphomas (Rosenwald, Alizadeh et al. 2001; Dave, Fu 
et al. 2006). Despite this there are a number of small molecular inhibitors to GSG2, which 
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would also further suggest its potential as a therapeutic target. Mitotic kinase inhibitors 
have been shown by a number of studies, to have fewer side effects than traditional 
cytotoxic drugs, and some of the inhibitors are in clinical trials such as those targeting cyclin 
dependant kinases (Vassilev, Tovar et al. 2006; Malumbres, Pevarello et al. 2008), PlK1 
(Gleixner, Ferenc et al. 2010) and aurora kinases (Harrington, Bebbington et al. 2004; 
Girdler, Gascoigne et al. 2006). Data on CHR-6494, a specific inhibitor of haspin, showed 
that it causes significant antitumor activity through mitotic catastrophe in apoptosing cells 
(Huertas, Soler et al. 2012). This would suggest that GSG2 would be a promising target for 
cancer therapy. 
3.1.4 Bradykinin Receptor B1 (BDKRB1) 
Bradykinin receptor B1 (BDKRB1), encodes a transmembrane protein which functions as a G-
coupled receptor named Bradykinin B(1) receptor (B1R). Bradykinin, a 9 amino acid peptide, 
can bind to B1R to mediate responses to a number of pathologic conditions. B1R is expressed 
at low levels in normal tissues however is upregulated during conditions of inflammation, 
trauma, burns, shock and allergy (Calixto, Medeiros et al. 2004; Leeb-Lundberg, Marceau et 
al. 2005). Additionally, there have been a number of reports which show it is up-regulated in 
cancers including breast (Esseghir, Reis-Filho et al. 2006), prostate (Taub, Guo et al. 2003) 
and lung (Gera, Fortin et al. 2006). Molina and colleagues, demonstrated up-regulation of 
the B1R receptor in breast cancer cells both in-vitro and in-vivo. Additionally, to investigate 
the consequences of stimulation of the receptor in these cells, they used various 
concentrations of a B1R agonist Lys-des[Arg9]-bra-dykinin, the B2R agonist bradykinin or EGF 
in-vitro. This lead to increased proliferation, through transactivation of EGF and lead to 
subsequent activation of the ERK1/2 mitogenic pathway. The significance of this as 
mentioned in chapter 1, is that a number of studies have shown that ERK1/2 signalling plays 
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a role in cancer progression (section 1.3.1.2). Silencing or antagonism of B1R is considered to 
be an effective option to decrease growth in breast cancer. Receptor activation has also 
been noted in prostate cancer cells to increase migration, cell growth and invasion (Taub, 
Guo et al. 2003). Additionally, Bradykinin signalling enhances cell migration and expression 
of integrin through activation of phospholipase C, protein kinase C and NFκB pathways 
(Yang et al 2010). Both studies would suggest that B1R inhibition would be an effective 
therapy for cSCC. 
3.1.5 Protease Serine 21 (PRSS21) 
Protease, serine 21 (PRSS21), also known as testisin, is a protease which was first reported 
to be highly expressed in testicular germ cells, but with little expression in normal tissue 
(Hooper, Nicol et al. 1999; Hooper, Bowen et al. 2000). In the testis it is required for 
epididymal sperm maturation and fertilizing ability, since mouse sperm lacking PRSS21 
display several functional abnormalities in sperm (Yamagishi, Honda et al. ; Netzel-Arnett, 
Bugge et al. 2009). The C-terminus domains of PRSS21 molecules are post-translationally 
modified with a glycosylphosphatidylinositol (GSI) anchor which localises it to cholesterol-
rich lipid rafts on the cell surface (Hooper, Nicol et al. 1999). Several of the membrane 
anchored serine proteases are over-expressed by tumour cells and are implicated in the 
promotion of cancer (Lee et al 2005, List et al 2005). Pericellular proteolysis is an important 
pathway by which cells can interact with the cell microenvironment, leading to tumour 
invasion and metastasis. PRSS21 is over-expressed in a number of cancers including: 
ovarian, cervical, melanoma and lymphoma (Hooper, Nicol et al. 1999; Hooper, Bowen et al. 
2000; Honda, Yamagata et al. 2002; Tang, Kmet et al. 2005). Furthermore, PRSS21 promotes 
transformation when over-expressed in cell culture and mouse xenograft model systems of 
which it’s catalytic; serine protease activity is required for transformation. Additionally, 
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siRNA depletion of PRSS21 expression increased apoptosis and diminished ability to form 
colonies in soft agar in ovarian cancer (Tang, Kmet et al. 2005). Another study, by Yeom and 
colleagues showed that PRSS21 increases invasion using its enzymatic activity (Yeom, Jang 
et al. 2010). They also showed using a yeast two hybrid system that it interacts with the 
tumour suppressor mammary serine protease inhibitor (maspin) to modulate cell death and 
invasion in cervical cancer cells. Thus inhibition of PRSS21 may prevent tumour progression 
in cSCC. 
3.2 RESULTS 
3.2.1 RNAi Screen Confirms PLK1, C20orf20 and PRSS21 as Important for Cell 
Survival and Identifies a Further Three Potential Novel Targets for cSCC 
In a similar manner to the original screen performed by Watt and colleges, an RNAi screen 
with cytotoxicity as a readout was used, to further confirm/identify potential targets for 
cSCC using the microarray data. Using a pool of all 3 oligonucleotides targeted to the 21 
cSCC specific genes that were identified in the microarray, a primary cSCC keratinocyte cell 
line SCCRDEB2 was assessed for cytotoxicity 48 hours following gene depletion (figure 3.2). 
This method identified C20orf20, PLK1 and PRSS21 to significantly (P<0.005) increase 
cytotoxicity in 4 independent experiments, 48h following transfection compared to a non-
targeting siRNA control (SCR). The SCR which was 40% was used as a baseline cytotoxicty 
which was slightly higher than expected.  Additionally, 3 other genes – poly[ADP-
ribose]polymerase1 (PARP1), fucosidase, alpha-L-1-plasma (FUCA2) and proteosome 
assembly chaperone 3 (PSMG3) were also found to significantly (P<0.05) increase 
cytotoxicity, as determined by the students t-test.  
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Figure 3.2 Cytotoxicity Screen Confirms C20orf20, PLK1 and PRSS21 as Potential Targets and Further Identifies Novel Targets for cSCC - PARP1, FUCA2 and PSMG3  
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Figure 3.2 
*** 
*** *** 
** 
** 
** 
Results represent the percentage cytotoxicity in SCCRDEB2 cells  compared to media only control, using the LDH assay, 48h post-transfection of siRNA 
targeted to the 21 cSCC specific genes identified in the microarray (Watt et al. 2011, see table 1 for gene IDs). Results show that depletion of C20orf20, PLK1 
and PRSS21 highly significantly (***<0.0005, highlighted in yellow) induces cytotoxicity compared to SCR. This screen also revealed depletion of PARP1, 
FUCA2 and PSMG3 as significantly (**<0.005, highlighted in maroon) able to induced cytotoxicty. Results represent the mean ± SD of 4 independent 
experiments with the probability calculated using the student’s t-test. PC represents the cell death positive control siRNA. Dotted line indicates base line, 
following normalisation to SCR. 
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In follow-up, cytotoxicity was explored in 2 cSCC cell lines, SCCIC1 and SCCRDEB2 cells, but  
also in primary normal human keratinocytes (NHK) using the individual siRNA duplexes to 
assess the contribution of each duplex to cytotoxicity and to monitor off target effects 
(figure 3.3). The genes explored were GSG2, PRSS21, PLK1, PSMG2, FUCA2 and PARP1. 
BDKRB1 was not included knockdown using individual siRNA duplexes had already been 
performed by a BMSc student in the lab (S.Gaw, University of Dundee, UK). For all the genes 
explored, knockdown induced no cytotoxicity in the NHK cells which increases their 
specificity as a molecular target for cSCC without affecting normal cells. Generally, both 
cSCC cell lines showed similar cytotoxicity following knockdown and are in agreement with 
the previous results. These results indicate that depletion of PRSS21 using 2/3 duplexes 
increases cytotoxicity for PRSS21.  
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Figure 3.3 Cytotoxicity Screen of GSG2, PRSS21, PLK1, PSMG, FUCA2, PARP1 Using Individual and Pooled Duplexes in Normal Human 
Keratinocytes, SCCIC1 and SCCRDB2 Keratinocytes 
Assessment of cytotoxicity following knockdown using individual (X_1,2,3) and pooled siRNA (X_P)duplexes. Cytotoxicity tested in SCCIC1 
(blue) SCCRDEB2 (red) and normal human keratinocytes (NHK, green) cell lines. Results represent the mean ± SEM of two individual 
experiments. SCR, scrambled, Pos Con; positive control. Black dashed line indicates base line cytotoxicity in the cSCC cells and the green 
dashed line indicates the base line cytotoxicity in the NHK cells. 
 
%
 cy
to
to
xi
ci
ty
 
Figure 3.3 
SCCIC1 
SCCRDEB2 
NHK 
108 
 
3.2.2 Validation of GSG2, BDKRB1 and PRSS21 as Molecular Targets for cSCC 
3.2.2.1 Germ Cell Associated 2 (GSG2) 
3.2.2.1.1 GSG2 is Over-expressed in cSCC Both at mRNA and Protein Level 
GSG2 is over-expressed both in-vitro (fold change of 5.8) and in-vivo (fold change of 1.2), in 
cSCC compared to NHK or normal skin, respectively, using microarray technology (Watt et 
al. 2011). To confirm this, qPCR was used to compare the expression of GSG2 in SCCRDEB2 
keratinocytes and NHK cells. This demonstrated an 11 fold increase in the levels of GSG2 in 
these cSCC cells compared to NHK (Figure 3.4A). Figure 3.4B uses immunoblotting to 
compare the expression levels of GSG2 in SCCRDEB2 to NHK lysates. This data confirms that 
the over-expression of GSG2 is seen at both protein and mRNA level. Both qPCR (figure 
3.4C) and western blot (figure 3.4D) were employed to look at GSG2 expression following 
knockdown of its expression using siRNA. Knockdown of GSG2 expression was statistically 
significant (p=0.005) using oligonucleotides – GSG_1 and GSG_3 compared to a non-
targeting control. However the knockdown using oligonucleotide GSG_2 was ~30% less 
effective than the other oligonucleotides at reducing GSG2 expression. Due to the off target 
effects of GSG_2, which would in turn dilute the overall effect of the pooled nucleotides 
(GSG_P), it was not included in any further knockdown experiments for GSG2. 
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Figure 3.4 GSG2 is Over-expressed at Both mRNA and Protein Level in cSCC Compared to Normal human Keratinocytes (NHK) 
(A) mRNA expression levels of GSG2 in NHK versus SCCRDEB2 cells results represent the mean±SD, n=6. (B) Relative expression levels of GSG2 
following knockdown with individual siRNA (GSG2_1, 2, 3) / pooled (GSG2_P) oligonucleotides, targeted to GSG2. Results expressed relative to 
the scrambled control (SCR) and represent the mean±SD, n=6 (C) Western blot showing increased protein expression of GSG2 in SCCRDEB2 
cells compared to NHK (D) Western blot showing protein expression following knockdown using individual / pooled oligonucleotides. 
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3.2.2.1.2 Knockdown of GSG2 Shows no Significant Increase in Apoptosis or 
Change in Cell Cycle  
Knockdown of GSG2 did not cause a significant increase in cytotoxicity, 48h following 
transfection (figure 3.2). Using a time course it was also confirmed not to cause a significant 
increase in cytotoxicity 24 and 72 hours post-transfection, using pooled siRNA (figure 3.5). 
Additionally knockdown of GSG2 did not significantly increase apoptosis compared to the 
non-targeting control (figure 3.6A).  
 
 
Figure 3.5 No Significant Induction of Cytotoxicity is Observed Following GSG2 Depletion 
in cSCC Cells 
Results show the assessment of cytotoxicity following knockdown of GSG2 24, 48 and 72 
hours post-transfection in SCCRDEB2 keratinocytes, indicating no significant induction of 
cytotoxicity  at these time points. Results represent the mean ± SD from 3 independent 
experiments. 
 
 
As GSG2 had been shown to cause misalignment of chromosomes following knockdown of 
its expression, it was hypothesised that knock down of GSG2 in cSCC cells may result in cell 
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cycle arrest (Higgins et al 2001a). Fluorescent staining and flow cytometry is a method of 
quantification of DNA in the cell cycle. BrdU is a synthetic analogue of thymidine that 
becomes incorporated into the DNA during S phase; subsequently DNA unwinding permits 
the access of an antibody and addition of a fluorescent secondary. However figure 3.5b 
shows that using BrdU cell cycle analysis in SCCRDEB2 cells, there is no change in the cell 
cycle 20h following GSG2 depletion, compared to the non-targeting control.     
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Figure 3.6 Knockdown of GSG2 Does not Induce Cell Cycle Arrest or Apoptosis in cSCC Cells 
(A) SCCRDEB2 keratinocytes transfected with a pool of 2 separate siRNAs targeting GSG2 or 
a cell death positive control siRNA (Sigma, PC) were assessed for induction of apoptosis 
using Cell Death ELISA assay, 20h after treatment. The results show no significant fold 
increase in cytoplasmic nucleosomes relative to the scrambled non-targeting control (SCR). 
(B) Cell cycle analysis in SCCRDEB2 keratinocytes treated with a pool of 2 separate GSG2 
targeting siRNA or PLK1, as a positive control (PC) and stained for bromodeoxyuridine 
(BrdU) and propidium iodide (PI). Results expressed as percentage of cells at the G0/G1, S 
and G2/M phases of cell cycle and sub-G0 20h following knockdown. Results represent n=4. 
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3.2.2.2 Bradykinin Receptor B1 (BDKRB1) 
3.2.2.2.1 Previous Work on BDKRB1 Performed in Our Lab 
Depletion of BDKRB1 using siRNA, resulted in a reduction in cell viability (Watt 2011). 
Subsequently S.Gaw, a BMSc student in the lab, showed that the reduction in cell viability 
was attributable to increased cytotoxicity as a consequence of apoptosis. S.Gaw 
demonstrated that siRNA knockdown of BDKRB1 in the SCCRDEB2 keratinocytes resulted in 
a 38% increase in cytotoxicity using the LDH assay. Using the apoptosis ELISA she also 
showed that depletion of BDKRB1 resulted in a 1.8 fold increase in cytoplasmic 
nucleosomes, indicating an increase in apoptosis 48 hours after transfection. Although 
S.Gaw was able to demonstrate that BDKRB1 was increased at mRNA level, she was unable 
to confirm this increase at protein level. In addition to this S.Gaw used agonists and 
antagonists to stimulate the B1R, however contrary to predictions they increased 
proliferation of cSCC cells. In follow up, the sections below attempt to confirm the 
expression of BDKRB1 at both mRNA level and protein level and to further evaluate the 
potential of the antagonist and agonists for treatment of cSCC. 
3.2.2.2.2 BDKRB1 is Overexpressed at mRNA level but not at the Protein Level in 
cSCC 
Using qPCR, the over-expression of BDKRB1 in cSCC was ~8 fold higher in SCCRDEB 
keratinocytes than NHK, which confirms its over-expression identified by the microarray 
(figure 3.7).   
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Figure 3.7 BDKRB1 is Over-expressed in SCCRDEB2 Cells at mRNA Level 
The relative expression of BDKRB1 was assessed in SCCRDEB cells by quantitative PCR. Data 
shows that expression is ~8 fold higher relative to the NHK.  Results are the mean ± SD, n=6. 
***p<0.005 compared to control. 
 
Westen blot was used to evaluate the protein expression of BDKRB1 in cSCC versus NHK. 
The expected band size of BDKRB1 is 40KDa. However, previous work done by S. Gaw, 
showed that in NHK there is both a band at 40KDa and 80KDa but in SCCRDEB2 cells the 
majority of the protein expression was at 80KDa. This result indicates that the protien may 
possibly be dimerising forming a band double of that expected. The problem may have been 
that the denaturation using our standard conditions was insufficient, and adding different 
buffers such as dithiothreitol (DTT) or urea may perturb this formation (figure 3.8a). 
However the 80KDa band still remained even with the use of stronger reducing agents and a 
recomended positive control K562 – a myloid leukemia cell line did not show the correct 
size of band either (figure 3.8b). This data would pose the question as to wither the 80KDa 
band is a dimer. However, the ability to knockdown the expression of BDKRB1 using 
targeted siRNA confirms that the 80KDa band is the receptor and not a non-specific band 
(figure 3.9). 
 
*** 
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Figure 3.8 BDKRB1 is Expressed at 80KDa Rather than 40KDa in cSCC  
(A) Protein expression of BRDKRB1 was assessed using different denaturing buffers, boil 
only (BO), dithiothreitol (DTT), urea (UR) or BO, DTT and UR (ALL). No expected 40KDa band 
was seen under any of the treatments in the SCCRDEB2 cells however in the NHK cells a 
40KDa band as well as the 80KDa band was detected using BO and DTT buffers. Arrows 
indicate 80KDa band (upper) and 40KDa (lower) band (B) K562, a myloid leukaemia was 
used as a positive control lysate in the data sheet provided with antibody. However no band 
at 40KDa was seen as expected in this cell line either. 
A. 
B. 
Figure 3.8 
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Figure 3.9 Expression of BDKRB1 at 80KDa can be Depleted Using BDKRB1 siRNA  
SCCRDEB2 keratinocytes were transfected with a pool of 3 separate siRNA targeting BDKRB1 
and BDKRB1 protein expression was determined using western blot. The siRNA targeting 
BDKRB1 reduces the band at 80KDa. n=1. 
 
3.2.2.3 Agonist Stimulation with R715 Causes a Reduction in Phosphorylation of 
ERK and Proliferation 
B1R antagonists R892 and R715 and agonists LDBK and DBK were used to target B1R and 
could be potentially used as therapies for cSCC. The MAP kinase pathway is known to be 
stimulated in other cancers, resulting in increased proliferation. As mentioned before in 
chapter 1 ERK1 and ERK2 are part of this pathway and they can be activated by 
phosphorylation. Looking at phosphorylation levels of ERK (pERK), can help to understand if 
the agonist and antagonist stimulation of B1R will have effects on proliferation and pERK. 
Figure 3.10A illustrates a reduction in pERK levels in SCCRDEB2 stimulated with all the 
agonists and antagonists tested, with stimulation using LBK and R715 causing the greatest 
reduction. In comparison, total ERK is equivalent in all cells and is not affected by ligand 
stimulation. Therefore ligand induced reduction in phosphorylation of ERK may reduce the 
proliferation in these cells. Subsequently LBK and R715 were used to target B1R and the 
effects on proliferation measured using MTS. Serial dilutions of each ligand were used to 
give a final concentration of 0.1, 1 and 3µM in serum free conditions as previously 
determined by S.Gaw. After 48h a dose dependant increase in proliferation is observed 
following SCCRDEB2 stimulation with agonist LDBK (figure 3.10B, upper panel). However 
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stimulation using antagonist R175 (figure 3.10B, lower panel) showed a reduction in 
proliferation after T48 hours using a concentration of 0.1µM, with the other concentrations 
having no effect on proliferation. Therefore this R175 agonist at a concentration of 0.1µM 
could be used to reduce proliferation in the SCCRDEB2 keratinocytes.  
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Figure 3.10 Agonist Stimulation with R715 Causes a Reduction in Phosphorylation of ERK and Proliferation in cSCC 
(A) SCCRDEB2 cells were stimulated with ligands LBK,R715,R892 and DBK) for 48 hours before collecting lysates for western blot analysis and blotting for 
phosphorylated-ERK (pERK) and total ERK (n=2). Figure shows a reduction in phosphorylation compared to control (media only). (B) MTS assessing cell 
viability in SCCRDEB2 cells in serum free conditions (SD±mean, n=3) 24, 48 and 96 hours after ligand stimulation, using 0.1, 1, 3 µM of either LBK (upper 
panel) or R715 (lower panel). Results show a dose dependant increase in proliferation, 48h following stimulation with LBK, compared to control. However 
stimulation with R715 shows a reduction in proliferation at all concentrations after 24h, which is maintained after 48 and 96h using a concentration of 
0.1µM 
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3.2.2.4 Protease Serine 21 (PRSS21) 
3.2.2.4.1 PRSS21 is Over-expressed at Both mRNA and Protein Level 
The serine protease PRSS21 was found to be over-expressed in cSCC versus normal 
cells/skin (Watt 2011) which was confirmed using qPCR (figure 3.11A). These results show 
that PRSS21 is over-expressed in both SCCRDEB2 (~10 fold) and SCCIC1 (~18 fold) 
keratinocytes compared to NHK. PRSS21 is also over-expressed at protein level in the 
SCCRDEB2 cells compared to the NHK and this expression can be successfully depleted using 
siRNA targeted to its expression (figure 3.11B).  
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Figure 3.11 PRSS21 is Over-expressed in cSCC at Both mRNA and Protein Level Compared 
to NHK 
 (A) Results show mRNA over-expression of PRSS21 in cSCC SCCRDEB2 and SCCIC1 cells 
relative to NHK. Results represent the mean±SD, n=2, ***p<0.005, (B) Relative protein 
expression levels of PRSS21 in normal human keratinocytes (NHK) and in SSCRDEB2 cells 
following transfection with a non-targeting control (SCR) and with individual 
oligonucleotides targeted to PRSS21 (PRSS21_1 & PRSS21_2) / pooled oligonucleotides 
(PRSS21_P) (n=6).  
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3.2.2.4.2 PRSS21 Depletion Reduces Cell Viability through Increased Apoptosis in 
cSCC 
Using MTS cell viability was assessed in the SCCRDEB2 cells following depletion of PRSS21 
using siRNA. This demonstrated that knockdown of PRSS21 reduces cell viability in 
SCCRDEB2 cells 48 hours post-transfection compared to the scrambled (Scr), non-targeting 
siRNA control (figure 3.12) by ~20% which was statistically significant. 
 
Figure 3.12 Depletion of PRSS21 Expression in cSCC keratinocytes Reduces Cell Viability 
compaired to Non-targeting control 
 Cell viability is significantly reduced in SCCRDEB2 keratinocytes using oligonucleotides 
targeted to PRSS21 compared to non-targeting control (Scr), 48 hours post-transfection. A 
positive cell death control was also included (PC). Results represent the mean ± SD, n=3, 
*P<0.01. The percentage viable cell number is shown relative to values at T0. 
 
 
siRNA knockdown of PRSS21 resulted in a significant increase in cytotoxicity with no effect 
on the normal keratinocytes (Figure 3.3). Using the Cell Death Detection ELISA, a 2.3 fold 
increase in cytoplasmic nucleosomes was detected 48h following depletion of PRSS21, 
which is significantly different (P<0.05) compared to the non-targeting control (figure 3.13).  
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Analysis of the cell cycle following knockdown of PRSS21 showed no change in the 
percentage of cells at the G1/G2 or S phase of the cell cycle however analysis of the sub-G0 
population tentatively representing the “dying” population, revealed double the number of 
cells within this group compared to the control (figure 3.14), reflecting the result from the 
cell death ELISA assay.  
 
** 
Figure 3.13 Depletion of PRSS21 Increases Apoptosis in cSCC Cells Compared to Non-targeting Control 
Using the cell death ELISA kit, results show an increase in cytoplasmic nucleosomes relative to non-
targeting siRNA in SCCRDEB2 following depletion of PRSS21. A positive cell death control (PC) is also 
included. Results are the mean ± SD, n=6. **p<0.001, compared to SCR control. 
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Figure 3.14 BrdU Cell Cycle Analysis Reveals an Increase in Sub-G0 Cell Population 
Following Depletion of PRSS21 in cSCC Keratinocytes Compared to the Non-targeting 
Control 
 
Results of cell cycle analysis in SCCRDEB2 keratinocytes following knockdown using a non-
targeting control (Scr), PLK1 (PC) which is known to induce a G2/M arrest and PRSS21 siRNA. 
Results expressed as percentage of cells at the sub-G0, G0/G1, S and G2/M phases of cell 
cycle 20h following knockdown, where an increase in the sub-G0 cell population is observed 
after depletion of PRSS21. Results represent n=4. 
 
3.2.2.4.3 Knockdown of PRSS21 Increases Caspase Activation and Annexin IV 
Staining in cSCC 
To assess the mechanism of cell death, the caspase 3/7 assay was used to assess caspase 
activity following siRNA depletion of PRSS21. This assay showed a 1.9 fold increase in 
caspase activity, compared to the non-targeted control, 48h post-transfection (figure 
3.15A). Apoptosis was also assessed 48h post-transfection using 7-AAD and Annexin V 
staining. 48h following transfection the number of live cells was significantly reduced 
compared to the positive control (figure 3.15B). Additionally there was a ~20% increase in 
apoptotic cells- comparable to the positive control.  
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Figure 3.15 Knockdown of PRSS21 Leads to an Increase in caspase Activity and Annexin V 
Staining in cSCC cells 
(A) Caspase activity is significantly increased following KD of PRSS21 in the SCCRDEB2 cells 
compared to the non targeting control (Scr). Additional controls included are a mock 
transfection (mock) and positive control (PC). Results represent the mean ± SD, n=3, 
*P<0.01. (B) Apoptosis was also assessed using FACS and the annexin V/7-AAD staining 
method. Results represent the mean ± SD, n=4 **P<0.001. 
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3.3 DISCUSSION 
The approach taken by our lab to identify molecular targets for cSCC has already yielded two 
promising targets, PLK1 and C20orf20 which reduce tumour growth in-vivo. In addition to 
these, three other potential targets from the 21 cSCC signature were highlighted, GSG2, 
BDKRB1 and PRSS21, depletion of which reduced cSCC viability in-vitro (Watt 2011). The 
aims of this chapter were to: 
 
1. Repeat the original RNAi screen of the 21 cSCC specific genes, performed by Watt 
and colleagues, however using a different endpoint. The original screen assessed cell 
viability and thereby using cytotoxicity as an endpoint differentiates between 
slowing of cell growth and genuine killing. This would essentially re-enforce the 
potential of the five genes (C20orf20, PLK1, GSG2, BDKRB1 and PRSS21) Watt et al. 
identified to reduce cell viability but also potentially identify novel targets for cSCC 
(Watt 2011). 
2. Further validate 3/5 genes identified by Watt et al. to reduce cell viability GSG2, 
BDKRB1 and PRSS21 as molecular targets for cSCC (Watt 2011). 
 
3.3.1 RNAi screen of 21 up-regulated genes using cytotoxicity as a readout 
Using siRNA targeted to the 21 cSCC specific genes with cytotoxicity as readout, confirmed 
that PLK1 and C20orf20 were important for tumour cSCC survival, as previously shown by 
Watt and colleagues (Watt 2011). In addition to these, depletion of the serine protease 
PRSS21, also consistently significantly increased cytotoxicity. A further three targets PARP1, 
FUCA2 and PSMG3 were also identified to increase cytotoxicity following knockdown and 
these were further explored in SCCIC1 and NHK cells. Subsequently, siRNA knockdown of 
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GSG2, PRSS21, PLK1, PSMG, FUCA2 and PARP1 was performed using 3 duplexes or a pool, 
with cytotoxicity as a readout. BDKRB1 and C20orf20 were not included as these genes were 
being studied by other members in our lab. The latter is also true of PLK1 however was 
included as a further positive control. Only PRSS21 and PLK1 showed ‘hits’ consistently in 
2/3 duplexes, furthermore they did so in two cSCC cell lines, SCCRDEB2 and SCCIC1 
keratinocytes with little effect on NHK. This was expected from PLK1 as data from our lab 
would suggest that depletion of PLK1, leads to G2/M arrest increasing mitotic catastrophe, 
and that PLK1 inhibition significantly reduces tumour volume in-vivo (Watt 2011). However 
although the mechanism of depleted PRSS21 induced cytotoxicty has not been fully 
explored, data in this chapter would suggest that it leads to a reduction in cell survival and 
increased apoptosis. This data would suggest that PRSS21 is important for cSCC cell survival. 
As for the novel targets identified, PSMG, FUCA2 and PARP1 the effect seen in figure 3.3 
could have been the result of off target effects. In light of this PSMG2 and FUCA2 were not 
followed up. 
3.3.2 Validation of Germ Cell Associated 2 (GSG2) As a Therapeutic Molecular 
Target in cSCC 
GSG2 would be an interesting molecular target as it plays a role in mitosis and cell cycle 
control; furthermore small molecular inhibitors are available which would fast track 
development of a therapeutic target. However, depletion of GSG2 in cSCC did not 
significantly increase cytotoxicity or apoptosis. To further support the lack of cytotoxicity 
seen with GSG2 Wang et al. show that histone H3 phospho Thr3 generated by haspin 
contributes to accurate positioning of the chromosomal passenger complex but is not 
necessarily required (Wang, Dai et al. 2005). As GSG2 is a mitotic kinase, one may assume it 
to act as an anti-mitotic compound however, using BrdU/PI cell cycle analysis in cSCC 
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keratinocytes did not show any disruption to the cell cycle following GSG2 depletion. 
Interestingly, Dai and colleagues showed that GSG2 acts as a mitotic kinase and depletion of 
GSG2 prevents normal metaphase alignment by assessing the distribution using 
immunofluorescence. However this group also failed to identify any change in cell cycle 
parameters. The data presented in this thesis suggest that GSG2 may not be a good target 
for cSCC. 
3.3.3 Validation of Bradykinin receptor B1 (BDKRB1) As a Therapeutic 
Molecular Target for cSCC 
BDKRB1 over-expression was confirmed at mRNA level however at protein level these 
results seem more complex. Despite the expected molecular weight of BDKRB1 being 
40KDa, the only band identified in cSCC cells was an 80KDa band – which is double the 
expected size. This could be due to receptor dimerisation which has been identified in other 
cancers – HER positive breast cancer, where the HER2 receptor can form heterodimers with 
other EGFR tyrosine kinases (Moulder, Yakes et al. 2001). Furthermore dimerisation can 
switch on signalling pathways and activate downstream events or change agonist affinity 
(Saltz, Meropol et al. 2004). There is evidence to suggest that B1R can dimerise with B2R, 
another subtype of bradykinin receptor, in prostate cancer cells, which has a molecular 
weight of 43KDa (Barki-Harrington, Bookout et al. 2003). Ligand labelling studies are 
required to elucidate BDKRB1 expression at protein level. Studies performed by S.Gaw – a 
student working in the lab, showed that the siRNA depletion of BDKRB1 lead to a reduction 
in cell viability due to an increase in cytototoxicty through apoptosis. These results suggest 
that BDKRB1 may be a good potential target for cSCC. However she also showed that 
antagonists R715 and R892 induce phosphorylation of ERK and proliferation in cSCC cells, 
making them not useful as targets in cSCC. However in this thesis it was demonstrated that 
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these agonists and antagonists actually reduce phosphorylation of ERK, although using MTS 
to assess proliferation yielded mixed results. This would indicate more work has to be done 
to elucidate the potential of BDKRB1 as a therapeutic target in cSCC. 
3.3.4 Validation of Protease Serine 21 (PRSS21) As a Therapeutic Target in cSCC 
siRNA depletion of PRSS21 lead to a reduction in cell viability which has been observed 
previously and in this chapter. Subsequently it was shown that the reduction in cell viability 
was due to a significant increase in cytotoxicity through activation of apoptosis. Previous 
studies have also shown that depletion of PRSS21 expression leads to apoptosis (Tang et al 
2005, Yeom et al 2010). Induction of apoptosis in cSCC was shown via two methods the 
Annexin V staining method and the caspase 3/7 assay, which confirmed that depletion of 
PRSS21, induces apoptosis through activation of caspases.  
 
In conclusion, from the data in this chapter it was decided to take PRSS21 forward and to 
undertake further study to determine if it would be a good molecular target for cSCC. 
PRSS21 will be further discussed in chapter 4. 
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2. Chapter 4 Assessment of the Function of PRSS21 in Cutaneous Squamous Cell Carcinoma 
4.1 INTRODUCTION 
In follow up of the microarray data (Watt et al 2011), chapter 3 further validates PRSS21 as 
a molecular target, showing that it is essential for cSCC survival. Serine proteases, such as 
PRSS21, control a wide range of proteolytic reactions essential for a diverse set of 
physiological and pathological functions. Additionally, in living systems, a balance between 
protease and their anti-proteases occur, and a disturbance of this balance leads to many 
diseases like cancer (Puente, Sanchez et al. 2003). The function and mechanism behind 
PRSS21 over-expression in cSCC are currently unknown, which is further explored in this 
chapter. 
4.1.1 Function of Proteases in Normal Tissue 
A plethora of proteases exist, which have a diverse range of fundamental functions in key 
biological processes, including inflammatory control, blood flow and immune regulation 
(Rawlings, Tolle et al. 2004). Evolutionarily, they derive from a large subset of catalytic 
enzymes which have the ability to hydrolyse peptide bonds (Puente, Sanchez et al. 2003). It 
was long considered that proteases sole role, was protein degradation, generally assigned to 
protein turnover and food digestion (Rawlings, Tolle et al. 2004). However, later work on the 
trypsinogen activation and blood clotting mechanism, revealed a previously unknown role 
for proteases in the tight regulation of biological pathways. The blood coagulation cascade, 
which is one of the most studied proteolytic cascades, involves sequential activation of pro-
enzymes or zymogens. The final activation step is thrombin which leads to fibrinogen 
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activation and blood clot formation (Davie, Fujikawa et al. 1991). By cleaving proteins, 
proteases are involved in the control of a large number of key biological processes such as 
cell cycle progression, cell proliferation, cell death, tissue remodelling, coagulation and 
immune response.  
 
The current identified sets of proteases are classified into five catalytic classes: metallo 
(194), serine (176), cystine (150), threonine (28) and aspartic proteases (21), the number of 
members within each class are in brackets. PRSS21 is a serine protease, so this group will be 
focused on below.  
4.1.1.1 Serine Proteases 
The serine proteases are the second largest and most conserved proteolytic family found in 
a number of tissues and biological fluids. For instance, trypsin one of the best characterised 
serine proteases, is expressed in skin, oesophagus, stomach, small intestine, colon, lung, 
kidney, liver, spleen and neuronal tissues (Koshikawa, Hasegawa et al. 1998). Serine 
proteases of the trypsin-like family contain N- or C- terminal domains which tether the 
catalytic domain to the plasma membrane, which allow proteolysis within the pericellular 
environment (Neurath and Walsh 1976). The membrane-anchored serine proteases can be 
divided into sub-groups depending on their structural features. For instance they can be 
anchored to the membrane by a C-terminal trans-membrane domain through a 
glycosylphosphatidylinositol (GPI) anchor or via an N-terminal trans-membrane domain with 
a cytoplasmic extension. PRSS21 is post-translationally modified with GPI anchor, and is 
subsequently found compartmentalised in lipid rafts of premiotic germ cells (Hooper, Nicol 
et al. 1999).  
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Serine proteases (figure 4.1) are characterised by the presence of three critical amino acids 
– histidine, aspartate and serine in their catalytic site, of which the serine acts as the active 
site (Davies, Pickard et al. 1998; Di Cera 2009). The catalytic domains are in the extracellular 
region, exposed to the pericelluar environment, requiring cleavage to become an active 
protein. The substrate specificities for the serine proteases hepsin, matriptase, prostatin 
and tryptase have been extensively characterised using peptide libraries however, very little 
information is available for other serine proteases such as PRSS21 (Herter, Piper et al. 2005; 
Beliveau, Desilets et al. 2009). The specific substrates targeted by these enzymes are 
important areas of study. 
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Figure 4.1 Domains and Catatytic Residues of Serine Proteases 
Serine proteases are defined by the serine residue (S) in the enzyme active site, which is 
part of a catalytic triad, also including histidine (H) and aspartate (D). Serine proteases can 
also contain a C-terminal domain which serves to anchor the serine protease domains 
directly to the plasma membrane. The example above is an example of a 
glycosylphosphatidylinositol (GPI) linked Serine Protease. 
 
4.1.2 Function of Proteases in Cancer 
Proteases in normal tissue are fundamental in carrying out important biological functions 
however in cancer they can be the cause of much disruption. Alterations in their expression 
patterns provide essential processes in cancer – proliferation, cell migration, invasion and 
angiogenesis (Puente, Sanchez et al. 2003). This would make proteases important at a 
number of stages in tumour progression and hence a worthy target for cancer therapy.  
 
It has long been recognised that proteolytic enzymes play a significant role in cancer 
invasion and metastasis (Chambers and Matrisian 1997; Lochter, Galosy et al. 1997; Mook, 
Figure 4.1 
 GPI  
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Frederiks et al. 2004; Deu, Verdoes et al. 2012). In 1946 Fisher proposed that the tumour 
associated proteolytic activity could be responsible for the degradation of the cell matrix 
and subsequent invasion into the surrounding tissue (Fisher A et al. 1946). Subsequently, in 
1957 Sylven and Malmgren reported the presence of proteases at the leading edge of 
tumours, where they showed that they were from the live tumour cells, not from leakage of 
dead cells either from the surrounding tissue or from the centre of the tumour (Sylven and 
Malmgren 1957). However, cancer cells can induce stromal cells to express proteolytic 
enzymes which promote cancer cell migration (Zucker, Cao et al. 2000). In the 1970s 
individual proteases began to be identified and over the next two decades molecular 
biological studies associated their gain-of function with invasion. By 1993 the general 
conception was that all 5 classes of proteases; serine, aspartic, threonine, cysteine and 
metalloproteinases, were involved in extracellular matrix (ECM) degradation. In particular, 
much of the attention has been given to the urokinase-type plasminogen activator (UPa) 
system, which is part of the serine protease group and the matrix metalloproteinases 
(MMPs), which is part of the metalloproteinase group. They have a well-recognised role in 
tumour invasion and metastasis and their levels and activities were found to be related to 
growth and distant spread of the tumour (Stetler-Stevenson, Aznavoorian et al. 1993; Dano, 
Romer et al. 1999). The enzymatic activity of proteases is regulated by levels of protease 
inhibitors which determine net enzyme activity on the cell surface and affect the extent of 
ECM degradation and tumour invasion (Puente, Sanchez et al. 2003). 
4.1.3 Serine Protease Inhibitors (serpin) 
In 1985 Carnell coined the term “serpin” to describe the family of serine protease inhibitors 
(Carrell and Travis 1985). Serpins, constitute the largest and most broadly distributed family 
of protease inhibitors which can be found in plants, fungi, bacteria, viruses and mammals of 
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which 36 have been confirmed in humans (Irving, Steenbakkers et al. 2002). The first serpins 
were found to tightly regulate blood coagulation (anti-thrombin) and inflammation (anti-
trypsin). While most serpins inhibit proteolytic cascades, certain serpins do not inhibit 
protease functions, but instead control functions such as storage, hormone carriage or have 
a tumour suppressive role (Getting 2002; Huntington 2011). Serpins can also be divided into 
extracellular (clade A) and intracellular (clade B) and some have cross class functions (i.e. 
inhibition of cysteine proteases). Characteristically, serpins have a reactive centre loop 
(RCL), a peptide stretch that is maintained in a rigid conformation for proteases to bind. The 
RCL allows for a conformational change which enables the site to provide an optimal state 
for binding and subsequent inhibition of a protease. Hence, the selectivity of a serpin to its 
protease is not always evident from its sequence, due to the structural change required to 
incorporate the protease (Hobson et al 2004). Also in existence, are serpins classed as non-
inhibitory, where their RCL is relatively short and unable to undergo a conformational 
change for protease inhibition- maspin (discussed in the following section) is an example of 
this subtype (Hopkins and Whisstock 1994; Pemberton, Wong et al. 1995). 
4.1.4 Mammary Serine Protease Inhibitor (maspin) 
Mammary serpin protease inhibitor (maspin) is a type II tumour suppressor first identified in 
mammary epithelial cells to inhibit invasion and motility in this cell type (Zou, Anisowicz et 
al. 1994). Of importance to this thesis, maspin was found to interact with PRSS21 in HeLa 
cervical cancer cells (Yeom, Jang et al. 2010). Using a yeast two hybrid screening method, 
DNA sequencing and basic alignment sequences revealed PRSS21 to interact with maspin. 
To confirm this interaction the authors used co-immunoprecipitation to show that PRSS21 
and maspin interact in 293 and HeLa cells and that they co-localise in the cytoplasm of HeLa 
cells. Furthermore, they show that in cervical cancer cells maspin modulated cell death and 
135 
 
invasion and that these effects could be inhibited by PRSS21, postulating that the ratio of 
maspin and PRSS21 may be important for tumour progression (Yeom, Jang et al. 2010).  
 
The maspin gene is located on chromosome 18q21.3-q23 and is frequently 
hypomethyalated in cancer (Futscher et al 2002). Its expression has been found to be 
predominantly down-regulated in a number of tumours – such as breast, gastric and 
melanoma however, it has also been shown to be over-expressed in some cancers which 
suggest that its role may be context dependant (Zou, Anisowicz et al. 1994). This difference 
may be accounted for due to the observations that maspin can localise to different sub-
cellular locations, either cytoplasmic or nuclear or perhaps due to maspin interacting with 
the surrounding extracellular matrix (Zou, Anisowicz et al. 1994; Chen, Florens et al. 2005; 
Lockett, Yin et al. 2006; Klasa-Mazurkiewicz, Narkiewicz et al. 2009). Maspin has sequence 
homology with members of the serpin family of protease inhibitors which acts as a serpin 
only to membrane bound serine proteases (Schneider, Schick et al. 1995; McGowen, Biliran 
et al. 2000).  
4.1.5 Cellular Function of Maspin 
In-vitro studies have revealed that the role of maspin as a tumour suppressor is a 
combination of increased cellular adhesion and apoptosis but also decreased angiogenesis. 
Several studies show that maspin increases cellular adhesion (Seftor, Seftor et al. 1998; 
Cella, Contreras et al. 2006). Furthermore, maspin knockout mice are embryonic lethal, 
partially due to disrupted visceral endodermal cell adhesion. Restoring the expression of 
maspin in invasive carcinoma cells alters the expression of proteins regulating cell death and 
cytoskeltal architecture – resulting in an increased apoptosis and reduced invasive capacity 
(Chen, Florens et al. 2005). Furthermore; tumour cells biologically induced to re-express 
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maspin exhibit significantly increased apoptotic responses to a variety of drugs (Jiang, Meng 
et al. 2002; Liu, Shi et al. 2013). 
 
Maspin is epigenetically regulated and its expression is closely associated with DNA 
methylation. The promoter methylation of maspin leads to silencing in a number of cancers. 
Maspin re-expression in breast tumour cells inhibits tumour invasion and metastasis (Zou, 
Anisowicz et al. 1994). Re-expression studies also confirmed that the inhibitory effect of 
maspin on tumour motility and invasion is localised on the tumour cell surface associated 
with increased ECM integrity and correlated with increased stability of cell ECM contacts 
(Sheng, Carey et al. 1996; Yin, Lockett et al. 2006). Finally of interest to this thesis, the 
clinical significance of maspin expression in SCC has been well documented in the literature, 
where re-activation of maspin may be important therapeutically in SCC of the cervix, oral 
and epithelia (Xia, Lau et al. 2000; Marioni, Staffieri et al. 2009; Liu, Shi et al. 2013; Marioni, 
Zanoletti et al. 2013). 
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4.2 RESULTS 
4.2.1 PRSS21 is Over-expressed in a Number of cSCC Cell Lines 
Before further investigating the function of PRSS21 in cSCC, its expression was quantified 
both at mRNA and protein level in a panel of cSCC cell lines isolated from a number of 
different patient types. The patient types investigated include RDEB, immunocompetant (IC) 
and transplant (T) and PRSS21 expression in these cells was compared to NHK. At mRNA 
level PRSS21 expression was up-regulated in all seven of the cSCC cell lines tested with the 
lowest expression seen in SCCRDEB3 and SCCRDEB4 cells (figure 4.2A). There was a good 
correlation between the mRNA and protein expression data (figure 4.2B), which also 
showed SCCRDEB3 and SCCRDEB4 to have the lowest expression, compared to NHK. These 
data would suggest that PRSS21 is over-expressed in a number of cSCC cell lines and hence 
is worth following up as a functional therapeutic target for the tumour type. 
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Figure 4.2 PRSS21 is Over-expressed in a Number of cSCC Cell Lines Compared to Normal Human 
Keratinocytes 
(A) qPCR comparing mRNA levels in primary normal human keratinocytes (NHK) to a panel 
of cSCC cell lines from recessive epidermolysis bullosa (SCCEB2,3 & 4), immunocompetent 
(SCCIC1 & 15) and transplant (SCCT1 & 2) patients. Results represent the mean±SD, n=2. (B) 
Protein expression of PRSS21 (35KDa) in a panel of cSCC cell lines (above) as determined by 
western blot (n=2).  
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4.2.2 PRSS21 is Localised to the Cytoplasm of cSCC Cells 
Immunofluorescence staining of cSCC cells, SCCRDEB2, SCCRDEB4 and SCCT8 show that 
PRSS21 is localised in the cytoplasm of cSCC cells with marked expression likely in the 
endoplasmic reticulum (ER). However, double staining with an ER marker would be required 
to confirm this localisation (figure 4.3). This is surprising as PRSS21 is a GPI linked protein 
which is supposed to localise it to the cell plasma membrane however other groups have 
also noted cytoplasmic localisation (Tang, Kmet et al. 2005; Yeom, Jang et al. 2010). 
Additionally loss of membrane polarity and the epithelial to mesenchymal transition can 
occur in tumour cells. There two processes have been previously shown to affect the cellular 
distribution of many of the membrane anchored serine proteases which may explain the 
misslocalisation observed in PRSS21 in cSCC cells (Lucas, J.M. 2008). Different fixatives did 
not change the localisation of PRSS21 (data not shown). 
 
 
 
140 
 
 
Figure 4.3 Immunofluorescent staining shows that PRSS21 is expressed in the cytoplasm of cSCC cells 
Methanol:acetone fixation of SCCRDEB2, SCCRDEB4 and SCCT8 cells followed by immunofluorescent detection for PRSS21 (top panel), 
shows that PRSS21 is localised in the cytoplasm of these cSCC cell lines. DAPI in the lower panel was used as a nuclear counter stain. 
Magnification 64x, n=3. 
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4.2.3 Retroviral Over-expression of PRSS21 Increases Migration and Invasion in 
K1 Cells 
The previous chapter 3, showed that the expression of PRSS21 was important for cSCC 
tumour cell survival, yet little is known about the function of PRSS21 in this tumour type. 
Proteases have been shown to function to increase motility and invasive capacity of a 
tumour. In order to explore this, PRSS21 was retrovirally over-expressed in HPV 
immortalised, normal human keratinocyte line – K1. Retroviral over-expression is a way to 
stably express a gene of interest, which is more useful when looking at the long term effects 
of a gene. By comparison, depletion of a gene using siRNA results in transient knockdown of 
the gene. K1 cells were chosen as they have very little endogenous levels of PRSS21, which 
allows the function of PRSS21 to be explored in this cell type. Using a retroviral transduction 
method (see materials and method section 2.5.7), these cells were transduced with either 
the empty pBABE vector as a control (K1pB) or with the pBABE vector containing PRSS21 
(K1PRSS21). Retroviral over-expression of PRSS21 was then confirmed in these two lines 
using both qPCR and western blot. qPCR (figure 4.4A) shows that the relative expression of 
PRSS21 is ~15 fold higher in the K1PRSS21 cells than the K1pB cells at mRNA level. PRSS21 
expression, at protein level was assessed using western blot (figure 4.4B) which shows a 
significant over-expression of PRSS21 in the K1PRSS21 cells compared to K1pB. Additionally, 
it confirms that the K1pB cells have no endogenous expression of PRSS21.  
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Figure 4.4 Confirmation of Retroviral Over-expression of PRSS21 (K1PRSS21) compared to 
Empty Vector (KipB) in K1 Cells at the mRNA and Protein Level  
 K1 cells were retrovirally transduced with an empty vector pBABE control (K1pB) or PRSS21 vector 
(K1PRSS21). (A) qPCR showing that the relative mRNA expression of PRSS21is ~15 fold higher than in 
K1pB. (C) Western blot showing the expression of PRSS21 in both the K1pB and K1PRSS21 at protein 
level, GAPDH acts as a loading control. (n=3) 
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4.2.4 Over-expression of PRSS21 Increases Cell Migration  
Cell migration is required for many important biological processes including tissue 
remodelling and tumour invasion. Many proteases act at the leading edge to direct cell 
migration and increase a tumours invasive phenotype. The scratch assay is a cheap effective 
method to investigate cell migration (Kohn & Liotta 1995)). Confluent cultures are grown 
and mitotically inactivated, using mitomycin C so that cell proliferation does not interfere 
with the cells migratory capacity. A scratch is created and representative images taken at 
0h, 8h and 18hs (see chapter 2, section 2.8.5 for the methods). Using the in-vitro migration 
assay figure 4.5A shows an increase in migration in the cells expressing K1PRSS21 relative to 
the empty vector K1pB control, 18h after the scratch was performed. These data suggests 
that the over-expression of PRSS21 in cSCC may increases cell migration. 
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Figure 4.5 K1PRSS21 Cells Migrate Faster Than K1pB Cells 
(A) Using the in-vitro migration assay, confluent K1pB or K1PRSS21 cells were scratched and images 
taken at 0h, 8h and 18h. The images taken at 8h and 18h show that K1PRSS21 cells migrate faster 
than K1pB cells to close the gap. n=3, images taken at 40x magnification.  
Figure 4.5 
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4.2.5 PRSS21 Expression in Keratinocytes Increases Invasion in 3D Culture 
Over the past decades the ability to mimic human skin in-vitro in three dimensional 
organotypic co-cultures of mesenchymal and epithelial derived cells supported by an 
extracellular matrix has evolved. A number of three dimensional methods exist such as 
scaffold-free platforms for spheroid growth, scaffolds, gels, bioreactors and microchips. 
Here, the collagen matrigelTM system was used as it is routinely used within Dr South’s lab. 
matrigelTM was first documented in 1972 by Hynda Kleinman and is reconstituted BM 
preparation extracted from Engelbreth-Holm-Swarm mouse Sarcoma, a tumour rich in ECM 
proteins such as lamina and collagen plus growth factors (for review see Kleinman 2005). 
The set-up involves stromal fibroblasts either being embedded in collagen I, MatrigelTM. 
Fibroblast embedded matrices are then used to support the growth of keratinocytes which 
are induced to stratify by being raised above the air-liquid interface (the assay is detailed in 
figure 2.1). Organotypic models have been extensively used to help model tumour invasion 
in the skin (Nystrom et al 2005, Martins et al 2009, Ng et al 2012).  Additionally these 3D 
models with incorporated fibroblasts allow the user to explore stromal-epithelial 
interactions, which have been previously shown to be important for tumour initiation and 
progression (Ng, Pourreyron et al. 2012). To examine whether the expression of PRSS21 had 
an effect on invasion, K1pB or K1PRSS21 transduced cells were cultured on 
collagen:matrigel gels with incorporated normal fibroblasts (figure 4.6A). Expression of 
PRSS21 increased invasion of keratinocytes into the gel almost 2 fold. Quantification of 
invasion showed that after a relatively short period of 7 days there was a 1.5 fold increase in 
invasion into the gel (figure 4.6B).  
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Figure 4.6 Collagen:matrigels Show Increased Invasion in K1PRSS21 Cells Compared to K1pB 
Transduced Cells. 
(A) K1pB or K1PRSS21 cells were seeded onto collagen:matrigels and gels processed after 7 or 14 
days. Sections were cut and stained using H&E which shows that the K1PRSS21 cells invade deeper 
than the K1pB cells. Results are representative of 2 independent experiments, with 8 sections 
stained from each. Images taken at 40x magnification (B) Depth of invasion was quantified using an 
invasion index showing that K1PRSS21 invades into the gel after 7days. Results represent the mean ± 
SD of 8 stained sections across 2 experiments.  
Figure 4.6 
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4.2.6 PRSS21 and Maspin Interact in cSCC Using the PLA Assay 
PRSS21 and maspin have been shown to interact in cervical cancer cells, and their 
relationship is thought to be important for tumour progression in this cell type (Yeom et al 
2010). The proximity ligation assay (PLA) has previously been used to detect protein-protein 
interactions using antibodies which are not suitable for the standard method of detecting 
interactions - co-immunoprecipitation. CO-IP was attempted; however the antibody to 
PRSS21 had a lot of background/non-specific staining using western blot which affected the 
ability to specifically detect bound proteins which have the ability to maintain stable 
interactions. The PLA principal is based on two primary antibodies raised in different species 
being able to recognise the target protein of interest i.e. PRSS21 and maspin (see section 
2.8.6). Subsequent incubation with a species specific secondary PLA probes, with short DNA 
strands attached binds to the respective primary antibody. After addition of the PLA probes, 
if they are in close proximity then the DNA strands can interact through addition of circle 
forming DNA which is amplified using phi29 DNA polymerase in rolling circle amplification 
(RCA). The resulting RCA product indicates a physical interaction between the two proteins. 
Additionally, an RCA product can be labelled by hybridisation of many fluorophore 
conjugated DNA oligonucleotides which allow fluorescent visualisation by microscopy. The 
resulting fluorescent staining indicates an interaction. Using PLA to determine if this 
interaction occurs in cSCC cells Figure 4.7 shows that PRSS21 and maspin both interact in 
the cytoplasm in-vivo in SCCRDEB2 xenograft tissue. A control with the secondary antibody 
only, shows that there is a slight background effect. The lower panel of images indicates 
DAPI counter staining for both images. 
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Figure 4.7 PRSS21 and Maspin Interact in-vivo in cSCC As Determined By PLA 
Images represent cytoplasmic protein-protein interaction between PRSS21 and maspin in xenograft 
SCCRDEB2 tissue as detected by the PLA assay. Results represent n=2 experiments. 
 
 
4.2.7 Depletion of PRSS21 Increases Maspin Expression at mRNA Level and 
Transient Over-expression of PRSS21 Significantly Reduces the 
Expression of Maspin in cSCC Keratinocytes 
Using siRNA to knockdown the mRNA expression of PRSS21 in cSCC keratinocytes figure 
4.8A shows a 60% increase in the expression of maspin using pooled siRNA (PRSS21_P) 
targeted to PRSS21 relative to the non-targeting control (SCR). Additionally, over-expression 
of PRSS21 using cDNA (OriGene, Rockville, MD) in SCCRDEB2 further reduces the expression 
of maspin at protein level 48 hours after transient transfection (figure 4.8B). 
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Figure 4.8 Depletion of PRSS21 Increases Maspin Expression at mRNA Level and Over-expression 
of PRSS21 Reduces the Expression of Maspin in SCCRDEB2 Cells at Protein Level 
(A) qPCR following siRNA knockdown of PRSS21 using individual oligonucleotides (PRSS21_1/2) or 
pooled oligonucleotides (PRSS21_P) shows a 60% increase in maspin expression in SCCRDEB2 cells. 
Results represent the mean±SD of 3 independent experiments. (B) Western blot showing protein 
expression of PRSS21 and maspin following transient transfection of SCCRDEB2 cells with PRSS21 
cDNA reduces the expression of maspin. β-Tubulin was used as a loading control. immunoblot is 
representative of 3 independent experiments. 
 
Figure 4.8 
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4.2.8 PRSS21 Expression is Reduced in Normal Human Skin Compared to a Panel 
of cSCC Xenogafts  
Immunofluorescence staining of PRSS21 and maspin in normal human skin shows that 
maspin is strongly expressed throughout the epidermis whereas PRSS21 expression is much 
lower (figure 4.9). Maspin is also predominantly expressed in the cytoplasm throughout the 
epidermis.  
 
In 5 out of the 6 tumours stained, PRSS21 expression (figure 4.10A1) is increased compared 
to maspin expression (figure 4.10A2). However, SCCIC8, which is a well differentiated 
tumour, is the only tumour to have stronger staining of maspin compared to PRSS21. 
Maspin is thought to be associated with well differentiated tumour types. Additionally 
SCCRDEB2 has patches of high maspin expression, which may be associated with an area of 
differentiation in this tumour type. DAPI was used as a nuclear counter-stain for the staining 
– these images are in figure 4.10B1, 4.10B2 for PRSS21 and maspin staining, respectively. 
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Figure 4.9 Immunofluorescent Staining of Normal Human Skin with Antibodies Raised Against 
PRSS21 and Maspin. 
Top panel shows that normal human skin (NHS) has no positive PRSS21 staining however 
the middle panel shows that NHS has positive maspin expression throughout the epidermis, 
with the majority of expression localised in the cytoplasm. The lower panel is a negative 
control for the secondary antibody. Results are representative of 2 experiments. All images 
taken at 16 x magnifications apart from inset of primary maspin antibody staining which is 
at 40x magnification.  
Figure 4.9 
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Figure 4.10A Expression of PRSS21 and Maspin in a panel of cSCC Xenograft Tumours 
Immunofluorescent staining of PRSS21 (1) or maspin (2) in formalin fixed paraffin embedded 
xenograft tumours. Tumours are from recessive dystrophic epidermolysis bullosa (RDEB), transplant 
(T) and immunocompetent patients (for more clinical details see table 2.1). Images taken at 16x 
magnification. N=2 
Figure 4.10A 
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Figure 4.10B DAPI for Xenograph Staining in Figure 4.7A 
Immunofluorescent staining of PRSS21 (1) or maspin (2) in formalin fixed paraffin embedded 
xenograft tumours. Tumours are from recessive dystrophic epidermolysis bullosa (RDEB), transplant 
(T) and immunocompetent patients (for more clinical details see table 2.1). Images taken at 16x 
magnification. N=2 
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4.2.9 Retroviral Over-expression of PRSS21 Reduces Maspin Expression in 
Organotypic Cultures 
Staining of collgan:matrigels with K1pB and K1PRSS21 with antibodies to maspin or PRSS21 
confirms there is an increased expression of PRSS21 in the cells transduced with PRSS21 
compared to the empty vector control cells (figure 4.11). Additionally, the expression of 
PRSS21 is more prominent at the leading edge of the invading cells in the gels with 
K1PRSS21. A concurrent reduction in maspin expression is also seen in these cells; K1pB 
express significantly more maspin than the K1PRSS21.  
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Figure 4.11A Retroviral Over-expression of PRSS21 Reduces Maspin Expression in Organotypic 
Cultures 
The top panel shows PRSS21 staining in K1PRSS21 collagen:matrigel organotypic cultures  is 
over-expressed compared to K1pB. The lower panel shows the opposite is true for maspin 
expression; which is highly expressed in K1pB cells but not K1PRSS21 organotypics. Images 
are representative of 2 independent experiments. Images taken at 16x magnification. 
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Figure 4.11B DAPI for collagen:matrigels in figure 4.11A 
The top panel shows DAPI staining for PRSS21 staining in K1PRSS21 collagen:matrigel 
organotypics in figure 4.8A. The lower panel shows the DAPI staining for maspin staining in 
K1pB collagen matrigel organotypic s in figure 4.8A. Images taken at 16x magnification. 
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4.2.10  Retroviral Over-expression of PRSS21 Reduces Involucrin Expression 
Previous work on maspin expression has shown its expression in skin and cutaneous 
carcinomas to be associated with differentiation status (Reis-Filoh et al 2002). Involucrin is 
marker of terminal differentiation and contributes to the cornified envelope of the skin 
(Eckrt & Green et al 1986). Haematoxylin and Eosin staining of 3D organotypic gels with 
cultured K1PRSS21 or K1pB cells, indicated that there was a decrease in keratin and the 
cornified envelope in the K1PRSS21 cells compared to K1pB (figure 4.6), indicative of a 
decrease in differentiation in this cell type. Using involucrin as a marker of differentiation, 
retroviral over-expression of PRSS21 in K1 cells reduces the expression of involucrin 
compared to the empty vector control after 7 days and 14 days (figure 4.12A and B. 
respectively).  
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Figure 4.12A K1PRSS21 Collagen:matrigels Have a Lower Expression of Involucrin After 7 days Compared to K1pB gels. 
Collagen:matrigels with either KIpB cells (top panel) or K1PRSS21 (lower panel) were stained with involucrin, 7 days after the gels were raised 
above the air:liquid interface. DAPI was used as a nuclear counter stain. Images taken at 16x magnification , n=2. 
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Figure 4.12B K1PRSS21 collagen:matrigels Have a Lower Expression of Involucrin After 14 Days compared to K1pB control collagen:matrigels 
Collagen:matrigels with either KIpB cells (top panel) or K1PRSS21 (lower panel) were stained with involucrin, 7 days after the gels were raised 
above the air:liquid interface. DAPI was used as a nuclear counter stain. Images taken at 16x magnification, n=2. 
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Figure 4.12C No Primary Antibody Control For Figures 4.12A, B 
Collagen:matrigels with either KIpB cells (top panel) or K1PRSS21 (lower panel) were stained 
without the primary antibodies, to control for background staining caused by the secondary 
antibody. Images represent the secondary antibody staining and DAPI counter stain control 
merged together to show that there is very little background staining with this antibody. 
Images taken at 16x magnification, n=2. 
Figure 4.12C 
K1pB K1PRSS21 
Da
y 
7 
Da
y 
14
 
161 
 
4.2.11 PRSS21 depletion induced caspase activity is dependent on maspin 
Previous work has shown that maspin is able to sensitise cancer cells to apoptosis (Liu, Shi et 
al. 2013). To analyse whether the PRSS21 siRNA induced caspase mediated cell death (figure 
3.15A) could be regulated by maspin, a double knockdown strategy was employed by 
depleting both PRSS21 and maspin simultaneously. This showed a clear attenuation of 
PRSS21 depletion induced caspase activation, when maspin levels were reduced (figure 
4.13). Hence PRSS21 depletion induced caspase activity is dependent on maspin. 
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Figure 4.13 PRSS21 Depletion Induces Caspase 3/7 Activation Which Can be Attenuated Upon Depletion of Maspin 
Using a siRNA knockdown strategy PRSS21 knockdown is shown to block maspin-induced caspase 3/7 activity. Positive cell death siRNA control (PC) siRNA 
was used as a positive control for caspase activation; “Mock” is a lipofectamine alone. All results show the mean ± SD,n=3, ***P<0.001. GAPDH was used as 
a loading control. 
Figure 4.13 
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4.3 DISCUSSION 
Previous work in our lab identified PRSS21 as being over-expressed in cSCC compared to 
normal human keratinocytes. This fits with a number of other publications showing that 
PRSS21 is over-expressed in a number of other cancers including ovarian, cervical, 
melanoma and lymphoma (Hooper, Nicol et al. 1999; Hooper, Bowen et al. 2000; Honda, 
Yamagata et al. 2002; Tang, Kmet et al. 2005). Subsequently, it was shown to induce colony 
formation and promote malignant transformation in ovarian cancer cells (Tang, Kmet et al. 
2005). Gene expression analysis identified PRSS21 to be over-expressed in cSCC in-vivo 
(average fold change of 1.5 over three independent data sets) compared with normal skin 
and in-vitro (7.4 fold, p<0.0005, n=8) compared to normal keratinocytes (Watt 2011). In the 
previous chapter 3, PRSS21 was shown to be important for cSCC cell survival. RNAi 
knockdown of PRSS21 decreases cell viability (figure 3.13), through increased cytotoxicity 
(figure 3.2). Normal primary keratinocytes are unaffected. Cell death is via apoptosis as 
detected by an increase in cytoplasmic nucleosomes (figure 3.14), caspase activity (figure 
3.16A) and Annexin V/7AAD positive cells (figure 3.16B). In this chapter, to explore the 
function of PRSS21 in cSCC keratinocytes, PRSS21 was over-expressed in a HPV immortalised 
normal human cell line, K1. K1 cells were chosen as they have low levels of endogenous 
PRSS21, which allows unequivocal exploration of its function and to observe if expression of 
PRSS21 transforms the behaviour of this keratinocyte cell line. Primary keratinocytes were 
not used as they cannot be split for successive rounds, as they tend to differentiate after 
three or more passages.  
 
Degradation of ECM is an important pre-requisite of local invasion and distant metastasis of 
tumour cells. Organotypic cultures on collagen:matrigel gels have previously been utilised to 
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study tumour invasion as they are a good 3D model of the skin tumour invasion. Developed 
by Fusenig and colleagues, these gels allow the user to assess the “invasion index” of 
tumour cells and highlight the importance of the underlying communicators – the stromal 
cells in modulating the ability of tumour cells to invade (Fusenig et al 1983). Additionally, 
they enable a 3D model which recapitulates the in-vivo situation more closely than 2D cell 
culture. Using this 3D method, cells over-expressing PRSS21 (K1PRSS21) invade deeper into 
the gel than those expressing the empty vector as a control. Additionally, even after 14 days 
an intact dermal-epidermal junction is present in the K1pB cells and they closely resemble 
an organotypic formed by normal keratinocytes with proper stratification. It would be useful 
to stain for basement membrane proteins to illustrate an intact dermal epidermal junction. 
Using a yeast two-hybrid system to identify an intracellular target of PRSS21, maspin was 
first shown to interact with PRSS21 in human HeLa cells – a cervical cancer cell line (Yeom, 
Jang et al. 2010). The authors show that the ratio of maspin and PRSS21 expression 
determines the invasiveness of two cervical cancer cells using transwell inserts coated with 
matrigel. siRNA knockdown of PRSS21 and maspin modulates the invasiveness of these 
cervical cancer cells, where siRNA depletion of maspin, increases the number of cells that 
have moved from the upper chamber to the lower chamber of the transwell insert, 
indicating an increase in invasion in the presence of PRSS21. Furthermore, maspin 
expression decreased the invasiveness of cervical cancer cells, and invasiveness was 
restored through expression of PRSS21 (Yeom, Jang et al. 2010). In this thesis, antibody 
staining of organotypic cultures with K1PRSS21 or K1pB cells demonstrates that maspin 
expression is reduced when PRSS21 is over-expressed in K1 cells. This reduction in maspin in 
addition to the expression of PRSS21 could aid the invasive phenotype of the K1PRSS21 
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cells. It is thought that maspin’s ability to bind to the surface is key to its ability in decrease 
invasion and motility in breast and prostate cancer cells. Perhaps what might be happening 
is that the over-expression of PRSS21 results in maspin being secreted out of the cell to act 
at the cell membrane to inhibit invasion. Also of striking appearance, is that the over-
expression of PRSS21 is highest at the leading edge of the tumour, which would be most 
important for its protease activity involved in invasion. One key experiment in follow up to 
these results would be to carry out site-directed mutagenesis on the essential serine in the 
catalytic domain of PRSS21 so that it loses its protease function and observe if this changes 
the amount of invasion. Unfortunately, due to time constraints this was not possible. 
Haematoxylin and eosin staining of collagen matrigels with K1PRSS21 and K1pB shows 
noticeable differences in cellular differentiation. K1pB organotypics have a much larger 
cornifed layer than that of the K1PRSS21. Following this observation, the organotypics were 
stained with the terminal differentiation marker involucrin. This showed that there was a 
significant decrease in involucrin upon PRSS21 over-expression thereby indicating a 
decrease in differentiation. The expression of maspin is associated with differentiation 
status in lung adenocarcinoma and oral cSCC and is therefore indicative of good prognosis 
(Xia et al. 2000, Lonardo et al 2005). Furthermore, two studies have shown that maspin is 
more likely expressed in well-differentiated subtypes; especially in keratinous pearls which 
are swirl shaped accumulations of keratin made by malignant squamous cells (Yasumatsu et 
al. 2001, Reis-Filho et al 2002). Hence, perhaps the expression of maspin in cSCC is 
responsible for increasing differentiation and this function contributes to its tumour 
suppressive mechanism in normal keratinocytes and early stage cSCCs.  
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To summarise the data on PRSS21 the following hypothetical model has been developed to 
show that the ratio of PRSS21 and maspin may be important for cSCC cancer progression 
(figure 4.11). In normal cells maspin is highly expressed and its localisation has been 
demonstrated to be not only cytoplasmic, but nuclear, membrane bound and secreted into 
extracellular compartment (Zou, Anisowicz et al. 1994; Khalkhali-Ellis 2006). However 
PRSS21 is expressed at low levels in normal keratinocytes perhaps due to the high levels of 
maspin acting as a tumour suppressor in normal cells.  In cSCC tumour cells a significant 
over-expression of PRSS21 reduces the expression of maspin perhaps through negative 
regulation. The ability of PRSS21 to increase proliferation and simultaneously increase 
invasion helps tumour cells to break away to colonise in other parts of the body. However 
maspin plays an opposing role as an important tumour suppressor which modulates tumour 
motility, inhibiting invasion and cellular migration. Maspin has been shown to affect cell 
adhesion through cytoskeletal reorganisation and integrin signalling transduction pathway. 
Additionally work here and in previous publications would suggest it also does this by 
contributing to differentiation. 
 
167 
 
 
Figure 4.11 PRSS21 cSCC Hypothesis 
(A) In normal tissues maspin is expressed at high levels to act as a tumour suppressor whereas PRSS21 is expressed at low levels in normal 
tissues. Following transformation of a normal cell into a tumour cell PRSS21 is substantially increased aiding tumour cell proliferation and 
invasion which helps it colonise new organs. Subsequently maspin expression is reduced, possibly through negative regulation by PRSS21 (B) 
Possible importance of the ration of maspin:PRSS21 in cancer progression, where a higher ratio of PRSS21 favours cancer progression. 
A. B. 
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Previous studies have shown that knockdown of PRSS21 expression leads to apoptosis 
(Tang, Kmet et al. 2005; Yeom, Jang et al. 2010). Using a caspase 3/7 assay and a double 
knockdown strategy it would appear that PRSS21 induced caspase activity is maspin 
dependant. Although it was shown that maspin does not directly regulate the activity of 
caspase-3 it appears to facilitate an upstream event that leads to its activation (Jiang, Meng 
et al. 2002). Figure 4.12 summarises the contribution of PRSS21 depletion and hence acts as 
a hypothetical model for cSCC therapy through PRSS21 inhibition. Chapter 3 showed that 
depletion of PRSS21 using siRNA lead to a significant reduction in cell viability, through 
increased cytotoxicity and cell death. The function of PRSS21 has been further explored in 
chapter 4 and shows that retroviral over-expression leads to a significant increase in 
invasion of keratinocytes. This would suggest that depletion of PRSS21 may reduce invasion, 
possibly by increasing maspin expression. This data together with existing literature 
suggests that PRSS21 may act to negatively regulate maspin expression and that small 
molecular inhibitors of PRSS21 may be useful for cSCC therapy either alone or in 
combination with another therapeutic target for cSCC. 
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Figure 4.12 Hypothetical Model for cSCC therapy through PRSS21 Inhibition 
Inhibition of PRSS21 may release its negative inhibition on maspin causing it to be 
upregulated. Work in this thesis has demonstrated that depletion of PRSS21 reduces 
proliferation and increases cell death through caspase activation.  
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5 Chapter 5 Assessing the Contribution of Notch Signalling to Differentiation in Cutaneous Squamous Cell Carcinoma 
5.1 INTRODUCTION 
5.1.1 Identification of loss of function mutations in notch receptors (Wang 2011) 
Exome level sequencing identified at least one notch1/notch2 mutation in 9/11 cSCC 
samples. Additionally, Sanger sequencing in one further cSCC and 14 cSCC cell lines, gave an 
overall mutation rate of ~75% (19/26) (Wang, Sanborn et al. 2011). Most of the mutations 
identified were truncations and a number of other mutations resulted in loss of function 
through point substitutions within the domains necessary for function. Of great importance 
to this project is the isolation and establishment of three notch1 null cSCC cell lines, which 
using Sanger sequencing have been identified to have a homozygous stop codon mutation. 
South and colleagues also undertook whole exome sequencing, in addition to targeted deep 
sequencing on a total of 102 cSCC tumour samples giving an overall frequency of 84%, thus 
confirming the importance of loss of function of notch in cSCC (South, unpublished). 
 
Additionally, eight BCCs were also Sanger sequenced, yet no notch1 and notch2 mutations 
were identified in this cell type (Wang, Sanborn et al. 2011). However, more recent work 
using a genome wide mutagenesis approach identified a role of notch1 as a potential driver 
in BCC suggesting that perhaps a larger n number may yield a higher number of mutations 
(Quintana et al 2013). In addition to the sequencing of these skin tumours, Wang and 
colleagues also describe a small number of loss of function notch1 and notch2 mutations in 
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lung SCC. However currently, the function of notch in this tumour type is debatable; gain-of-
function notch1 mutations have also been previously described in this tumour type 
(Westhoff, Colaluca et al. 2009). In parallel, two independent groups published back-to-back 
studies in Science identifying loss of function notch mutations in 15-20% of head and neck 
SCC, further endorsing a role for notch in SCC (Agrawal, Frederick et al. 2011). The recent 
identification of such mutations has arisen as, due to the notch genes being so large, 
conventional screening of entire ORF by Sanger sequencing was generally prohibited by cost 
and it was only the advent of next generation sequencing technologies where such 
mutations were identified. For an introduction to the notch pathway please see the section 
1.1.2, p31. 
5.1.1.1 Sanger sequencing 
Fred Sanger’s method of DNA sequencing was based on the earlier work of Arthur Kornberg 
on DNA replication, where a new DNA strand is synthesised using an existing strand as a 
DNA template (Sanger, Nicklen et al. 1977). To begin the sequencing process the DNA is 
amplified, usually by PCR. Following amplification the next major step is to expose the target 
sequence to DNA polymerase; polymerisation is driven in a sequence specific manner to 
construct a new DNA strand. The method also known as chain termination sequencing is 
based on the use of modified nucleotides, which when integrated into the DNA sequence 
prevent further addition of nucleotides thus terminating the chain. Following the 
termination step, these chained fragments remain bound to the DNA template strand. 
These strands are then heated and separated using high resolution denaturing gel 
electrophoresis. The sequence of the original strand is then deduced from the relative 
positions on the gel due to the terminators being labelled (Smith, Sanders et al. 1986).  
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The concept of next generation sequencing is similar to Sanger sequencing, in that the bases 
if a small fragment of DNA are sequentially identified from signals emitted as each fragment 
is re-synthesised from DNA template strand. However next generation sequencing extends 
this process across millions of reactions in a massively parallel fashion rather than being 
limited to a single/few DNA fragments (Mardis 2008). 
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5.1.2 Notch as an Oncogene 
Although the focus of this thesis is regarding notch as a tumour suppressor, it must be noted 
that notch can also serve as an oncogene in some cellular contexts. Notch was first 
identified as an oncogene in the early 90’s following the finding of a balanced translocation 
involving notch1 gene and the TCRβ locus in a subset of acute lymphoblastic leukaemia, 
which lead to a constitutively active truncated notch (Ellisen, Bird et al. 1991). This 
translocation was observed in mice, however rarely occurred in humans, occurring in less 
than 1% of the population of human T-cell acute lymphoblastic leukaemia/lymphoma (T-
ALL). Although this specific translocation has rarely been seen, notch1 gain-of-function 
mutations have been identified in almost 60% of primary T-ALL patients.  Activating 
mutations in human T-ALL are mainly confined to notch1 with the most common mutations 
falling within the trans-membrane domain that allow ligand independent activation or 
within the PEST domain which result in persistence in activation signal for notch (For a 
detailed review of oncogenic notch mutations in T-ALL see Aster et al 2008).  
5.1.3 Notch as a Tumour Suppressor 
On the contrary, loss of function signalling has been seen in a number of tumour types such 
as skin cancer, small-cell lung cancer, head and neck cancer and cervical cancer (Wang et al 
2011, The Cancer Genome Research Network 2012, Agrwal et al 2011, Maliekal et al 2008). 
The focus of this chapter is on the function of notch in the skin/keratinocyte system. 
Radtke’s group were the first to describe notch as a tumour suppressor through the 
increased incidence in skin cancers in conditional notch1 knockout mice which formed a 
number of BCC and papallomas in mice at 8-12 months of age. However, using a specific 
inhibitor of the Notch transcription complex, dominant negative MAML1, led to the 
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development of cSCC in murine skin (Proweller, Tu et al. 2006). The differences observed by 
these two groups have been attributed to increased severity when knocking down all four 
receptors with DN-MAML. Notch1 deficient mice are also more susceptible to development 
of skin cancer in oncogenic RAS background (Lefort, Mandinova et al. 2007). This work 
suggests that notch may be required for ras-induced clonal expansion and fits with data 
from our lab that 60% of HRAS-driven lesions have notch mutations (South et al submitted). 
The genetic studies above demonstrate a role for notch, particularly notch1 as a potent 
tumour suppressor in skin. Notch1 is expressed in the suprabasal layers of the epidermis 
and is a direct transcriptional target of p53 (Lefort, Mandinova et al. 2007), Notch2 is 
expressed in the basal layer and its contribution to tumour suppression is less clear (Dotto 
2008). While the timing of these Notch lesions thoroughout cancer progression is not 
known, data supports the role of notch in cSCC progression rather than in initiation. Wang 
and colleagues described a high frequency of G>A transitions induced by UV after 
homozygous p53 loss (85% of notch mutations) (Wang, Sanborn et al. 2011). 
 
A number of tumour suppressive mechanisms have been proposed for notch in the skin (for 
review see (Dotto 2008, South 2012). In-vitro work carried out by Dotto’s group show that 
notch activation induces differentiation through interferon regulatory factor 6 (IRF6) 
(Restivo, Nguyen et al. 2011) and an important role for p21 as a mediator of notch1 induced 
cell cycle arrest suggesting that loss of notch function in cSCC enables tumours to continue 
growing (Rangarajan, Talora et al. 2001). Besides cell cycle withdrawal, keratinocyte 
differentiation is elicited by induction of differentiation markers of the suprabasal layers 
(keratin 1/10, involucrin; (Rangarajan, Talora et al. 2001), (Nickoloff, Qin et al. 2002)). Cross 
talk between a number of pathways linked to skin carcinogenesis including RAS, NFκB, Wnt 
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and Hedgehog have also been described to contribute to tumour suppressive activity. 
Kopan’s group conversely suggest that the loss of function of notch produces a chronic 
inflammatory state that promotes tumour growth through factors released by the 
fibroblasts creating a tumour micro-environment through increased inflammation (Demehri, 
Turkoz et al. 2009). However, the downstream molecular mechanisms remain to be defined 
and currently discrepancies between mouse and human models are evident. For instance, 
notch induced up-regulation of p21 is associated with suppression of Wnt (Devgan, 
Mammucari et al. 2005) in mouse keratinocytes but in human keratinocytes notch activation 
leads to suppression of growth and induction of differentiation related, in part due to 
reduced p63 expression rather than increased p21 (Nguyen, Lefort et al. 2006). 
5.1.4 Targeting Notch for Cancer Treatment 
Notch can act as either an oncogene or a tumour suppressor, suggesting that notch 
signalling is highly context and cell type dependant which has complications for targeted 
therapy. One current approach to inactivate notch signalling in an oncogenic setting is via 
the inhibition of the gamma secretase complex. At present there are a number of gamma 
secretase inhibitors (GSI) available which were originally formulated for the treatment of 
Alzheimer’s disease. Gamma secretase is implicated in the pathogenesis of Alzheimer’s as it 
cleaves amyloid β peptide- the principle component of the characteristic cerebral plaques 
found in Alzheimer’s. The use of GSIs for this disease resulted in the formation of skin 
tumours without improvement of the disease itself and hence termination of the clinical 
trial. Following termination of the trial it was discovered that the tumour formation was a 
result of loss of notch signalling in brain tissue. Currently GSIs which don’t inhibit notch 
signalling are being developed (Tang, Kmet et al. 2005). However a new niche for these 
compounds is being explored, in tumours where notch is oncogenic. Phase I and II clinical 
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trials are being carried out for various malignancies including breast, advanced solid 
tumours and pancreatic (Tolcher et al 2012, Krop et al 2012). However these trials aim to 
carefully modulate notch expression to prevent any secondary cancers forming that may 
outweigh the treatment benefits. 
 
On the flip-side agents which interfere with the epigenetic silencing of notch are currently in 
investigation for tumours with loss of notch function. Histone deacetylase inhibitors 
inhibitors have previously been reported to reduce tumours through reduction of notch in 
pre-clinical models (Pinchot et al 2011). Additionally a phase II study using Valporic acid 
showed that notch1 expression significantly increased after treatment (Mohammed et al 
2011). However a more context and functional understanding of the notch pathway in the 
context of each cancer is required. 
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5.2 RESULTS 
5.2.1 Activated ICN1 is reduced in cSCC compared to normal human 
keratinocytes 
In order to confirm that notch1 is reduced in cSCC a panel of cSCC cells were assessed for 
protein expression of the activated form of notch1 (activated ICN1). Western blot of a panel 
of cell lines showed that in all of the cSCC lines tested, cleaved notch1 (ICN1) is reduced 
compared to normal human keratinocytes (figure 5.1A). The addition of 1µM GSI inhibited 
the expression of ICN1 however in cSCC cell lines the expression of ICN1 was not completely 
inhibited by this concentration, suggesting that these cells harbour a resistance mechanism 
to the concentration of GSI used. A dose response curve may be required to elucidate the 
appropriate concentration. Additionally below the protein data is a table showing the 
mutational status of notch1 in these lines which has been identified using Sanger 
sequencing ((Wang, Sanborn et al. 2011), figure 5.1B). Even in the T8 cells, which have wild 
type expression of notch1 the expression at protein level is reduced suggesting that that 
other mechanisms may be acting on the signalling pathway to reduce the expression of 
notch signalling in these cells. Additionally immunoblot confirms that the SCCIC15 cells, 
which contain a stop codon mutation, have no protein expression of ICN1 which is as 
expected.  
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Figure 5.1 The Expression of Notch is Reduced in cSCC Compared to Normal Human Keratinocytes (NHK) 
(A) Protein expression of activated notch (ICN1) was explored in a panel of cSCC cell lines compared to normal human keratinocytes, with and 
without gamma secretase inhibitor (1µM, GSI). Protein expression of ICN1 is significantly reduced in cSCC compared to normal human 
keratinocytes. Results represent two experiments. (B) Table shows the mutational status of the panel of cell lines selected above for ICN1 
protein expression. RDEB; recessive dystrophic epidermolysis bullosa, T; transplant, IC; immunocompetant (Wang et al 2011). 
Figure 5.1 
ICN1 
GAPDH 
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5.2.2 The Effect of GSI in Normal and cSCC Keratinocytes on Cell Viability 
Previously notch signalling has been shown to reduce proliferation in keratinocytes through 
increased differentiation and cell death (Rangarajan, Talora et al. 2001). Therefore in order 
to confirm these data and to assess whether GSI had an effect on cSCC cells were seeded 
into 96 well plates and treated with different concentrations of GSI, ranging from 0.1-
100µM and the impact of GSI on percentage cell viability assessed using the MTS assay 
(figure 5.4). The human telomerase reverse transcriptase (hTERT) cell line and the K17 cell 
line are both immortalised normal human cell lines. It has been shown that HPV16 interacts 
with MAML, one of notch’s targets and has been shown to subsequently upregulate notch 
expression and activity. Therefore notch signalling may be dysregulated in cells with positive 
HPV status (Tan et al 2012). GSI slightly increases cell viability in the hTERT (figure 5.2A) 
after 72h, apart from at the highest dose, 100µM which reduces cell viability. However, in 
the K17 (figure 5.2B) cell line GSI slightly reduces the percentage cell viability which is similar 
to the effect seen in the cSCC notch null cell lines. In both SCC1C15 (figure 5.4C) and SCCIC8 
(figure 5.4D) a slight reduction in cell viability is seen after 72 hours. The greatest reduction 
is using the 100µM concentration. 
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Figure 5.2 The Effect of GSI in Normal and Notch Null cSCC Keratinocytes 
Percentage cell viability was assessed using the MTS assay. Immortalised normal keratinocytes, either the (A) hTERT or the (B) K17 which has been 
immortalised using either human telemorase reverse transcriptase or papilloma virus, respectively were assessed along with notch null cSCC keratinocytes 
(C) SCCIC15 and (D) SCCIC8. Results show that GSI slightly increases % cell viability in the hTERTS following 72h incubation with GSI compared to control. 
However in the K17, SCCIC15 and SCC1C8 cell lines GSI causes a slight reduction in proliferation. Results represent n=4±SD 
Figure 5.2 
A. B. 
C. D. 
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5.2.3 There is a correlation between mutational status of notch1, and protein 
expression of ICN1 in SCCIC12, SCCT2 and SCCIC8 cells 
Currently the tumour suppressive mechanism behind notch is unknown. One theory is that 
it functions as a tumour suppressor through mediation of pro-differentiation signals 
(Restivo, Nguyen et al. 2011; Rangarajan, Talora et al. 2001). The mutational status of these 
three lines was confirmed using western blot and immunohistochemistry (figure 5.3). The 
mutational status of the cSCC cell lines was identified using Sanger and exome sequencing 
of which three lines were chosen for study, the immunocompetent cell lines SCCIC12, 
SCCIC8 and SCCT2 which is an cSCC derived from a transplant patient (figure 5.3A). The 
SCCIC12 cell line was found to be wild type for notch1. The SCCT2 cell line was found to be 
loss of function (LOF) which has a number of mutations E415D, C409F, D469G. Of note the 
E415D and the D469G lie within the N-terminal extracellular portion, of which functional 
study of the E415D mutation suggests that this mutation causes LOF by disrupting the 
structure of EGF repeats required for ligand binding (Wang, Sanborn et al. 2011). The effects 
of the notch1 mutations on protein were confirmed using an antibody raised against full 
length notch (NOTCH1 total) which was a kind gift from Jon Aster and NICD (figure 5.3B). 
SCCIC12 and SCCT2 both have immune-reactivity at 300KDa, indicating the presence of full 
length notch however SCCIC8, which is a notch null cell line, has no identifiable protein 
expression as determined by immunoblotting which is expected. Using an antibody raised 
against activated notch SCCIC12 which is wild type for notch is the only cell line to display a 
band at 100KDa indicating NICD, again as expected. 
 
Additionally the mutational status was confirmed using immunohistochemistry of xenograft 
tumours (figure 5.3C). These sections were stained using an immunohistochemistry protocol 
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optimised by Jon Aster’s group for the Ventana auto-stainer and were kindly performed by 
Tayside Tissue Bank (Kluk et al 2013, Tayside Tissue Bank, Dundee). Using this method with 
the monoclonal cleaved notch1 antibody (ab4147), the SCCIC12 showed positive nuclear 
staining which was absent in the SCCT2 and SCCIC8 cell lines. The positive staining in the 
SCCT2 section is fibroblast staining, thus providing a robust internal control. Together the 
immunoblot and immunohistochemistry results confirm the mutational status of these cSCC 
cell lines. 
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Figure 5.3 Correlation Between Notch Mutational Status, Protein and IHC in cSCC 
(A) Mutational status of SCCIC12, SCCT2 & SCCIC8 as obtained from the Sanger and Exome sequencing study (Wang et al 2011, South et al 
submitted). (B) Protein expression of SCCIC12, SCCT2 & SCCIC8 was assessed using full length notch1 Ab (notch1, kind gift from Jon Aster), 
cleaved notch (NICD, Val1447) and GAPDH as a loading control. Data confirms the mutational status wild type SCCIC12 has both full length and 
activated notch protein expression, SCCT2 has only full length confirming its loss of function of notch. SCCIC8 has no bands for either full length 
NOTCH1 or NCID indicating its NOTCH1 null status. (C) Immunohistochmistry staining using JC Aster’s method (Kluck et al 2013) kindly 
performed by Tayside Tissue Bank, Dundee. Staining was performed using a monoclonal, cleaved notch1 antibody (ab4147). Where positive 
staining is seen in the nucleus of SCC1C12 however, no positive keratinocyte staining is seen in the SCCT2 and SCCIC8 cell lines. 
Figure 5.3 
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5.2.4 Involucrin and Keratin 10 staining of NHK, SCCIC12, SCCT2 and SCCIC8 cells 
is Affected by Notch Inhibition Using a Gamma Secretase Inhibitor 
In order to understand the relationship between differentiation and mutational status fibrin 
gels with either normal human keratinocytes, SCCIC12, SCCT2 and SCCIC8 were grown either 
without or in the presence of GSI to inhibit expression in the cell types with notch 
expression. Fibrin gels are a form of 3 dimensional cultures, prepared from fibrinogen and 
thrombin, which are key proteins involved in blood clotting and its unique polymerisation 
mechanism of fibrin allows the formation of a dense network of fibres. Fibrin gels were 
chosen to study differentiation as they provide a stronger base than the collagen matrigel 
system to support differentiation.  To begin the expression of ICN1 was confirmed using 
imunohistochemistry using an antibody raised against cleaved notch1. Both NHK and 
SCCIC12, which have wild type notch, showed positive nuclear staining (figure 5.6A). 
However the expression of ICN1 in the NHK is localised in the supra-basal layer whereas in 
the SCCIC12 cell line it is distributed throughout the epidermis – perhaps suggesting a 
change in function. No positive nuclear staining is seen in the SCCT2 and SCCIC8 cell lines, 
which have a loss of function notch1 mutation and notch1 null, respectively. Additionally, no 
positive staining is seen in fibroblasts suggesting that they do not express ICN1 (figure 5.4B). 
These gels were then stained using involucrin or K10, which are known markers of 
keratinocyte differentiation to identify if the notch1 status affected terminal differentiation. 
In the gels cultured with normal human keratinocytes (figure 5.4A) and SCCIC12 (figure 
5.7B) which have wild type notch1, the addition of GSI reduced the expression of involucrin 
in these keratinocytes however in the T2 (figure 5.4C) cell line which has a LOF notch1 
mutation, the reduction in the expression of involucrin was not as great following GSI 
inhibition. Immunofluoresecent staining of the SCCIC8 (figure 5.4D) cells with an antibody 
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raised against involucrin showed a significant reduction in immune-reactivity compared to 
normal human keratinocytes suggesting that terminal differentiation is reduced in this cell 
type. The addition of GSI to the media of SCCIC8 cells did not have an effect on involucrin 
expression in this cell type. 
 
Immunofluorescent staining using an antibody raised against keratin 10 (K10) yielded similar 
results to the involucrin staining, incubation of both NHK (figure 5.5E) and the SCCIC12 
(figure 5.5F) with the K10 antibody, resulted in a reduction in K10 expression indicating the 
importance of notch for differentiation in both cell types. Compared to the normal human 
keratinocytes all three of the cSCC cell lines have reduced K10 expression, with the SCCT2 
(figure 5.5G) expressing the least amount of K10. Surprisingly, SCCIC8 cells (figure 5.5H) 
which are Notch null, show positive K10 expression which is not reduced following 
incubation of GSI. It would seem that differentiation is under tight control by notch in the 
NHK cells however in the cSCC cells, which presumably contain a whole host of mutations 
which influence other differentiation pathways other than notch – differentiation cannot be 
controlled as regimentally. 
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Figure 5.4A Immunohistochemistry Shows GSI Regulatable Positive Nuclear Staining in Both NHK 
and SCCIC12 Which Express Wild Type Notch1 
Immunohistochemistry staining of fibrin gels, fixed 7 days after being raised. Staining was 
performed using JC Aster’s method (Kluck et al 2013) and was kindly performed by Tayside 
Tissue Bank, Dundee using a monoclonal, cleaved notch1 antibody (ab4147). Positive 
nuclear staining in the suprabasal layer is seen in the normal human keratinocytes (NHK, 
Top, LHS panel) in the presence of DMSO. This nuclear expression is lost following the 
addition of 1µM GSI in the top, RHS panel. Similarly, SCCIC12 which also expresses wild type 
notch expresses positive nuclear staining throughout the epidermal layers. This expression is 
GSI regulatable.  
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Figure 5.4B Immunohistochemistry Shows No Positive Nuclear Staining in SCCT2 or SCCIC8 
Keratinocytes Which Are Notch Mutant 
Immunohistochemistry staining of fibrin gels, fixed 7 days after being raised. Staining was 
performed using JC Aster’s method (M.Kluk et al 2013) and was kindly performed by Tayside 
Tissue Bank, Dundee using a monoclonal, cleaved notch1 antibody (ab4147). No positive 
nuclear staining is seen in either the SCCT2 which has a loss of function notch mutation (top 
panel, LHS) or the SCCIC8 cells which is notch null (bottom panel, RHS). The addition of 1µM 
GSI does not alter this result in either cell line (RHS panel). 
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Figure 5.5A GSI Reduces Involucrin Expression in Normal Human Keratinocytes 
Fibrin gels cultured with normal human keratinocytes with/without a gamma secretase inhibitor (GSI) and stained for the terminal 
differentiation marker, involucrin. LHS panel is the black and white image for involucrin staining only, middle is the corresponding DAPI for this 
image and the RHS images are the involucrin staining (RED) and DAPI (BLUE) images merged together in colour. The top set is grown without 
(1µM) GSI in DMSO and the bottom is in the presence of GSI. There is a reduction in involucrin staining in the presence of GSI. These images 
show that there is a reduction in involucrin following addition of GSI. Images are taken under 43 x objective.  
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Figure 5.5B GSI has no effect on involucrin expression in SCCIC12 
Fibrin gels cultured with SCCIC12 with/without a gamma secretase inhibitor (GSI) and stained for the terminal differentiation marker, 
involucrin. LHS panel is the black and white image for involucrin staining only, middle is the corresponding DAPI for this image and the RHS 
images are the involucrin staining (RED) and DAPI (BLUE) images merged together in colour. The top set is grown without (1µM) GSI in DMSO 
only and the bottom is in the presence of GSI. There is a reduction in involucrin staining in the presence of GSI. These images show that there 
is a reduction in involucrin following addition of GSI. Images are taken under 43 x objective. 
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Figure 5.5C GSI has no effect on Involucrin Expression in SCCT2 
Fibrin gels cultured with SCCT2 with/without a gamma secretase inhibitor (GSI) and stained for the terminal differentiation marker, involucrin. 
LHS panel is the black and white image for involucrin staining only, middle is the corresponding DAPI for this image and the RHS images are the 
involucrin staining (RED) and DAPI (BLUE) images merged together in colour. The top set is grown without (1µM) GSI in DMSO only and the 
bottom is in the presence of GSI. There is a reduction in involucrin staining in the presence of GSI. These images show that there is a reduction 
in involucrin following addition of GSI. Images are taken under 43 x objective.   
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Figure 5.5D GSI has no effect on Involucrin Expression in SCCIC8 
Fibrin gels cultured with SCCIC8 with/without the gamma secretase inhibitor and stained for the terminal differentiation marker, involucrin. 
LHS panel is the black and white involucrin staining only, middle is the corresponding DAPI for this image and the RHS images are the involucrin 
staining (RED) and DAPI (BLUE) images merged together. The top set is grown without (1µM) GSI in DMSO only and the bottom is in the 
presence of GSI. There is a reduction in involucrin staining in the presence of GSI. Images are taken under 43 x objective. 
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Figure 5.5E GSI Reduces K10 Expression in NHK 
Fibrin gels cultured with NHK with/without the gamma secretase inhibitor and stained for the terminal differentiation marker, K10. LHS panel 
is the black and white K10 staining only, middle is the corresponding DAPI for this image and the RHS images are the K10 staining (RED) and 
DAPI (BLUE) images merged together. The top set is grown without (1µM) GSI in DMSO only and the bottom is in the presence of GSI. There is 
a reduction in K10 staining in the presence of GSI. Images are taken under 43 x objective. 
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Figure 5.5F GSI Reduces K10 Expression in SCCIC12 
Fibrin gels cultured with SCCIC12 with/without the gamma secretase inhibitor and stained for the terminal differentiation marker, K10. LHS 
panel is the black and white K10 staining only, middle is the corresponding DAPI for this image and the RHS images are the K10 staining (RED) 
and DAPI (BLUE) images merged together. The top set is grown without (1µM) GSI and the bottom is in the presence of GSI. There is a 
reduction in K10 staining in the presence of GSI. Images are taken under 43 x objective. 
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Figure 5.5G GSI Reduces K10 Expression in SCCT2 
Fibrin gels cultured with SCCIC8 with/without the gamma secretase inhibitor and stained for the terminal differentiation marker, K10. LHS 
panel is the black and white K10 staining only, middle is the corresponding DAPI for this image and the RHS images are the K10 staining (RED) 
and DAPI (BLUE) images merged together. The top set is grown without (1µM) GSI in DMSO only and the bottom is in the presence of GSI. 
There is a reduction in K10 staining in the presence of GSI. Images are taken under 43 x objective. 
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Figure 5.5H GSI has no effect on K10 Expression in SCCIC8 
Fibrin gels cultured with SCCIC8 with/without the gamma secretase inhibitor and stained for the terminal differentiation marker, K10. LHS 
panel is the black and white K10 staining only, middle is the corresponding DAPI for this image and the RHS images are the K10 staining (RED) 
and DAPI (BLUE) images merged together. The top set is grown without (1µM) GSI and the bottom is in the presence of GSI. There is a 
reduction in K10 staining in the presence of GSI. Images are taken under 43 x objective. 
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5.2.5 Transduction of SCCIC8 Notch1 Null keratinocytes with a GSI Regulatable 
Notch construct dE to Allow Expression of Notch in This Cell Type 
Jon Aster kindly sent a notch1 vector “dE” which when over-expressed in cells does not 
require notch ligand stimulation for notch signalling to be switched on but only requires GS 
to be activated (see below for representative image of construct compared to full length 
notch).  
 
 
SCCIC8 cells were then retrovirally transduced with the dE vector (figure 5.6). The cells 
transduced with dE notch construct (SCCIC8dE), not in the presence of GSI, are 
morphologically different from those in the presence of GSI and the SCCIC8pB control. 
These cells appeared rounded, phase bright and were growing on-top of one another. The 
SCCIC8dE cells in the presence of the GSI, did not have the same morphology, however did 
have areas of cells which were more stacked on-top. SCCIC8pB cells which had been 
transduced with the pB empty vector control did not show any morphological differences – 
either with or without GSI. 
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Figure 5.6 Transduction of SCCIC8 with dE Vector 
SCCIC8 notch null cSCC cells were transduced with the dE construct, in the presence of 1µM GSI or DMSO. Cells transduced without GSI 
appeared more rounded and growing on-top of each other compared to those transduced in the presence of GSI. No morphological difference 
was noted between the SCCIC8pB cells wither with or without GSI. Results represent 3 experiments.  
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5.2.6 Washout Strategy Shows That dE Can Be Controlled By GSI 
 Previous work by Jon Aster and colleagues suggested that following removal of GSI from 
the media re-expression of activated notch occurred after 24h in lymphocytes. Using this 
strategy in keratinocytes to “switch on” notch expression as shown in figure 5.9, activated 
notch can be switched on in the SCCIC8 cells that have been transduced with the dE vector. 
Western blot looking at the expression of full length notch1 (notch1) and ICN1 in cells 
transduced with the empty vector control (SCCIC8pB) do not show any expression of Notch1 
or activated notch as expected even following washout of GSI. However IC8 cells transduced 
with the GSI regulatable vector (SCCIC8dE) in the presence of GSI have a band a 150KDa 
indicating expression of dE however this band disappears following washout of GSI and a 
band appears at 110KDa indicating that notch has been activated in these cells. 
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Figure 5.7 Washout Strategy Shows That dE Can Be Switched On Following GSI Removal 
 Western blot using a GSI washout strategy were cells (either SCCIC8dE/SCCIC8pB) were 
cultured in the presence of GSI and GSI is then removed. Removal of GSI from the SCCIC8dE 
cells switches on activated notch (ICN1). GAPDH was used as a loading control. Immunoblot 
represents n=3. 
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5.2.7 Washout of GSI leads to nuclear localisation of ICN1 signal in SCCIC8dE cells 
as determined by immunofluorescence 
Immunofluorescence staining of SCCIC8dE cells shows that in the presence of GSI (Figure 
5.8A, panel 1) full length notch is located in the endoplasmic reticulum (ER) whereas ICN1 
expression is located perinuclear. Washout of GSI from the SCCIC8dE notch cells leads to a 
change in localisation of ICN1 from cytoplasmic to nuclear with the localisation of the full 
length notch (notch1) being unaffected, as expected (figure 5.8A, panel 1). These data 
further confirms that it is possible to washout the GSI in order to switch on the expression of 
notch. Staining of SCCIC8pB cells with notch1 or ICN1 shows no positive staining either in 
the presence of GSI (figure 5.8A & 5.8B, Panel 2).  
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Figure 5.8A Washout of GSI Leads to Nuclear Localisation of ICN1 Signal in SCCIC8dE Cells as 
Determined By Immunofluorescence. 
SCCIC8dE cells were grown on cover-slips in the presence of GSI and 24h before fixation GSI 
was removed from the cells in panel 1. Following fixation cells were stained using the 
staining method in (2.7.1) using 2 primary antibodies – full length NOTCH1 (NOTCH1) or 
activated NOTCH1 (ICN1). Staining shows that on removal of GSI, ICN1 is localised to the 
nucleus however NOTCH1 is unchanged. Results represent two independent experiments. 
Images taken with 43x objective. 
Figure 5.8A 
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Figure 5.8B Immunofluorescence of SCCIC8pB Cells Following GSI Washout  
SCCIC8pB cells were grown on cover-slips in the presence of GSI and 24h before fixation GSI 
was removed from the cells in panel 1. Following fixation cells were stained using the 
staining method in (2.7.1) using 2 primary antibodies – full length NOTCH1 (NOTCH1) or 
activated NOTCH1 (ICN1). No positive staining is seen with either antibody. Results 
represent two independent experiments. Images taken with 43x objective. 
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5.2.8 Overexpression of dE Notch Increases Involucrin Expression With a 
Reduction in c-Myc 
Compared to the cells which express the empty vector pB control, SCCIC8pB there is an up-
regulation of involucrin in the cells which express the construct SCCIC8dE (figure 5.9). This 
expression was reduced with the addition of GSI which reduces notch expression. This 
increase in involucrin suggests an increase in differentiation, which is greater in the 
presence of activated notch, and can be reduced through the removal of GSI. In addition to 
the rise in involucrin is a simultaneous decrease in c-Myc in the SCCIC8dE cells. This 
decrease in c-Myc is reversed with the addition of GSI to a protein level to a similar level 
seen in the SCCIC8pB lysates. 
 
Figure 5.9 The Expression of Notch in the SCCIC8 cells Increases Involucrin While Reducing c-myc. 
Western blot shows increased expression of involucrin in the SCCIC8dE cell line which overexpress a 
GSI regulatable form of notch, dE. This expression is reduced following the addition of GSI. Cells 
which express the empty vector control, SCCIC8pB, shows much less involucrin expression. 
Additionally the results show a simultaneous reduction in c-myc expression. SCCIC8dE cells have 
reduced c-myc expression which is increased with the addition of GSI. A similar level of c-myc is seen 
in the SCCIC8pB, pBABE empty vector control. Additionally, the expression of c-Myc is restored with 
the addition of GSI. Results represent three independent experiments.   
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5.2.9 MTS Shows a Reduction in Proliferation Following Washout of GSI in the 
SCCIC8dE Cells 
Following washout of GSI from the SCCIC8dE cells there was a reduction in proliferation over 
96h (figure 5.10) as determined by the MTS assay. This was not seen in the SCCIC8pB cells 
suggesting that inhibition of notch signalling with GSI was the cause of the effect.  
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Figure 5.10 MTS Shows a Reduction in Proliferation Following Washout of GSI in SCCIC8dE Cells 
Assessment of proliferation, using the MTS assay in the SCCIC8dE cells showed a slight reduction in proliferation following washout of GSI. This 
reduction in proliferation is not seen in the pBABE empty vector control cells, SCCIC8pB. Results expressed are the mean of 3 experiments ±SD. 
Figure 5.10 
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5.2.10 The use of 3D organotypic confirms notch over-expression but Identifies 
Leaky Expression in SCCIC8dE cells 
SCCIC8dE cells were grown on fibrin gels as previously described in the material and 
methods chapter (2.6.1.2).  These gels were then kept in the presence of GSI or without and 
fixed after 7 days and stained for cleaved notch. The images show that in the absence of 
GSI, notch is activated and present in the nucleus (figure 5.11). However, with the addition 
of GSI notch staining is not entirely switched off. Fibrin gels were also fixed following 42 
days after they had been raised above the liquid interface (figure 5.12). This showed similar 
results in that the expression of the dE notch in the SCCIC8dE cells is reduced however some 
expression is still retained in the basal layer. This means that the current concentration of 
GSI is not switching off notch expression completely, which is also observed after 7 days. 
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Figure 5.13 GSI Reduces the Expression of ICN1 7 Days After Being Lifted 
Fibrin gels with SCCIC8dE keratinocytes grown on-top were grown either in the presence of GSI or without 
and then fixed after 7 days. They were then stained with cleaved notch to detect the presence of activated 
intracellular notch. Without GSI ICN1 was present in the nucleus however GSI reduces the expression of 
notch in this cell type. Staining was performed using Jon Aster’s groups staining protocol (M.Kluk 2013) by 
the Tayside Tissue Bank Dundee. 
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Figure 5.12 GSI Reduces the Expression of ICN1 Expression 42 Days After Being Lifted 
Fibrin gels with SCCIC8dE keratinocytes grown on-top were grown either in the presence of GSI or without and then fixed after 7 days. They 
were then stained with cleaved notch to detect the presence of activated intracellular notch. Without GSI ICN1 was present in the nucleus 
however GSI reduces the expression of notch in this cell type. Staining was performed using Jon Aster’s groups staining protocol (M.Kluk 2013) 
by the Tayside Tissue Bank Dundee. 
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5.2.11 SCCIC8dE Increases Involucrin in 3D Organotypics 
Over-expression of the dE construct in SCCIC8 cells increases involucrin staining in 3D 
organotypic cultures which confirms the western blot data shown in figure 5.9 (figure 
5.13A). Additionally this expression of involucrin can be reduced with the addition of 1µM 
GSI. However involucrin staining is still evident suggesting that the dose of GSI may not 
completely switch the expression of involucrin off. Comparatively, the SCCIC8pB cells show a 
much lower expression of involucrin, both in the presence of GSI and without, suggesting 
that the increase in involucrin staining is due to the expression of the dE construct (figure 
5.13B).  
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Figure.15A SCCIC8dE Cells Have Increased Involucrin Immunofluorescence Staining Which is Reduced Following Incubation With GSI 
Fibrin gels cultured with normal human keratinocytes with/without the gamma secretase inhibitor and stained for the terminal differentiation 
marker, involucrin. LHS panel is the black and white involucrin staining only, middle is the corresponding DAPI for this image and the RHS 
images are the involucrin staining (RED) and DAPI (BLUE) images merged together. The top set is grown without GSI and the bottom is in the 
presence of GSI. There is a reduction in Involucrin staining in the presence of GSI. Images obtained using the 16x objective. 
Involucrin DAPI Merged 
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Figure 5.15B SCCIC8pB Has Reduced Involucrin Staining Compared to SCCIC8dE 
Fibrin gels cultured with normal human keratinocytes with/without the gamma secretase inhibitor and stained for the terminal differentiation 
marker, involucrin. LHS panel is the black and white involucrin staining only, middle is the corresponding DAPI for this image and the RHS 
images are the involucrin staining (RED) and DAPI (BLUE) images merged together. The top set is grown without GSI and the bottom is in the 
presence of GSI. There is a reduction in Involucrin staining in the presence of GSI. Images obtained using the 16x objective. 
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5.3 DISCUSSION 
The sequencing data produced from our lab identified a high prevalence of biallelic 
inactivation of notch1 and notch2 genes, which as with the tumour suppressor p53, appear 
to act as critical tumour suppressors in cSCC. Notch receptors participate in a highly 
conserved signalling pathway, which elicits a duality of critical cellular functions including, 
differentiation, survival, growth and death occurring in a context dependant manner. In 
many tissue lineages, notch signalling can enhance stem cell potential and suppress 
differentiation while in keratinocytes it exerts an opposite effect (Artavanis-Tsakonas et al 
1999). It is well established that in haematological malignancies Notch1 functions as an 
oncogene (for a review see Aster 2008) (Di lanni et al 2009, Fabbri et al 2011, Kridel 2012). 
However in the skin, loss of function experiments has unequivocally demonstrated Notch1 
tumour suppressing ability (Nicolas et al 2003, Proweller et al 2006, Lefort et al 2007). This 
dichotomy between tumour promoting and suppressing function remains to be investigated 
but undoubtedly has implications on notch as a target for cancer therapy. Furthermore, this 
apparent dichotomy is convoluted by the novel finding that a small population of patients 
with myeloid leukaemia have inactivating notch mutations- suggesting a tumour suppressive 
and tumour promoting role within the same tumour (Klinakis et al 2011). A similar situation 
has been unveiled in pancreatic cancer where mouse models have used to reveal that notch 
receptors can either promote or inhibit pancreatic neoplasia depending on cellular context 
(Avila and Kissil et al 2013). 
 
This chapter has focused on the role of notch1 as a tumour suppressor in the 
skin/keratinocyte system. Previous reports have suggested a pro-differentiation role for 
notch activation in normal keratinocytes (Lowell et al 2000, Rangarajan et al 2001, Nickoloff 
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et al 2002a, Nguyen et al 2006, Letfort et al 2007) which has been further disseminated in 
this chapter using two approaches. Firstly, through immunohistochemistry staining of three 
cell lines of known genotype and secondly, through over-expression of a GSI regulatable 
notch in a notch null cSCC cell line. Following the sequencing data, which identified loss-of 
function of notch in cSCC, protein expression analysis in a panel of cSCC confirmed that the 
expression of notch was markedly reduced in all six of the cSCC cell lines tested. Surprisingly, 
even in the SCCT8 cell line which expressed wild type Notch. This may suggest that notch 
signalling is reduced in all cSCC in one way or another irrespective of the mutational status. 
Further work needs to be done to establish exactly how notch synthesis is activated and 
inhibited. Notch signalling is under tight control by a number of complex mechanisms. One 
mechanism is through membrane trafficking – where several factors modulate notch signal 
perception at the membrane (Struhl and Greenwald 1999, Seugnet 1997, Wilkin et al 2008). 
Studies, mainly in Drosophila, have identified a number of proteins that are involved in 
endocytosis such as Dynamin a GTPase at the cell surface; numb a cytoplasmic protein and 
Sanpodo a multipass transmembrane protein which is localised to the cell membrane 
(Fortini 2009). Additionally, ubiquitination of notch using E3 ligases is an important 
regulatory mechanism of notch signalling (Wilkin et al 2004). DSL endocytosis and 
endosomal trafficking within the signal sending cell, using other E3 ligases such as 
Neutralised (Neur) and Mindbomb (Mib) can also alter Notch activation through 
ubiquitination (Wang and Struhl 2005). Finally, a second endocytotic event to further 
activate notch proteolytic cleavages has been proposed - a “pulling force” which triggers 
trans-endocytosis of the NICD (Meloty-Kapella 2012). Once activated nuclear events can 
occur in order to switch off Notch signalling. Nuclear kinases can phosphorylate NICD, which 
is thought to be important for the stability of NICD and hence it is activity (Espinosa et al 
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2003, Fryer et al 2004). Furthermore, E3 ubiquitin ligases FBXW7, modifies NICD and targets 
it for proteosomal degradation (Gupta-Rossi et al 2001). These few processes mentioned 
above are but a small proportion of the control mechanisms on notch’s complex pathway. 
Further to this complexity our group have also identified a number of mutations in genes 
within the notch pathway which would undoubtedly have an effect activation or inactivation 
of the pathway. Genome-scale studies in Drosophila have revealed an extraordinarily 
complex network of genes that control this highly conserved pathway (Giot L, 2003). This 
means we are faced with serious challenges in understanding the control mechanisms for 
notch signalling in human disease. Currently our collaborators are performing RNAseq 
analysis of one of our notch null cell lines that over-express a GSI regulatable form of notch 
and comparing it to these cells expressing the empty vector control. This experiment will 
hopefully provide valuable global insights into biological networks following the expression 
of notch in these cells and hopefully, with the use of GSI help our understanding of the 
implications of switching notch signalling off in cSCC cells. 
 
Inhibition of notch activation using GSI at a concentration of 1µM was enough to inhibit 
notch activation in normal human keratinocytes but not in cSCC keratinocytes. This 
concentration of GSI was chosen, as Jon Aster, our collaborator was able to inhibit notch 
expression in Jurkat cells, a T cell leukaemia cell line with activated notch expression. 
Perhaps the cSCC cell lines tested have mutations in the gamma secretase complex, which 
reduces its sensitivity to GSI. It has been previously reported that knockout of nicastrin, a 
component of the gamma secretase complex, produces myeloproliferative disorder in mice 
(Klinakis et al 2011). Additionally gamma secretase interacts with a number of other 
substrates including E-Cadherin and CD44 which are important for cell-cell adhesion and 
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have been reported to be down regulated in cSCC perhaps a reduction in them is related to 
GSI sensitivity (Lyakhovitsky et al 2004). Additionally this concentration of GSI was unable to 
switch off notch expression following stable retroviral over-expression of the dE notch 
construct. This was only evident when carrying out immunohistochemistry staining on 
organotypic cultures and could not be confirmed by western blot which is much quicker and 
less labour intensive than the former. This was also confirmed by our collaborators whom 
were unable to switch off notch signalling at mRNA level using GSI. They also tried switching 
the dE notch off using a dose response and were still unable to switch off the expression. 
Further to this our collaborators have developed 3 other constructs and expressed one of 
these in the notch null cSCC cells and are now performing RNAseq on these cells. 
 
Using three cell lines of known genotype the SCC1C12 cells with wild type notch, the SCCT2 
cells with loss of function notch and the notch null SCCIC8 cell line, the function of notch in 
differentiation was explored. Using the 1µM concentration to inhibit notch expression in 
these cell types fibrin gels were grown and fixed after 7 days and stained with involucrin or 
K10, which are markers of differentiation in the suprabasal layers which have been 
previously shown to be elicited by notch activation (Rangarajan et al 2001, Nickoloff et al 
2002). The expression of both involucrin and K10 was reduced in the presence of GSI, in the 
normal human keratinocytes and the SCCIC12 cell line which both express wild type notch, 
This would suggest that notch contributes to differentiation in normal but also tumour 
keratinocytes. Of note the involucrin expression is not completely obliterated with 1µM GSI 
possibly due to involucrin being already expressed in a small fraction of keratinocytes 
undergoing spontaneous differentiation under low calcium conditions (Brissette et al 1996). 
Although there is evidence to suggest that notch signals non-autonomously within the 
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epidermis to regulate differentiation there is still much to be learned about notch’s complex 
interaction with other pathways. Additionally it is important to explore the possibility that 
different levels of notch have different outcomes through investigating cell lines with 
different mutational statuses. Furthermore the organotypic system allows the user to 
explore the contribution of fibroblasts autonomous induction of differentiation. 
 
In addition to this, looking at the DAPI counterstaining for both the normal human 
keratinocytes and the SCCIC12 cells shows that there are significant differences in the 
numbers of cells in the presence of GSI in the SCCIC12 cells but not the normal human 
keratinocytes. This would suggest that the function of notch is different in normal human 
keratinocytes and cSCC. Additionally, these data suggests that differentiation is markedly 
decreased in the cSCC cells compared to normal human keratinocytes, with the notch null 
SCCIC8 cells expressing the least. 
 
 In conclusion these data suggests that notch contributes to carcinogenesis through a 
reduction in differentiation. Keratinocyte specific re-activation of notch would therefore be 
a potential therapy for cSCC. Possible methods of reactivation include re-expression of 
notch using a targeted antibody or through inhibition of the co-repressor complex CSL. 
However in cancers which are harboured with notch mutations re-expression may prove 
more difficult. Hence determination of networks and pathways associated with notch 
activation in both normal and mutated cell lines is essential. RNAseq would be crucial for 
elucidating these associated networks.   
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Chapter 6 Final Conclusions and Future Work 
 
Carcinogenesis results from the accumulation of genetic and epigenetic events. Studies to 
understand these changes are paramount in finding a treatment for this disease of which 
emerging genomic technologies will no doubt, facilitate this pursuit. Dr South’s group have 
utilised two methods; microarray technology and Sanger sequencing which has yielded a 
number of potential molecular targets for cSCC, some of which are demonstrated within this 
thesis.  
6.1 VALIDATION OF MOLECULAR TARGETS FOR CSCC 
Genetic screens have previously been used to further validate molecular targets and identify 
the gene function within that cell type. Within this thesis, the original screen performed by 
Watt and colleagues was repeated, however using cytotoxicty as an endpoint. Although a 
further three targets PARP1, FUCA2 and PSMG3 were identified using this method, these 
targets were not pursed due to time constraints and the desire to further study a target 
which showed potential in a number of different assays and cell lines. Furthermore, this 
cytotoxicty screen highlighted the target PRSS21 which had also been highlighted in the 
previous screen by Watt et al 2011, making it a good candidate as a molecular target in 
cSCC.  
 
In follow up of the screen performed by Watt and colleagues, three genes, BDKRB1, GSG2 
and PRSS21 were explored as potential molecular targets for cSCC. A number of functional 
assays of cell viability and cell death were utilised to determine if these genes were 
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important for cSCC cell survival. Using this method PRSS21 showed most promise as a 
molecular target using a series of different assays.  
6.2 IDENTIFICATION OF PRSS21 AS A POTENTIAL MOLECULAR TARGET FOR 
CSCC 
PRSS21 was identified as being a potential molecular target for cSCC being able to 
significantly reduce cell viability and induce cytotoxicity through an increase of apoptosis, 
leading to the conclusion that PRSS21 over-expression is essential for cSCC cell survival. 
Using cell migratory and collagen matrigel assays, retroviral over-expression of PRSS21 in K1 
keratinocytes resulted in significantly increased migration and invasion into the gel 
compared to the empty vector control. Following on from this result it would be useful to 
further identify if the protease function of PRSS21 was required for invasion, using site 
directed mutagenesis of PRSS21’s catalytic activity. Furthermore, this retroviral over-
expression of PRSS21 led to the reduction in the expression of the tumour suppressor 
maspin, which is frequently down-regulated in cancer. Interestingly maspin, has been shown 
to inhibit tumour growth and suppress metastasis in a number of malignancies however the 
underlying mechanisms of maspin’s tumour suppressing ability are currently unclear. This 
thesis shows that PRSS21 potentially negatively regulates maspin over-expression in cSCC. 
Suggesting that inhibition of PRSS21 may not only reduce PRSS21 levels but re-introduce 
maspin expression in cSCC. Primarily, further work to evaluate the function of maspin in 
both NHK and cSCC is necessary. Information as to wither RNAi depletion of maspin affects 
proliferation and cell death in NHK would also be useful for our understanding in cSCC. 
Furthermore, retroviral over-expression of maspin in cSCC and exploration of its effects on 
cell migration and matrigel invasion, compared to the empty vector control, would 
determine if re-introducing maspin would be a potential therapy. Additionally the potential 
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of both PRSS21 and maspin to serve as biomarkers for disease progression, where PRSS21 
may indicate invasive tumour potential and maspin act as a indicator of good prognosis, 
further reinforces them to pave the way for the development of improved diagnostics and 
therapies for cSCC.  
  
Overall, the data show that PRSS21 would be a promising molecular target for cSCC and that 
development of inhibitors to PRSS21 may have clinical use. Although having high affinities, 
previous studies have shown that small molecular inhibitors to proteases often lack 
specificity. However PRSS21 is predominantly expressed in the testis, which would reduce 
any non-specific effects on normal tissue.  
6.3 THE CONTRIBUTION OF NOTCH LOSS OF FUNCTION TO CSCC 
Loss-of-function mutations were found in ~75% of cSCC, suggesting that Notch is an 
important tumour suppressor within this tumour type. The mechanism of this loss-of-
function remains undefined, so exploration of the regulation and function of this gene 
network in the skin is important. Culture of keratinocytes in 3D cultures at the air-liquid 
inter-phase allows the production of a cornified layer and hence allows the user to study the 
differentiation program at the level of the granular and cornified layer which is important 
for notch function. Using this method a reduction in differentiation is seen following 
incubation with GSI in both NHK and cSCC cells. Additionally, differentiation is reduced 
overall in cSCC compared to the NHK and is not as responsive to GSI regulation of notch 
regardless of the genotype. In parallel to these differentiation experiments, it would have 
been interesting to identify if proliferation was also being regulated through notch 
expression. Using an antibody raised against Ki67 which is a marker of keratinocyte 
proliferation would be one quick method of identifying this. Using this 3D organotypic 
220 
 
model it would be useful to explore the function of the fibroblasts to notch differentiation, 
as recently Dotto’s group have demonstrated a role for rbpjk-/- fibroblasts to increase 
proliferation and suppress differentiation of the overlying keratinocytes (Hu 2012).                                                               
However, interestingly staining of 3D organotypic gels for activated notch, in this thesis 
showed no positive staining in the fibroblasts of these gels (figure 5.6). Overall the data 
suggests that notch contributes to differentiation however this still remains to be resolved 
mechanistically in addition to working towards the development of a drug which could re-
express it.   
 
6.4 CONCLUSION 
To conclude, three potential molecular targets have been identified by the work in this 
thesis. The over-expression of PRSS21 provides a mechanism by which cSCC cells can 
migrate and invade into the surrounding extracellular matrix, thus potentially contributing 
to tumour progression. Furthermore, the over-expression reduces the TS maspin suggesting 
that inhibition of PRSS21 would simultaneously re-express maspin in addition to inhibition 
of PRSS21 expression, and may be effective for cSCC therapeutic intervention. Additionally 
notch is a potential molecular target for cSCC due to large number of LOF mutations that 
occur within this cell type. This thesis demonstrates that loss of notch functions to 
decreases epidermal differentiation in cSCC, suggesting that re-expression of notch would 
reduce tumour progression.  
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